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ABSTRACT 
 Breast cancer associated with mutations in the breast cancer genes BRCA1 and 
BRCA2 often occurs at an earlier age and individuals with a mutation have increased 
risk for developing breast, ovarian, and other cancers.  The cancers may be more 
difficult to treat, have higher rates of recurrence, and have poor outcomes.  Genetic 
counseling can facilitate informed decision-making about risk-reducing strategies that 
have shown to be effective but carry their own risks.  However, genetic counseling use 
is low, even among individuals considered high risk for having a BRCA mutation.  The 
reason for this is not clear.  Existing knowledge is limited by 1) inconsistent findings, 2) 
potential bias from highly selected samples (e.g., recruited only African American 
women, or only Hispanic women, or patients at a cancer risk evaluation clinic at an 
academic facility), 3) inadequate representation of rural populations, 4) small sample 
sizes, and 5) cross-sectional design.  
This dissertation describes a secondary analysis of existing data from a group of 
young breast cancer survivors identified using a state cancer registry.  Of 859 
participants, 281 (32.7%) used genetic counseling.  Of 546 participants who did not use 
genetic counseling, 357 (65.4%) reported that “No one ever suggested it.”  In fact, 
genetic counseling is recommended for all participants in this study due to their 
personal diagnosis of breast cancer at age younger than 50.   
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There was no significant difference in genetic counseling use between medically 
served and underserved participants (=.05, p=.32).  However, the analysis was 
underpowered and this finding should be interpreted with caution.  Variables that 
showed positive associations with counseling use could be interpreted as facilitators 
and were the same for served and underserved groups: perceived positive 
consequences for family, perceived positive consequences for self, and provider 
recommended.  The associations were moderate to strong with Pearson’s r>.50.  
Variables that showed negative associations could be interpreted as barriers.  The 
strongest associations were still weak with Pearson’s r<-.25.  These were: perceived 
negative consequences to self (among served) and convenience factors (among 
underserved).    
Logistic regression was done using data from the entire sample.  The following 
were significant and increased odds of using genetic counseling: having an additional 
risk factor (OR=2.292; 95% CI=1.604-3.275; p=.000), income (OR=1.356; 95% 
CI=1.091-1.686; p=.006).  Knowledge of breast cancer genetics also showed increased 
odds of using genetic counseling (OR=1.208; 95% CI=1.137-1.282; p=.000) but 
because 32.7% of participants already received genetic counseling at the time of the 
study, the knowledge score may be an outcome of genetic counseling rather than a 
predictor.  Motivation to comply with healthcare provider showed lower odds of using 
genetic counseling (OR=.360; 95% CI=.162-.803; p=.013).  Challenges in 
operationalizing variables due to being a secondary analysis led to exclusion of some 
variables from analyses and were a limitation of the study.  Triandis’s model of 
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interpersonal behavior still shows promise as a framework for guiding research on the 
predictors (barriers and facilitators) of cancer genetic counseling use.  
To prevent worsening disparities in the context of having a heritable mutation for 
cancer, additional work needs to ensure equitable opportunity to use genetic 
counseling.  Prospective studies might oversample for rural populations and individuals 
of racial and ethnic minority background.  Integration into the health care system, 
measured by regular use of preventive health services, may be a helpful criterion for 
determining underserved status in the context of the specialized health service of 
cancer genetic counseling.   
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CHAPTER I 
Introduction 
The burden of cancer can be described in multiple ways and from many 
perspectives.  Cancer is the second leading cause of death in the United States; 
medical costs and lost productivity from cancer cost the United States an estimated 
$263.8 billion in 2010; approximately 575,000 people died of cancer and more than 1.5 
million people had a diagnosis of cancer in 2011 
(http://www.cdc.gov/chronicdisease/resources/publications/aag/dcpc.htm).  Extending 
beyond these numbers, however, is the emotional burden of cancer for individuals and 
their families.  By this measure, hereditary cancers arguably claim one of the highest 
burdens associated with cancer.  Some characteristics suggestive of hereditary cancers 
that contribute to burden include younger-than-usual age at tumor diagnosis, multiple or 
recurrent cancers in one individual, and same or related tumors present in multiple 
family members (Lindor, McMaster, Lindor, & Greene, 2008).  Hereditary breast and 
ovarian cancer (HBOC) is one syndrome associated with increased risk for cancers due 
to heritable mutations.  With HBOC, carrying a mutation in the breast cancer gene 
BRCA1 or BRCA2 substantially increases risk for cancer of the breast, ovary, prostate, 
and others (Antoniou et al., 2003a; Chen and Parmigiani, 2007a).  Existing strategies 
have been associated with significant reductions in risk of developing cancer due to 
inherited mutations and reducing associated morbidity (Nelson et al., 2013a).  However, 
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some strategies such as risk-reducing surgeries can have severe consequences, 
affecting future fertility, body image, and other morbidity.  The decision to implement 
these strategies must be an informed one and tailored to individuals at greatest risk.  
Genetic counseling and genetic testing can reduce the potential for developing cancer 
among individuals with the known risk factors.  However, disparities may exist in who 
uses the genetic services that can lead to informed decision-making.   
Approximately 1 in 8 women in the US will develop invasive breast cancer at 
some point in their lifetime, making breast cancer the most common cancer among 
women in the United States excluding skin cancer (ACS, 2015).  A very small segment 
of the general population, between 0.2 - 1%, has a mutation in one of the breast cancer 
susceptibility genes BRCA1 and BRCA2 (Kurian, 2010).  In the U.S., where there were 
an estimated 233,000 cases in 2012 (women only) 
(http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx), approximately 2,330 individuals 
carry one of the mutations increasing their susceptibility to cancer of the breast, ovary, 
prostate, pancreas, and other cancers.  These mutations account for approximately 5-
10% of all female breast cancers, 5-20% of male breast cancers, and 15-20% of familial 
breast cancers (ACS, 2015).  BRCA1/2 mutations are found at higher rates among 
certain ethnic or other groups whose ancestors or “founders” were geographically 
isolated for a period of time.  Rare mutations in these populations became more 
common within the group as a result of isolation and interbreeding. 
Founder mutations have been identified among European populations, including: 
Ashkenazi Jewish, Icelanders, Norwegians, Finns, Swedes, French, Dutch, and Italians 
from Calabria and Italians from Sardinia; they have also been identified among non-
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European populations, including: French-Canadians from Quebec, Hispanics from 
South California, Hispanics from Columbia, Afro-Americans, South Africans, 
Iraqi/Iranian Jewish, Chinese, Japanese, Malaysians, Filipinos, and Pakistanis (Ferla et 
al., 2007).  A review of these and additional studies consisting of clinic-based samples, 
population-based samples, and individuals with and without strong family history of 
cancer, concluded that the prevalence of of BRCA1/2 mutations among individuals of 
African, Asian, white, and Hispanic descent is comparable (Kurian, 2010a).  This finding 
is supported in a recent study with a national commercially insured sample (Armstrong 
et al., 2015).   
BRCA1 and BRCA2 are tumor suppressor genes.  Each has its own mechanism 
of action but both play important roles in the maintenance of genome stability through 
DNA damage signaling, DNA repair, chromatin remodeling and transcription.  Carrying 
a mutation in the BRCA1 or BRCA2 genes means a substantially increased risk of 
developing cancer of the breast, ovary, prostate, pancreas, and others.  Having a 
mutation in the BRCA1 gene can increase lifetime risk of developing breast cancer to 
57-65% and risk of developing ovarian cancer to 39-40% (Antoniou et al., 2003a; Chen 
and Parmigiani, 2007a).  For BRCA2 mutation carriers, risk for breast and ovarian 
cancers are slightly lower with lifetime risk for breast cancer being 45-49% and risk for 
ovarian cancer being 11-18%.  However, these risk levels are still substantially higher 
than the general population risk (those who do not carry a mutation associated with 
increased susceptibility to cancer) of 12.3% for breast cancer and 1.3% for ovarian 
cancer.  (Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, 
Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, 
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Cronin KA (eds). SEER Cancer Statistics Review, 1975-2012, National Cancer Institute. 
Bethesda, MD, http://seer.cancer.gov/csr/1975_2012/, based on November 2014 SEER 
data submission, posted to the SEER web site, April 2015.). 
Although the prevalence of cancer due to a BRCA1/2 mutation may seem low, 
the potential burden to individuals who develop these cancers is no less significant.  In 
addition to increased risk of developing a variety of cancers as mentioned above 
(though breast and ovarian are most common), individuals who carry BRCA1/2 
mutations may get multiple or recurrent cancers (Lindor et al., 2008).  Compounded with 
an uncertainty of when or if one will develop cancer, when or if a cancer will recur, and 
the shock of cancer onset at a young age, being at risk for having a BRCA1/2 mutation 
can prove to be a challenge.  Although the risks associated with having a mutation 
seem significant, a recent review of the literature (Lynn C. Hartmann & Lindor, 2016) 
supports previous findings on the efficacy of risk-reducing surgeries for the prevention 
of breast and ovarian cancers.  With the exception of one study which did not show a 
significant reduction in the risk of subsequent breast cancer after bilateral mastectomy 
(Skytte et al., 2011), recent additional studies  (Domchek et al., 2010; Evans et al., 
2009; Heemskerk-Gerritsen et al., 2007) support the findings of studies done between 
1999 and 2004 (L. C. Hartmann et al., 1999, 2001; Meijers-Heijboer et al., 2001; 
Rebbeck et al., 2004) that showed a reduction of 90% or more in the risk of subsequent 
breast cancer among women who underwent prophylactic mastectomy.  Additionally, 
one meta-analysis and seven efficacy studies on risk-reducing salpingo-oophorectomy 
also support previous findings of significant reduction in risk for ovarian cancer – 
approximately 80% among BRCA1 and BRCA2 mutation carriers (Domchek et al., 
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2006, 2010; A. Finch et al., 2006; A. P. M. Finch et al., 2014; Kauff et al., 2002, 2008; 
Rebbeck et al., 2002; Rebbeck, Kauff, & Domchek, 2009).  As in the case of 
prophylactic mastectomy to reduce the risk of breast cancer, it should be noted that a 
substantial decrease in risk for ovarian cancer results from risk-reducing salpingo-
oophorectomy, but some risk does remain.  Although there are advantages to these 
surgeries, some of the risk-reducing strategies such as surgery carry their own risks 
such as infection and other morbidity.  The risk-reducing surgeries can be considered 
drastic and must be weighed with the individual’s level of risk as well as awareness of 
remaining risk and potential complications after risk-reducing approaches.  Genetic 
counselors can facilitate discussions about these and similar factors to consider in order 
for individuals to make informed decisions and arriving at a plan that minimizes risk are 
of utmost importance.   
Genetic counselors’ expertise in evaluating risk and discussing strategies to 
minimize risk and potential outcomes can be invaluable.  However, the proportion of 
individuals receiving genetic counseling is far from optimal.  Data from the National 
Health Interview Survey (NHIS) and the Centers for Disease Control and Prevention, 
National Center for Health Statistics (CDC/NCHS) found only 34.6% of women with a 
family history of breast and/or ovarian cancer received genetic counseling in 2005 
(http://www.healthypeople.gov/node/4502/data_details#revision_history_header).  The 
US Preventive Services Task Force (USPSTF) recommended in 2005 in that all women 
with a family history suggestive of increased risk for clinically significant mutations in the 
BRCA1 or BRCA2 genes be referred for genetic counseling and evaluation for mutation 
testing (U.S. Preventive Services Task Force, 2005a).  Yet, as recently as 2015, studies 
  
5 
where all participants met criteria for genetic counseling are still reporting that fewer 
than 50% of study participants pursued genetic counseling (Anderson et al., 2012a; 
Armstrong et al., 2015; Cragun et al., 2015a).  In one of these studies (Cragun et al., 
2015a), a mere 35% were referred for genetic counseling despite all participants 
meeting national guidelines for referral.  Of the 440 participants who completed surveys, 
91 saw a genetic counselor.  This translates to 21% of the sample.  
Although use of genetic services (genetic counseling and genetic testing if 
applicable) may be relatively new, disparities in the use of genetic services may be next 
in contributing to persistent disparities in health and health outcomes.  Breast cancer 
mortality rates have been decreasing since 1989 (ACS, 2015), with the overall decline 
being attributed largely to early detection and better treatments (Berry et al., 2005).  
Declines in mortality rate, however, have been greater for some segments of the 
population than for others.  For example, mortality rates have been reported as 
declining by 1.8% in whites, 1.5% in Hispanics, 1.4% in blacks, and 1.0% in 
Asians/Pacific Islanders, but have been unchanged among American Indians/Alaska 
Natives (Howlader et al., 2012; http://seer.cancer.gov/csr/1975_2012/).  The difference 
in rates of decline is likely due to a combination of factors including biological factors 
(e.g., tumor characteristics, genetic predisposition to cancer, obesity, age at first live 
birth, breastfeeding), social factors (e.g., cultural beliefs, historical influences, concerns 
about discrimination), and structural factors (e.g., insurance coverage, access to care 
which can influence stage at diagnosis and treatment) (De Ridder et al., 2016; Friebel, 
Domchek, & Rebbeck, 2014).  These factors may also contribute to disparities in 
mortality among the subpopulations who may carry mutations in the BRCA1/2 genes.   
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An analysis of a testing repository of individuals who underwent clinical full-
sequence DNA testing for mutations in the BRCA1 and BRCA2 genes between 1996 
and 2006 (through Myriad Genetic Laboratories, Inc., the only company in the United 
States offering this testing from 1996 to June 2013) found that women of African 
ancestry and Latin American ancestry had significantly higher prevalence of deleterious 
BRCA1/2 mutations (15.6% [OR 1.3 (1.1-1.5)], and 14.8% [OR 1.2 (1.1-1.4)], 
respectively) compared to women of Western European ancestry (12.1%) (Hall et al., 
2009).  BRCA1 mutations have been found to be less prevalent among African 
Americans compared to whites but African Americans diagnosed with breast cancer 
under 35 years of age have the highest rate of BRCA1 mutations (16.7%) than any 
other racial/ethnic group except Ashkenazim (66.7%) in age-matched analyses (John et 
al., 2007).  About 69% of breast cancers that develop in individuals who carry a BRCA1 
mutation are estrogen-receptor (ER)-negative, progesterone-receptor (PR)-negative, 
and human epidermal growth factor receptor 2 (HER2)-negative, or “triple-negative 
breast cancers”.  Triple-negative breast cancers tend to be more aggressive and are 
associated with poorer prognosis (Lacroix & Leclercq, 2005; Mavaddat et al., 2012; 
Rakha, Reis-Filho, & Ellis, 2008).  
A review of the studies reporting the above findings, along with other studies, 
highlights important differences in the prevalence of BRCA1 compared to BRCA2 
between racial/ethnic groups and differences in frequency of results containing variants 
of unknown significance (VUS) between racial/ethnic groups (Kurian, 2010a).  In 
addition to the finding of higher prevalence of BRCA1-associated tumors among African 
American women under 35 years of age mentioned above (John et al., 2007), 
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individuals of African descent showed VUS nearly three times more than did whites 
(16.5% in African Americans compared with 5.7% in whites) (Hall et al., 2009).  
Individuals of Hispanic descent showed VUS nearly two times more than whites (10.1% 
in Hispanics compared with 5.7% in whites). 
The scientific community has acknowledged the effects that inadequate 
knowledge about certain groups can have on health outcomes.  One breast cancer risk 
assessment tool, for example, states that the original version was based on data from 
white women but has been updated as additional data has become available 
(http://www.cancer.gov/bcrisktool/about-tool.aspx).  The tool now more accurately 
estimates risk for African American and Asian/Pacific Islander women.  However, risk 
estimates may not be accurate for American Indian, Alaskan Native, and Hispanic 
women as the calculations are based on data from white women.  For recent 
immigrants from some parts of Asia, risk is stated to be “probably” lower than predicted 
by the model.   
In recent literature, scientists have also called for greater participation among 
groups traditionally underrepresented in research, such as ethnic minorities.  One area 
in which this has been recognized, for example, is in clinical trials on cancer therapies.  
Without sufficient participation from groups of diverse backgrounds, treatment effects 
would be uncertain and perhaps suboptimal.  Studies in genetics and genomics face a 
similar challenge of having the majority of knowledge coming from non-Hispanic whites.  
For example, the frequency of VUS in individuals of African and Hispanic descent is 
much higher than that in whites because of lack of information from individuals of 
African and Hispanic descent.  A VUS is, as its name suggests, a variation from a gene 
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sequence that has been defined as the normal, and the significance of this variation is 
unknown.  The variations often are single nucleotide polymorphisms or alterations to 
noncoding regions of the gene and may or may not affect the function of the resulting 
protein.  Receiving a result of a VUS is not clinically useful.  In some cases, receiving a 
result of a VUS can be distressing due to the ambiguous, uninformative nature of the 
finding.  The tests to identify a mutation in the BRCA1/2 genes developed from gene 
sequences of white individuals and thus have the gene sequences of white individuals 
as the “normal”.  Interestingly, the reported frequency of BRCA1/2 VUS in a population 
is inversely proportional to the dissemination of genetic testing (Kurian, 2010a).  
BRCA1/2 mutation prediction models, again developed largely from samples of white 
individuals, have also shown to be better in white individuals.  The high rate of VUS and 
greater inaccuracy of mutation prediction models for groups other than non-Hispanic 
whites can be discouraging and potentially lead to less use of testing and further 
disparities. 
A recent meta-analysis of 11 genome-wide association studies (Michailidou et 
al., 2015) reports identifying 15 new susceptibility loci for breast cancer, increasing from 
the 68 susceptibility loci for breast cancer identified in a prior report (Michailidou et al., 
2013).  The previous meta-analysis had reported that further analyses suggested more 
than 1,000 additional loci could be involved in breast cancer susceptibility.  Genetic 
variants at these loci include the widely known BRCA1 and BRCA2 mutations.  
Development of tests for mutations at these newfound loci may increase the relevance 
and utility of testing to a broader range of individuals.  One caveat of these findings, 
however, is that they are based on controls that were of European ancestry; application 
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to individuals not of European ancestry is unclear.   While potentially useful for 
individuals with European ancestry, the findings carry the potential to furthering 
disparities in risk assessment for individuals and groups of other ancestry.  
Recognition by the scientific community of factors that may further widen 
disparities in health and health outcomes is an important step in ameliorating the long-
standing problem.  However, it is insufficient.  Policy also can also influence disparities.  
Guidelines for breast cancer screening, for example, have been a widely controversial 
topic for at least the past decade.  In 2009, the United States Preventive Services Task 
Force (USPSTF) released breast cancer screening recommendations, recommending 
against mammography for women aged 40 to 49 years (US Preventive Services Task 
Force, 2009).  The USPSTF is an independent group of experts in prevention and 
evidence-based medicine who assign recommendations for preventive services based 
on rigorous reviews of peer-reviewed evidence.  The recommendations are intended to 
help primary care clinicians and patients decide whether a preventive service is right for 
each patient.  Although the USPSTF recommendations themselves do not make 
statements about whether preventive services should be covered by insurance, the 
Affordable Care Act (ACA) does use the recommendations to determine what services 
private insurance companies are required to cover without cost sharing (The Henry J. 
Kaiser Family Foundation, 2015). 
The 2009 USPSTF breast cancer screening recommendations were the topic of 
many heated debates by clinicians, scientists, politicians and patients alike.  The 
recommendations were released at a time when soaring healthcare costs were 
becoming clearly unsustainable and health care reform was vital.  Inefficiency and 
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waste were suspected and led to questions about overtreatment.  The USPSTF 
recommendations were made taking into consideration reports about the harms 
associated with false-positive findings on mammograms (e.g., biopsies, pain and 
anxiety associated with biopsies, prophylactic mastectomy and associated morbidities).  
The USPSTF recommended against routine screening mammography in women aged 
40 to 49 years, and stated that rather, the decision to start screening should be an 
individual one, taking into account each individual patient’s context, including the 
patients values regarding specific benefits and harms.  The backlash following the 
recommendations involved accusations about rationing of health care and concerns 
about whether mammograms would be covered by insurance for individuals under 49 
who may still wish to get annual mammograms.  The latter concern still exists today, 
with the recent release of the new guidelines for breast cancer screening from the 
American Cancer Society (ACS) (Oeffinger et al., 2015).  The ACS guidelines 
recommend that women with an average risk of breast cancer – which is most women – 
should begin yearly mammograms at age 45, then decrease to every other year at age 
55.  However, the recommendation also states that women should be able to start the 
screening as early as age 40 if they want to, that women age 55 should be able to 
continue having yearly mammograms if they want to, and that they can continue to do 
so as long as they are in good health with a life expectancy of 10 years or longer.  The 
2016 USPSTF recommendations are for biennial screening mammography for women 
aged 50 to 74 years; women who place higher potential benefit on potential harms may 
choose to begin biennial screening between the ages of 40 and 49 years.  The two 
organizations provide different recommendations.  If insurance companies base 
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coverage criteria on these recommendations, differences in type of insurance can 
worsen existing health disparities.   
The effects of the ACS and USPSTF recommendations can be particularly 
important to individuals at high risk for having a BRCA1/2 mutation.  Although genetic 
counseling and BRCA testing, if appropriate, are considered a preventive service and 
must be made available without cost-sharing under the Affordable Care Act, “if a 
recommendation or guideline does not specify the frequency, method, treatment, or 
setting for the provision of that service, the plan or issuer can use reasonable medical 
management techniques to determine any coverage limitations” 
(https://www.cms.gov/CCIIO/Resources/Fact-Sheets-and-
FAQs/aca_implementation_faqs12.html#fn7).  If one chooses not to get genetic testing 
and instead opts for frequent surveillance, there may be challenges with insurance 
coverage for services.  Furthermore, if receipt of these services is dependent on an 
individual’s personal financial resources, this can also worsen existing health disparities. 
Reflecting the increasing scientific evidence on the benefits of family health history and 
genetic tests, “Genomics” was created as a new topic area of Healthy People 2020 
(http://www.healthypeople.gov/2020/topics-objectives/topic/genomics/objectives).  Two 
objectives were set: 1) increasing the proportion of women with a family history of 
breast and/or ovarian cancer who receive genetic counseling, and 2) increasing the 
proportion of persons with newly diagnosed colorectal cancer who receive genetic 
testing to identify Lynch syndrome (or familial colorectal cancer syndromes.  This 
proposed study will focus on the first objective.   
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The lost opportunity from identifying an individual as a mutation carrier only after 
cancer has developed has been regarded as a failure of cancer prevention (King, Levy-
Lahad, & Lahad, 2014).  Mary-Claire King (2014), a pioneer in the field and awarded for 
“bold and imaginative contributions to medical science and society,” one of which was 
her discovery of the BRCA1 gene, has proposed population-based genetic screening.  
King cites that World Health Organization criteria for population screening for genetic 
predisposition to disease (the disease is an important public health burden in the target 
population; risk of disease due to mutations in the screened genes is known; and 
effective interventions exist to reduce morbidity and mortality among genetically 
susceptible individuals) (Khoury, McCabe, & McCabe, 2003) are met in BRCA1/2-
related cancers, and highlights flaws in existing mutation probability models (Weitzel et 
al., 2007).  Smaller families, fewer opportunities for the mutations and/or cancer to 
manifest, have been considered akin to missing data (Weitzel et al., 2007).  Thus, 
probability models cannot be relied on for determining eligibility for mutation analysis.  
King suggests that there are too many missed opportunities for cancer prevention.  
Clinical practitioners and the health care system may not yet be prepared to handle 
population-based genetic screening, as part of routine medical care, but King’s bold 
proposal highlights the potential for disease prevention, flaws that need to be addressed 
in order to prepare for population-based genetic screening, and a glimpse of the 
possibilities in the future of genomics. 
Genetics research has consistently ranked second highest in NIH-funded 
research after Clinical Research since at least 2011 
(http://report.nih.gov/categorical_spending.aspx).  However, the low uptake of genetic 
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services indicates that the benefits of current research efforts may not be fully being 
realized.  While genomics carries a potential to improve health outcomes through 
predictive genetic testing and implementation of risk reducing strategies, the potential 
for widening disparities in health outcomes due to inequitable access and utilization of 
services also exists.  In order to prevent further widening of long-standing and persistent 
disparities in health outcomes, equitable use of cancer genetic services that evaluate 
risk and guide the use of risk-reducing strategies must be ensured.  Multiple factors and 
pathways can lead either to using genetic services or away from using genetic services.  
Because of the number and entwined relationships of some of those factors, the reason 
why genetic service use is low is still poorly understood.  This information, however, is 
essential for developing interventions to address the causes among individuals who 
may benefit. 
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CHAPTER II 
Theoretical Framework and Literature Review 
The Triandis model of interpersonal behavior 
Multiple factors can influence the use of genetic services.  These factors can 
occur at the individual level, interpersonal or social level, and structural level.  Culture 
can play a role at each of these levels.  Harry C. Triandis, from the field of sociology, 
has done extensive research on behavior and the role that culture can play.  The 
relationship between culture and behavior in the context of using genetic services is an 
important one but is not yet well understood.  From Triandis’s extensive work on culture, 
he distinguished between individualistic and collectivistic cultures.  Much of this work 
contributed to the development of his theory of interpersonal behavior (Triandis, 1977).  
The theory considers the complex interplay of human cognition, emotion, social 
influences, and physical or structural barriers in predicting behavior and shows potential 
for being applicable in the context of predicting the use of genetic services.  In order to 
further explore the theory’s applicability in the context of using genetic services, a 
literature review was conducted using the theory as an organizing framework. 
Triandis conducted extensive work on individualistic and collectivistic cultures 
which increased the understanding of norms, values, attitudes, and behaviors among 
individuals from diverse ethnic and cultural backgrounds (Berman, 1990).  Hui and 
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Triandis (1986) found that members of collectivist cultures have greater concern 
about the results of their actions on others.  This is in contrast to individualist cultures, 
which place greater value on individual self-development, autonomy, and privacy, and 
regard the individual as the basis of society.  Collectivism is often internalized to the 
extent that members act according to in-group norms automatically, without doing any 
calculation about the benefits and consequences to themselves (Berman, 1990).  The 
resulting behaviors may or may not be congruent with what their preference would be if 
they were to do a calculation of benefits and consequences for themselves.  Principles 
of individualism and collectivism can vary at multiple levels, including the individual, 
interpersonal, and societal levels.  Presently, which of these levels is most influential in 
the use of genetic services is not known.  However, culture may likely play an 
overarching role in the use of genetic services. 
According to Triandis, the components that contribute to a behavior are: habit 
hierarchies, social factors, affect, the value of perceived consequences, and facilitating 
conditions.  The model posits that the probability of a behavior depends on three major 
factors: 1) the strength of the habit of producing a behavior, which is indexed by the 
number of times the behavior has already occurred in the history of the individual, 2) the 
intention to produce the behavior, and 3) the presence or absence of conditions that 
facilitate performance of the behavior.  Triandis distinguishes between behaviors that 
are done with little thought and are almost automatic (resulting largely from habit), and 
behaviors that are more deliberate, requiring more thought and planning (involving 
greater intention).  The habit and intention components are dynamic, fluctuating in the 
amount of influence they have on a behavior.  The components might vary according to 
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individuals, type of behavior, and context such as life stage.  To account for this 
variation, Triandis weights variables according to importance.    
The model also describes determinants of behavioral intentions.  These are: 1) 
social factors which include norms, roles, social contracts, self-monitoring, and self-
concept, 2) affect associated with the behavior, and 3) the value of the perceived 
consequences.  Triandis proposes that the value of perceived consequences is derived 
from first identifying the consequences that an individual perceives as likely to follow a 
behavior, then summing up how likely they perceive each of those consequences to 
occur and how much they value those consequences.  Conceptual definitions and 
details about how values for each of the variables can be considered are shown in  
Table 2.1.  The relationship of concepts based on Triandis’s theory are shown in Figure 
2.1.
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Table 2.1.  Concepts of Triandis model defined 
 
Concept Conceptual definition Related concepts 
Habits 
Behaviors that occur with 
frequency 
Number of times the person 
has committed a behavior 
Facilitating conditions 
Conditions that enable the 
person to carry out a 
behavior  
Includes the person’s ability, 
arousal, and knowledge to 
carry out a behavior 
Intention 
Cognitive antecedent of a 
behavior 
Product of social factors, 
affect attached to the 
behavior, value of the 
perceived consequences of 
the behavior, and the 
weights of each 
Social factors 
Influential factors derived 
from the relationship 
between the person and 
other people 
Includes norms, roles, 
contractual arrangements, 
self-monitoring, self-concept 
Affect 
Emotions that the person 
feels at the thought of the 
behavior, can be positive 
(pleasant) or negative 
(unpleasant), and strong or 
weak 
 
Perceived consequences 
Subjective probability that 
certain consequences will 
follow a behavior; may differ 
from actual consequences 
 
Value of perceived 
consequences 
How good or bad one would 
feel if a particular 
consequence actually 
happened 
Sum of the products of the 
subjective probabilities that 
particular consequences will 
follow a behavior, and the 
values of (or affect attached 
to) those consequences 
Source: Interpersonal Behavior by H.C. Triandis (1977).   
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Figure 2.1.  Conceptual framework of Triandis’s theory 
 
 
According to Triandis, cultures differ significantly on the emphasis they place on 
the individual being part of and belonging to a “collective”, with mainstream US culture 
being extremely individualistic (Triandis, 1977).  From very impressionable ages, 
individuals learn behaviors that stem from the attitudes and beliefs of their culture.  
These attitudes and ways of thinking are ingrained into individuals starting from a very 
young age.  As memberships and roles in various groups with their own subcultures 
evolve, so do the individuals’ attitudes and beliefs.  These experiences and their 
consequences shape an individual and their behaviors.   
Reports of study findings about a particular racial or ethnic group may imply that 
the participants’ race or ethnicity had a direct role in an outcome when in fact cultural 
beliefs may not have been measured, and race/ethnicity may simply be a background 
factor or at most associated with an outcome, not predictive of it.  Participants’ race or 
ethnicity may have been drawn from a simple question in a questionnaire.  This 
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presents limitations, for example among multi-cultural/multi-ethnic individuals, and it 
does not address differences in level of acculturation and assimilation within the 
sample.  Furthermore, comparison of studies, replication, and verification of findings 
involving specific races/ethnicities can be challenging due to limited numbers of specific 
cultural/ethnic populations in some geographic areas.  Using characteristics of cultures 
– such as collectivist versus individualist cultures – as a way of defining groups and 
exploring the association with and effect on an outcome is an alternative approach that 
has yet to be explored.   
Measures of collectivism and individualism are not readily found in research on 
the use of health services.  However, medical underservice is a more recognizable 
characteristic and may be suitable as a proxy for culture.  Medical service (not living in a 
federally designated medically underserved area) will be used as a proxy for 
individualist culture, and not having medical service (living in a federally designated 
medically underserved area) will be used as a proxy for collectivist culture.  The medical 
service (alternatively, underservice) piece incorporates socioeconomic and system-
related structural factors; using these as a proxy for the traits of individualist and 
collectivist cultures, respectively, will incorporate the cultural piece, presenting a 
multidimensional analysis of the influence of culture in the use of genetic counseling. 
 
Literature review 
The act of using genetic services is multi-faceted and still not well understood.  
As mentioned earlier, the proportions of individuals who are at high risk for carrying a 
BRCA1/2 mutation and for whom genetic counseling is appropriate are far below 
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optimal.  In a population-based study of women diagnosed with breast cancer before 
age 50, widely recognized as a red flag for possible hereditary mutation such as BRCA1 
or BRCA2, fewer than 50% of women pursued genetic counseling (Anderson et al., 
2012).  Even more recently, in another study where Black women diagnosed with 
invasive breast cancer were at or below age 50, 49% of participants were neither 
referred for genetic counseling nor accessed genetic services, and a mere 35% were 
referred for genetic counseling despite all participants meeting national guidelines for 
referral (Cragun et al., 2015).  To understand more about the barriers and facilitators 
around the use of genetic services, a review of the literature was conducted in Medline, 
Scopus, and CINAHL and included the key terms genetic testing, genetic counseling, 
intention, BRCA, decision making, psychology, social support, health knowledge, 
attitudes and practice. The use of genetic services is the primary interest of this review. 
Both genetic testing and genetic counseling were used because counseling may not 
necessarily precede testing and testing may not necessarily follow counseling. 
However, important lessons may be learned from literature in both cases. Decision 
making, psychology, social support, health knowledge, and attitudes were chosen to 
retrieve studies on the cognitive aspect of determining a preference to use genetic 
testing and genetic counseling. Practice was included to retrieve studies on the actual 
uptake of services. The search using this combination of terms produced results with 
the highest relevance to the aim of this review. Reports of the link between the BRCA 
genes and increased predisposition to breast, ovarian, and other cancers were reported 
in the late 1990s (Miki et al., 1994; Wooster et al., 1994). Articles published between 
2000 and 2014 were included.  Abstracts were reviewed for applicability. Articles were 
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chosen if they examined factors that influenced the use of genetic testing or genetic 
counseling for hereditary breast cancer. Because genetic tests for other syndromes with 
hereditary links to breast cancer such as Cowden’s and Li-Fraumeni syndrome are not 
as well established, results were limited to articles on BRCA1/2 mutations. Some 
related articles from search results were also included. Both qualitative and quantitative 
studies were included. 
The findings of the review can be found in Appendix A.  Findings are organized 
by the constructs of the Triandis model (habits, facilitating conditions, social factors, 
affect, and perceived consequences) in the rows, and categories under which the 
influential factors derived from the literature search fit (personal factors/characteristics, 
social and cultural influences, healthcare system factors, government policy, and the 
industry/market) in the columns.  
 
Social factors 
This concept encompasses the various relationships between a person and other 
people that can be influential.  The social factors associated with or found to predict use 
of genetic services in the literature can be categorized under two variables: 1) perceived 
expectations and 2) motivation to comply with perceived expectations.  The most 
commonly reported reasons for using genetic services, whether genetic counseling or 
genetic testing, is to benefit the family in addition to identifying risk for oneself 
(Anderson et al., 2012; K. Armstrong et al., 2000; Thompson et al., 2002).  Among 
Latinas, a perceived expectation that was commonly reported as influencing the use of 
genetic services was in prioritizing the family’s needs over one’s personal needs (Glenn, 
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Chawla, & Bastani, 2012; Sussner, Jandorf, Thompson, & Valdimarsdottir, 2013).  This 
has been reported as a cultural belief in multiple studies.  Among Asians, stigma of 
having “bad genes” was a common theme for concerns about using genetic services to 
obtain genetic information (Glenn et al., 2012).  In that culture, where family approval of 
a suitable marriage partner involved asking about the family’s medical history, there was 
an expectation to keep the medical record free of such information.  
A common theme found across different backgrounds was stigma from having a 
BRCA1/2 mutation.  Among some Ashkenazi-Jewish, there is concern that increased 
awareness of higher frequency of this mutation occurring among individuals with this 
background will lead some to associate the group with having bad genes or inbreeding 
(Davis, 2000).  Stigma of having bad genes is also associated with concern for abuse in 
the context of eugenics and denigrating groups, particularly among African-Americans 
who have experienced similar abuses in the past (Glenn et al., 2012).  Other than 
among Ashkenazi-Jewish, concerns about social factors like these are not reported 
among non-Hispanic white participants.  A gap in knowledge is whether these or similar 
social factors are not significant concerns among non-Hispanic whites or simply that 
studies exploring this topic have involved primarily understudied and underrepresented 
groups in research. 
Although some interesting themes have emerged from studies on this topic, 
important limitations of studies mentioned above are 1) small sample sizes and 2) 
limited ability to corroborate findings due to few comparable studies.  
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Affect   
Relief and worry are the predominant themes for emotions that influence the use 
of genetic services.  Existing literature primarily involves the emotions from anticipated 
consequences to the self, with some literature on emotions related to consequences to 
family.  Positive emotions associated with getting genetic counseling and testing 
included feeling relief from a negative result (not having a mutation) (Chin et al., 2005; 
Thompson et al., 2002) and having a better sense of personal control (Chin et al., 
2005).  Negative emotions included worry about passing a mutation on to children and 
for relatives who may be carriers, fear of positive results (having a mutation), and not 
wanting to hear bad news (Chin et al., 2005; Thompson et al., 2002).  Knowing the truth 
or receiving a diagnosis makes some feel empowered with the opportunity to then take 
actions that can potentially affect their outcome.  However, the truth may be disabling if 
they were to become consumed with worry.  This finding emerged from a study within 
the context of end-of-life care (Blackhall, Frank, Murphy, & Michel, 2001) but may be 
applicable in the context of using genetic services to identify predisposition to cancer.  
Individuals who do not wish to know the truth about their risk may choose to forego 
genetic services.  Worry about whether their children or other family members are 
carriers has been a top perceived barrier to genetic testing (Thompson et al., 2002).  
Another possible emotion is guilt about passing a mutation on to children, not having the 
mutation though a family member might, or causing burden or worry to family by being 
diagnosed with a mutation (Glenn et al., 2012; Sussner et al., 2013).  Existing literature 
suggests that individuals with ethnic minority background, particularly African-American 
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and Asian backgrounds, may be more likely to experience worry.  However, this may 
vary with level of acculturation to Western attitudes and practices.   
 
Perceived consequences 
Triandis describes the value of perceived consequences as the sum of the 
products of the subjective probabilities that particular consequences will follow a 
behavior, and the values of (or affect attached to) those consequences (Triandis, 1977).  
No studies were found assessing or reporting subjective probabilities of particular 
consequences occurring.  However, some studies report percentages of participants 
who agree or strongly agree with a factor being important (Thompson et al., 2002) or 
report most frequently reported reasons (Anderson et al., 2012).  ‘Benefits to the 
family’s future’ has been among the most frequently reported reasons for receiving 
genetic counseling in multiple studies (Anderson et al., 2012; Chin et al., 2005; Glenn et 
al., 2012).  The negative consequences frequently reported are loss of privacy and 
potential discrimination.  There are no studies, however, on which of the following 
influence the use of genetic services more: positive perceived consequences or 
negative perceived consequences, and whether consequences to the self or to 
family/others are more influential.  These findings present an important gap in the 
literature which may be useful in identifying targets for interventions aiming to increase 
the use of genetic services to decrease cancer risk.  
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Intention  
The literature search did not yield studies measuring intention to use genetic 
services.  Intention has long been part of theories of behavioral change such as the 
Theory of Reasoned Action (Fishbein & Ajzen, 1975) and the Theory of Planned 
Behavior (Ajzen & Fishbein, 1980), which have been widely studied, evaluated, and 
used in predicting behavior change.  If the use of genetic services is considered a 
health behavior, theories aiming to predict the behavior (use of genetic services) should 
include intention.  Triandis has theorized that intention is derived from an individual 
considering 1) social factors, 2) affect or emotions at the thought of engaging in the 
behavior, and 3) perceived consequences (Triandis, 1977).  However, the relationship 
of these three factors with actual intention has not been studied in the context of using 
genetic services. 
 
Facilitating conditions 
Perhaps the largest amount of literature regarding the use of genetic services is 
on facilitating conditions.  According to Triandis, facilitating conditions enable an 
individual to follow through with a desire to engage in a behavior.  Regardless of the 
habits or intention to engage in a behavior, the facilitating conditions must be present 
and sufficient.  Provider recommendation has been cited as one of the most consistent 
predictors of genetic counseling (Anderson et al., 2012) and genetic testing (McCarthy 
et al., 2013; Marc D. Schwartz et al., 2005). A recent large, population-based study 
aimed at evaluating rates and predictors of physician recommendation for BRCA1/2 
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testing among patients with breast cancer found the correlation between provider 
recommendation and undergoing testing to be greater than .9 (McCarthy et al., 2013). 
Over 80% of women who reported receiving a provider recommendation had testing, 
while fewer than 6% of those not receiving a recommendation went ahead to pursue 
testing.  Individuals with limited access to a knowledgeable healthcare provider or 
extensive network of individuals with personal experience may be at a disadvantage 
when it comes to receiving appropriate recommendations.  Individuals living in medically 
underserved areas, by definition, have more limited access to healthcare providers 
(http://www.hrsa.gov/shortage/mua/).  Therefore, they may be less likely to receive a 
provider recommendation and less likely to use genetic services.  However, no studies 
in this review of the literature explored the relationship between individuals living in 
medically underserved areas and receiving a recommendation from their provider for 
genetic services, and subsequently whether the individuals went on to get genetic 
services.  Additionally, no studies are known to have explored the relationship between 
the existence of facilities providing genetic services, proximity of these facilities to 
residence, and use of genetic services.  Little is known about the presence or absence 
of facilities offering genetic services in medically underserved areas. 
Having received a referral for genetic counseling, perceived risk, availability of 
transportation and childcare, and social support have been described as facilitators 
(Anderson et al., 2012; Chin et al., 2005; Sussner et al., 2013); while lack of knowledge 
about genetic services and next steps, and being too busy or viewing other things as 
being more important, have been reported as barriers (Anderson et al., 2012; Chin et 
al., 2005; Glenn et al., 2012).  Each of these can be considered a facilitating condition; 
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variables reported in the literature as facilitators can also be thought of as having been 
identified as present and sufficient by the study participants, while the the absence or 
shortage of the same variables were reported as barriers.   
Knowledge about how to navigate the health care system may be another 
facilitating condition.  Among a sample of Arab-American women where some 
participants were recent immigrants, use of genetic services was negatively influenced 
by difficulty navigating the system (Mellon, Gauthier, Cichon, Hammad, & Simon, 2013).  
Insufficient knowledge of how to navigate the system may be a barrier for others who 
lack experience with it.  The medically underserved, for example, who may have 
insufficient knowledge about or experience with navigating the system, may find that it is 
a barrier also, especially with more specialized health care services such as genetic 
counseling or genetic testing.  The experience of medically underserved in this respect 
is lacking in the literature.  
Characteristics of the healthcare system can be facilitators or barriers in the use 
of genetic services.  For example, the availability of female physicians may influence 
women who have strong beliefs related to modesty during physical exams and other 
interactions (Mellon et al., 2013).  Concerns about insurance coverage and cost of 
counseling and testing have been frequently reported in the literature as a barrier 
(Anderson et al, 2012; Glenn et al., 2012).  Having a clinic close to home, having a clinic 
with flexible hours, and the provision of services by phone have also been reported to 
facilitate use of genetic counseling (Anderson et al., 2012).  It is plausible that having a 
clinic close to home, or proximity to a clinic that provides these services may facilitate 
use of genetic services.  However, other factors may be necessary or increase the 
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ability of proximity to influence use of genetic services.  For example, living within 
walking distance to a clinic may be helpful but without financial resources, lack of 
perceived risk, or provider recommendation, the proximity to the clinic may be 
insignificant.  In that case, flexible hours and availability of services by phone may be 
irrelevant as well.  Whether the availability of clinics providing genetic services close to 
home would make a significant difference and what factors may work synergistically 
with that remains largely unexplored.  However, some researchers have cited the 
potential for genetic counseling via telephone to increase reach and access, and to 
maximize cost savings (Kinney et al., 2014; M. D. Schwartz et al., 2014).  Noninferiority 
trials of telephone counseling compared to usual care in the context of genetic 
counseling and testing for BRCA1/2 mutation have found telephone counseling to be 
noninferior to usual (in-person) counseling.  Both studies found lower uptake of genetic 
testing with groups receiving telephone counseling.  The difference was not statistically 
significant, but approximately 10% (95% CI = 3.9% to 16.3%).  
Another interesting finding from one of the studies (Kinney et al., 2014) was that 
uptake of testing was higher among rural participants compared with urban participants.  
Although not statistically significant, the authors of the study believe that this suggests 
that rural participants – for whom geography may be a barrier – may have genetic 
screening interests that are underserved by existing health care systems.  Individuals 
living in federally designated medically underserved areas (MUAs) may experience 
similar barriers and a similar increased uptake of genetic counseling and testing when 
the opportunity to receive the services is made more readily available.  Because there 
are a variety of ways to define rural, using residence in an MUA as a study variable may 
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more comprehensively capture underserved individuals for whom interventions can be 
aimed.  
Having family that is supportive and helpful can facilitate the use of genetic risk 
assessment and counseling among those who wish to do so (Mellon et al., 2013).  
Individuals who were married were more interested in BRCA testing (Schwartz et al., 
2001) but the reason behind this is unclear.  Conversely, lack of social support, for 
example by family members or cultural beliefs may influence an individual to not use 
genetic services (Sussner et al., 2013).   
Important limitations of the studies above are small sample sizes and lack of 
multiple similar studies to corroborate the findings.  The findings of the single study with 
an Arab-American sample described above demonstrates how cultural beliefs that are 
different from the majority can be a barrier.  In the context of using genetic services, 
there were no other studies that support these findings among another Arab-American 
sample.  Studies with Hispanic women also show culturally-related factors that influence 
use of genetic services, but again, these are few in number.  The opportunity for 
individuals or groups to benefit from the value of genetic services cannot be deferred 
until they become better represented in the literature, however.  One approach to 
explore differences in behavior related to deep-seated influences such as culture, may 
be through a lens of individualist and collectivist cultures.   
Nations with more individualist traits are developed, wealthy, have more 
economic development, have modern industry, urbanization, and greater social mobility.  
Nations that show more collectivist traits are underdeveloped, poor, have less economic 
development, are more agricultural, and have less social mobility (Triandis, 1977).  
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Triandis’s extensive study of the influence of culture and cross-cultural psychology led 
to recognition of differences in aspects of the self and social behavior among individuals 
from individualist compared to collectivist cultures (Triandis, 1977).  The variable of 
living in a medically underserved area may provide a similar lens through which 
differences in the use of genetic services may be examined.  Designation as a medically 
underserved area (MUA) by the federal government includes consideration of demand 
for and access to primary care, infant mortality rate for a specified area, and prevalence 
of poverty in an area (http://www.hrsa.gov/shortage/mua/).  Medically underserved 
areas, which have higher demand and lower access to primary care, higher infant 
mortality rates, and higher poverty, can be compared to the traits of collectivist nations.  
Areas that are not medically underserved may be comparable to individualist nations 
which, related of greater wealth and being more developed, may offer better access to 
primary care, lower infant mortality rates, and lower poverty.  
 
Habits 
According to Triandis, habits stem from behaviors that occur with certain 
frequency and can be identified by assessing the number of times the individual has 
committed the behavior in the past.  By this definition, genetic services would need to 
have been used more than once.  Repeat testing may be useful for individuals who 
received a result indicating a variant of unknown significance (VUS), for which ongoing 
scientific developments may lead to reclassification of the VUS as deleterious or 
pathogenic.  Reclassification may have implications for clinical management 
recommendations such as surveillance with mammography or risk-reducing surgeries 
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(G. F. Schwartz et al., 2009).  However, there were no studies that discussed use of 
genetic services as a habit.  A related question is whether individuals who engage in 
health maintenance behaviors such as recommended screenings, may be more likely to 
use genetic services.  For example, a predisposition to use health services was found to 
be associated with higher likelihood of breast cancer screening behaviors (Katapodi, 
Pierce, & Facione, 2010).  A limitation of the study reporting this was that there were a 
limited number of participants over age 40 and therefore eligible to receive a 
recommendation for breast cancer screening.  Examining the relationship may be more 
informative with a sample who is high-risk, for whom screening is indicated, and for 
whom screening could be a health-maintenance behavior.    
Lack of a personal and family history of using health services can result in little 
knowledge about one’s health history.  Some feel ill-equipped for using genetic services 
which would involve assessment of personal and family past medical history and 
therefore may defer doing so (Glenn et al., 2012).  These findings are limited by the few 
number of studies and small sample sizes, and the relationship between use of health 
services in general, and cancer screening or risk assessment services requires further 
investigation.  Future studies may identify approaches for system-related interventions 
to facilitate use of health services in the context of genetic services.   
 
Background factors 
 The USPSTF put forth a recommendation statement for BRCA-related risk 
assessment (U.S. Preventive Services Task Force, 2013).  Contained in that 
recommendation statement is a referral screening tool wherein personal and family 
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history of breast and ovarian cancer are assessed (from (Bellcross, Lemke, Pape, Tess, 
& Meisner, 2009).  Individuals indicating yes to two or more items should receive a 
referral for genetic counseling and, if indicated after counseling, genetic testing.  The 
tool asks about breast cancer at 50 years or ovarian cancer at any age among self, 
mother, sister, daughter, mother’s side grandmother, aunt, father’s side grandmother, 
aunt, 2 cases of breast cancer after age 50 years on the same side of the family, male 
breast cancer at any age in any relative, and Jewish ancestry.  Some other professional 
organizations that have put forth guidelines for referral to genetic counseling are the 
American College of Medical Genetics and Genomics (ACMG) and National Society of 
Genetic Counselors (NSGC), National Comprehensive Cancer Network (NCCN), 
American Society of Clinical Oncology (ASCO), The American College of Obstetricians 
and Gyncologists (ACOG), American Cancer Society (ACS).  The USPSTF guidelines 
are based on a comprehensive systematic review of literature by content experts 
following a protocol consistent with the Agency for Healthcare Research and Quality 
(AHRQ) methods for systematic reviews, and posted for public comment for 4 weeks.  
The process described in the statement put forth by the USPSTF seems to be of 
sufficient rigor.  Therefore, the criteria listed in the referral tool described above will also 
be used in data analyses to be described further below for this proposed study. 
 
Summary 
This review of the literature shows a significant amount of the literature is on 
facilitating conditions.  Study findings are largely limited by small sample sizes and lack 
of a large number of studies that are comparable in participant characteristics and study 
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focus.  Despite the number of studies exploring various facilitating conditions, there is 
still a lack of understanding of what factors – and in what combination – predict use of 
these services.  One observation that emerged from the review of the literature is that 
women with ethnic minority backgrounds are more likely to refuse genetic services than 
are non-Hispanic white women, for a variety of reasons.  The reasons include: having 
competing demands; having perceived role expectations that are incompatible with 
undergoing genetic services and associated physical exams and clinic visits; concerns 
about stigma from positive results; concerns about inadequate knowledge related to 
lack of family history from not using health care previously, unfamiliarity with navigating 
the health care system, or discomfort with aspects of the system (e.g., preferring a 
female provider, distrust due to racially-related reasons).  Although these reasons for 
not using genetic services comes from women with ethnic minority backgrounds, they 
may not be limited to or always true for women with an ethnic minority background.  
From a broader perspective, there seems to be a theme of requiring the support or 
approval of a community, whether that is the spouse, family, community where one lives 
and works, and/or compatibility with broader ethnic/cultural beliefs.  This resembles 
beliefs of collectivist cultures.  Therefore, studying medically underserved samples (who 
share characteristics of collectivist cultures as described earlier) may inform about a 
focus for interventions aimed at individuals who do not use genetic services but who 
could benefit from them.   
A few existing studies have reported findings from samples of women who 
received a diagnosis of breast cancer at age younger than age 50 (Cragun et al., 2015; 
Levy et al., 2011).  These individuals met multiple guidelines that recommend genetic 
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counseling at a minimum, then genetic testing if applicable, yet still showed low uptake 
of genetic counseling (approximately 30-36%).  This population – women diagnosed 
with breast cancer at age younger than 50 – may be an ideal population to study 
because they have an identified risk factor that hints at the possibility of having a 
mutation that substantially increases risk for multiple and recurrent cancers.  
Furthermore, there appears to be consensus from professionals based on research and 
clinical experience that genetic services could be beneficial for them.  However, this 
population is rather small; researchers must be careful not to burden the individuals 
belonging to this group with numerous requests for participation in research.  Attempts 
should be made to obtain as much knowledge as possible from existing data.  This 
proposal outlines the use of existing data on a population-based sample of young breast 
cancer survivors (diagnosed at younger than 50 years old) to understand more about 
the barriers and facilitators to using genetic services.  Figure 2.2 on the following page 
shows the Triandis framework modified to include the specific variables that will be 
evaluated in this study. 
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Figure 2.2.  Triandis framework with specific variables to be evaluated in this study 
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CHAPTER III 
Methods 
Studies on predictors of using genetic services (either genetic counseling or 
genetic testing) are few in number, demonstrate incongruent findings, and have small or 
convenience samples, therefore, more research is needed on what predicts the use of 
genetic services.  Understanding the experience around genetic services use in young 
breast cancer survivors may be particularly informative because women diagnosed with 
breast cancer before the age of 50 represent a group that is at high risk and could 
benefit from genetic services, as early diagnosis is one indicator of a potential BRCA1/2 
mutation.  Young survivors and their relatives may benefit the most from using genetic 
services and gaining knowledge about their risk (i.e., genetic predisposition to cancer). 
The proposed study will be a secondary analysis of existing data from women who 
received a diagnosis of breast cancer before the age of 50 (also known as a young 
breast cancer survivor, or YBCS).  The outcomes will contribute to understanding about 
this important, yet scarce population.   
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The specific aims of this study are:  
1.  Evaluate whether genetic counseling use differs between medically underserved 
versus medically served.  For this study, medically underserved is defined as 
resident of a HRSA designated medically underserved area (MUA) in Michigan. 
a. Hypothesis:  YBCS who are from medically underserved areas will have 
reported less frequent genetic counseling use compared to YBCS who are 
not from medically underserved areas. 
2. Identify the correlates of using genetic counseling for hereditary breast and 
ovarian cancer risk among the medically underserved YBCS versus not 
medically underserved YBCS.   
a. It is hypothesized that among the medically underserved segment of 
YBCS from this sample, using genetic counseling will be most strongly 
correlated with social factors (perceived expectations of relatives, 
motivation to comply with perceived expectations of relatives), perceived 
consequences (perceived negative consequences to family), and 
facilitating conditions (provider referral, insurance or ability to pay, family 
support, distance from facility offering genetic counseling), and habits 
(history of using health services).  
b. It is hypothesized that among the YBCS who are not medically 
underserved, using genetic counseling will be most strongly correlated 
with perceived consequences (perceived positive consequences to self, 
perceived negative consequences to self), habits (history of using health 
services), intention (intention to use genetic counseling).  
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3. Evaluate the ability of the Triandis model to explain the use of genetic counseling 
overall (based on data from the entire sample of YBCS) and for medically 
underserved YBCS.  
a. It is hypothesized that for the entire sample of YBCS, facilitating 
conditions, perceived consequences, habits, and intention, will explain the 
use of genetic counseling the most, i.e., account for a high percentage of 
variance for the outcome of genetic counseling.  It is hypothesized that for 
the medically underserved YBCS, the addition of social factors will further 
increase variance explained for the outcome of genetic counseling.   
 
Expected outcomes generated by this study will improve understanding about 
barriers and facilitators to using genetic counseling, in particular among individuals who 
have a risk factor for carrying a BRCA1/2 mutation but did not use genetic counseling.  
The outcomes may inform potential targets for interventions aimed at increasing the use 
of genetic services among the underserved population, who may face unique and less 
understood barriers to using genetic services.  This goal is consistent with the genetics 
objective of Healthy People 2020 – to increase the population of women with a family 
history of breast and ovarian cancer who receive genetic counseling.  
 
Study overview 
The proposed study will be a secondary analysis of data from a completed study 
on an intervention to increase breast cancer screening among young breast cancer 
survivors and their high-risk female relatives.  The secondary analysis will use data from 
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the baseline surveys of young breast cancer survivors only.  This group are established 
to be at high risk for having a genetic predisposition to cancer given their breast cancer 
diagnosis at age younger than 50 and genetic services are indicated for them.  The 
purpose of this study is to gain an understanding of genetic services use among young 
breast cancer survivors (YBCS) who are at high-risk for having a heritable genetic 
predisposition to cancer and identify whether differences exist in genetic services use 
among YBCS living in a medically underserved area versus YBCS not living in 
medically underserved area. 
 
Data source 
The completed study on which the proposed secondary analysis will be done 
was chosen for its large sample of YBCS.  The identification and recruitment of 
individuals using the Michigan Cancer Surveillance Program (MCSP) cancer registry 
allowed for a population-based sample, reducing the potential for bias from including 
only individuals who have access to centers conducting this type of research.   
 
Sample 
Participants for the completed study were identified and recruited from the 
Michigan Cancer Surveillance Program (MCSP), a central cancer registry for in situ and 
invasive malignancies.  From approximately 9,000 cases of young women diagnosed 
with cancer in situ or invasive breast cancer between 20 to 45 years old from 1994 to 
2008, a sample of 3,000 women were randomly selected; deceased YBCS were 
excluded.  A total of 859 YBCS completed baseline surveys with 100-120 women (11.6-
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14%) reporting having used genetic services (either genetic counseling or genetic 
testing).  To increase inclusion of minority and underserved women, the sample was 
stratified by race and oversampled YBCS who are black and living in counties with the 
highest mortality rates for young women with breast cancer.  
 
Inclusion criteria 
The proposed study will explore only data from the YBCS from the original study.  
Participants had to be female, age 25-64 years old, diagnosed with unilateral or bilateral 
invasive breast cancer between 20 and 45 years old or diagnosed with unilateral or 
bilateral ductal carcinoma in situ between 20 and 45 years old, Michigan resident at 
time of diagnosis, and able to read and understand English. 
 
Exclusion criteria 
Women who were pregnant, incarcerated, or institutionalized at the time of the 
study were excluded because they may not have been able to follow recommendations 
for breast cancer screening and genetic counseling.  Relatives of participants in the 
original study will be excluded from the proposed study because they may not have 
known about their increased risk of being a BRCA1/2 mutation carrier prior to the study.  
Therefore, they may not have had adequate time to use genetic services. 
 
Variable determination 
The operationalization of the variables to be examined is described in Table 2 
below.  The variable “medically underserved,” shown in Figure 2 under Background 
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Factors was not measured in the original study.  However, medically underserved 
groups may face additional barriers to using genetic services and experience disparities 
in health and health outcomes as a result.  Because a long-term goal of this program of 
research is to develop interventions to improve health disparities related to health 
behaviors that will decrease cancer risk, including among traditionally underserved 
groups, extra effort was made to create a medically underserved variable to be included 
in analyses.   
To guide the creation of a medically underserved variable for this proposed 
study, a search of the literature was conducted on how the term “medically 
underserved” is defined in studies on the use of genetic services.  A search on PubMed 
yielded zero results and the search was therefore expanded with keywords “medically 
underserved” and “healthcare utilization.”   Limits were: publications from the past 5 
years and printed in English.  This yielded a total of 139 results.  Fifty-six articles were 
excluded because they either reported on studies conducted outside of the United 
States (n = 32 articles) (Afridi, 2013; Arya & Agarwal, 2011; Austin et al., 2014; Ban, 
Karki, Shrestha, & Hodgins, 2012; Blumenthal et al., 2013; Canada, 2013; Eskandari et 
al., 2013; Fagan, Cannon, & Crouch, 2013; Frey et al., 2013; Haile, Ololo, & Megersa, 
2014; Haque, Louis, Phalkey, & Sauerborn, 2014; Harrison & Britt, 2011; Hasselback et 
al., 2014; Hirayama et al., 2013; Holloway, Mathai, Gray, & Community-Based 
Surveillance of Antimicrobial Use and Resistance in Resource-Constrained Settings 
Project Group, 2011; Hurune, O’Shea, Maguire, & Hewagama, 2013; Kalter et al., 2011; 
Karari et al., 2011; Khanal, Sauer, & Zhao, 2013; Kuo, Loresto, Rounds, & Goodwin, 
2013; Martiniuk et al., 2011; Mitton, Dionne, Masucci, Wong, & Law, 2011; Mohammed, 
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Elnour, Mohammed, Ahmed, & Abdelfattah, 2011; Na, Kim, & Lee, 2014; Qumseya et 
al., 2014; Sangeda et al., 2014; Timony, Gauthier, Hogenbirk, & Wenghofer, 2013; 
Turner, Mulholland, & Taylor, 2011; van Roosmalen & Meguid, 2014; Whitehead et al., 
2012; Wong, Heng, Cheah, & Tan, 2012; Wood, Vial, Martinez-Gutierrez, Mason, & 
Puschel, 2013), did not give a definition (a few of these articles were brief commentaries 
or policy briefs) (n = 18) (Aksu, Phillips, & Shaefer, 2013; Genz et al., 2015; Jha, Orav, 
& Epstein, 2011; Lalude, Gutarra, Pollono, Lee, & Tarwater, 2014; Little, Motohara, 
Miyazaki, Arato, & Fetters, 2013; Runkle, Zhang, Karmaus, Martin, & Svendsen, 2012;) 
(Allen, 2011; Casamassimo, 2014; Delzell, 2013; Frellick, 2011; Merchant, 2011; 
Raduege, 2012; Sahota, 2014; Sprague, 2014; Waldman & Perlman, 2014; Weigel et 
al., 2015; Xiong et al., 2015); No authors listed (132), or the articles were not obtainable 
through the University’s electronic library (n = 5 ) (Diringer & Phipps, 2012; Hawk, 2011; 
Rivera-Colón et al., 2013; Sederstrom, 2015; Tanner, Kim, Friedman, Foster, & 
Bergeron, 2015).  One article (Chi, Momany, Jones, & Damiano, 2011) was excluded 
because the focus involved intellectual or developmental disability which may have 
involved additional barriers.   
Eighty-two articles provided a definition of medically underserved in the study 
being reported.  The majority of articles (n=45) defined medically underserved using 
multiple factors (Arvey, Fernandez, LaRue, & Bartholomew, 2012; Bazargan, Chi, & 
Milgrom, 2010; Beazoglou, Lazar, Guay, Heffley, & Bailit, 2012; Bocker, Glasser, 
Nielsen, & Weidenbacher-Hoper, 2012; Chodosh et al., 2015; Dodd, Logan, Brown, 
Calderon, & Catalanotto, 2014; Dragun, Huang, Gupta, Crew, & Tucker, 2012; Dumont, 
Brockmann, Dickman, Alexander, & Rich, 2012; Enard & Ganelin, 2013; Engelman et 
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al., 2011; Glassman, Harrington, Namakian, & Subar, 2012; Golbeck et al., 2011; Harris 
et al., 2011; Heffernan et al., 2011; Jerkins, Zarzaur, & Fabian, 2013; Kapoor & Thorn, 
2014; Klein et al., 2013; Langellier, Guernsey de Zapien, Rosales, Ingram, & Carvajal, 
2014; Larkey et al., 2012; LeMasters et al., 2014; Lobb et al., 2011; Lustria, Smith, & 
Hinnant, 2011; Lynch et al., 2014; McCullough, Zimmerman, Bell, & Rodriguez, 2014; 
Northington et al., 2011; Ogbuanu et al., 2012; Ogunwale et al., 2015; Onoye et al., 
2013; Pieh-Holder, Callahan, & Young, 2012; Purnell et al., 2012; Remler et al., 2011; 
Rustveld et al., 2013; Sadowski, Devlin, & Hussain, 2011; Samantaray et al., 2011; 
Samuel, King, Adetosoye, Samy, & Furukawa, 2013; Shaw, Vivian, Orzech, Torres, & 
Armin, 2012; Snyder & Milbrath, 2013; Summerfelt, 2011; Valencia, Savage, & Ades, 
2011; Vlahov, Bond, Jones, & Ompad, 2012; Wallack, Loafman, & Sorensen, 2012; 
Wells et al., 2013; Whitley, Main, McGloin, & Hanratty, 2011; Xierali, Phillips, Green, 
Bazemore, & Puffer, 2013; Ziller, Lenardson, & Coburn, 2012).  Factors used included 
being under- or uninsured, “low-income” (not further specified), ethnic minority, 
receiving care at a community health center, safety net facility, public hospital, small 
practice, or federally qualified health care center (FQHC), living in a health professional 
shortage area (HPSA), living in an area with a shortage of particular specialist (e.g., 
surgeon, dentist, behavioral health providers, etc.), living in a particular state or region, 
living in a rural area, living in a geographic isolated area (specified in some cases as 
living in Appalachia, number of miles from residence to a health care center or 
metropolitan center, and other times not specified at all), being a migrant or resort 
worker, homeless, and having limited access to care.  Articles differed in number and 
type of factors used and there was no discernible pattern in choice.  
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The second largest group of articles (n=36) defined medically underserved using 
single criterion.  The criterion included: being uninsured/underinsured without 
parameters (n=6) (Chi & Leroux, 2012; Hwang, Liao, Griffin, & Foley, 2012; Kamimura, 
Christensen, Mo, Ashby, & Reel, 2014; Montealegre et al., 2015; Notaro et al., 2012; 
Schiefelbein, Olson, & Moxham, 2014); “economically disadvantaged,” parameters not 
defined (n=1) (Franklin et al., 2014); enrolled in Medicaid (n=1) (Chi & Raklios, 2012); 
received care through a “safety net program” (n=1) (Bailit & D’Adamo, 2012); live in a 
specified urban area (n=1) (Handy et al., 2013); live in an urban community with poor 
health status and high emergency department use (n=1) (Song, Hill, Bennet, Vavasis, & 
Oriol, 2013); total distance travelled to reach the healthcare center (n=1) (Pfeiffer et al., 
2011); availability of providers (e.g., supply of subspecialists per county or radius of 
specific number of miles) (n=2) (Grindlay, Lane, & Grossman, 2013; Ray, Bogen, 
Bertolet, Forrest, & Mehrotra, 2014); live in a state with incidence and mortality for 
particular condition that is higher than the national rate (n=1) (Greene et al., 2012);  live 
in a geographically isolated or remote area (specifically, Appalachia) (n=2) (Head, 
Vanderpool, & Mills, 2013; Wilson, Kratzke, & Hoxmeier, 2012); live in a “rural” area 
with no parameters defined (n=1) (Siminerio, Ruppert, Huber, & Toledo, 2014); live in a 
rural area defined by federally established Rural Urban Commuting Area Codes (RUCA 
Codes) (http://www.ers.usda.gov/data-products/rural-urban-commuting-area-
codes.aspx) (n=3) (Doescher, Andrilla, Skillman, Morgan, & Kaplan, 2014; Gruca, Nam, 
& Tracy, 2014; Keenum et al., 2013); ethnic/racial minority without supporting rationale 
(n=2) (Christopher Gibbons, 2011; Roman et al., 2014); ethnic/racial minority with 
supporting rationale such as incidence, mortality, lower rates of screening than non-
  
53 
Hispanic Whites (n=1) (Holt et al., 2013), ethnic/racial minority with the rationale of 
minority group having disproportionately higher mortality versus White women (n=1) 
(Ochoa-Frongia, Thompson, Lewis-Kelly, Deans-McFarlane, & Jandorf, 2012).  One 
article defined medically underserved as living in a health professional shortage area 
(HPSA) (Brown et al., 2011).  Seven articles defined medically underserved as receiving 
care at a federally qualified health center (FQHC) (Benkert et al., 2014; Connolly & 
Crosby, 2014; Hanson, West, Thackeray, Barnes, & Downey, 2014; Hoffman et al., 
2015; Olayiwola, Sobieraj, Kulowski, St Hilaire, & Huang, 2011; Walker, Clarke, Ryan, & 
Brown, 2011; Young et al., 2012), and four articles defined medically underserved as 
receiving care in an area federally designated as a medically underserved area (a.k.a. 
“MUA”) (Coughlin, Kushman, Copeland, & Wilson, 2013; Holt et al., 2013; Ogbuanu, 
Goodman, Kahn, Long, et al., 2012; Zach, Dalrymple, Rogers, & Williver-Farr, 2012).  
The results of this review of recent literature on healthcare utilization among the 
medically underserved show a lack of consensus around the definition of the term 
“medically underserved” and that a minority of studies use a definition consistent with 
any established definition.  One established definition that relates to the medically 
underserved has been developed by HRSA.  HRSA designates an area as an MUA 
based on a set of measures collectively termed the Index of Medical Underservice, or 
IMU.  The IMU consists of four variables:  1) ratio of primary care medical care 
physicians per 1,000 population, 2) infant mortality rate for a service area or for the 
county or subcounty area which includes it, 3) percentage of the population with 
incomes below the poverty level, and 4) percentage of the population age 65 or older 
(http://www.hrsa.gov/shortage/mua/). Because FQHCs must be in MUAs, the articles 
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defining medically underserved in terms of FQHCs and MUAs, if considered together, 
total 11 articles that could be considered to use the HRSA definition and is the most 
frequently used definition. The index score provided by the IMU seems to 
comprehensively capture medically underserved groups and provides a clear and 
measurable definition that can facilitate identification of groups.  The ability to 
comprehensively capture the medically underserved is important for exploring whether 
being part of a medically underserved population (via living in a medically underserved 
area) plays a role in the use of genetic services.  Having a medically underserved 
variable defined in this way will allow for exploration about whether the underserved are 
more or less likely to use genetic services than those who are not considered 
underserved, and then to identify variables that the underserved and not underserved 
have in common along with differences in the variables between the underserved and 
not underserved.  This information will help identify ways that interventions can facilitate 
use of genetic services among those for whom genetic services are appropriate yet may 
be unattainable due to unknown variables.  
The distinction as medically underserved or not medically underserved, as 
discussed in the beginning of Chapter 2 (along with discussion of Triandis’s theory), is 
serving as a proxy for the concepts of collectivism and individualism, respectively.  No 
published studies have thus far been identified as taking this approach.  However, one 
study with a medically underserved population did report the importance and preference 
for programs or interventions with collectivist underpinnings (Lana Sue Ka’opua & 
Anngela, 2005).  These findings were used in the development of a breast cancer 
screening intervention for native Hawaiian women (L. S. Ka’opua, 2008).  Studies 
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reporting the importance of considering collectivist and individualist ideologies in 
understanding behavior and designing interventions have specifically obtained 
participants belonging to groups who are at risk for being medically underserved (e.g., 
Mexican immigrants) (Sampson, Kim Witte, Kelly Morrison, 2001).   One article 
discussed the importance of considering collectivist and individualist values in 
understanding behavior and designing interventions for women whose individual cultural 
background are incongruent with that of the majority, or the culture of the larger society 
in which they live (Haj-Yahia & Sadan, 2008).  The authors explore the challenges of 
addressing abuse in women with collectivist backgrounds yet living in an individualist 
context and being treated according to individualist norms and ideologies.  The authors 
of the article state that their discussion does not refer only to remote cultures, but rather 
“to collectivist communities that exist within and alongside individualist cultures”.  The 
findings of the studies above highlight the importance of considering collectivist and 
individualist traits and ideologies in understanding behavior, preferences, and designing 
interventions.  The choice of the medically underserved or groups at risk for being 
medically underserved to represent collectivist cultures in some of the studies above 
lends support for hypothesizing a link between medically underserved areas and 
collectivist traits.   
Another variable that will require development is distance to genetics services.  
The website for the National Society of Genetic Counselors 
(http://nsgc.org/p/cm/ld/fid=164) offers the ability to search for genetic counselors by 
state or within up to a 50-mile radius of a zip code.  Search results list work setting.  
These workplaces will be contacted and asked to verify that genetic counseling and/or 
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genetic testing were offered at the facility in 2012-2013 when the parent study was 
open.  Distance will be calculated from participants’ zip codes to the zip codes to the 
facilities.  The minimum and maximum distances from YBCS zip code to facility zip code 
will be used in analyses.  Number of facilities within a 50-mile radius will also be 
reported.  The search results from the NSCG website will only list members of the 
NSGC, therefore facilities employing only genetic counselors who are not members of 
the NSGC may be missed.  To account for this, other websites will be searched and 
contacted in the same manner as above to verify whether genetic counseling and/or 
testing were provided in 2012-2013.  These websites are: the American College of 
Medical Genetics 
(https://www.acmg.net/ACMG/Find_Genetic_Services/ACMG/ISGweb/FindaGeneticSer
vice.aspx?hkey=720856ab-a827-42fb-a788-b618b15079f9), Myriad 
(https://ms360.myriad.com/patient-resources/find-a-provider/), the National Cancer 
Institute (http://www.cancer.gov/about-cancer/causes-prevention/genetics/directory), 
and GeneTests (https://www.genetests.org/clinics/?region=usa).   
Variables to be controlled for:  age, ethnicity, race, insurance, whether participant 
was adopted, and male relative with breast cancer.  If the number of participants who 
report being adopted and having a male relative with breast cancer are very low, these 
will be dropped from the model.  Age will be controlled for because the inclusion criteria 
of YBCS may mean a larger number of younger women.  Race and ethnicity will be 
controlled for because the findings of the literature review discussed above suggests 
that women with an ethnic minority background are less likely to use genetic services 
than are women of a non-Hispanic White background.  Having insurance will be 
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controlled for because lack of insurance or ability to pay has been frequently reported to 
be a barrier and has been found to be a predictor of not using genetic services.  
Whether a participant was adopted will also be controlled for.  Lack of family history has 
discouraged use of genetic services.  Although the evidence behind this is limited, it is a 
plausible confounding factor.   Finally, having a male relative with breast cancer will also 
be controlled for as this is very rare and a red flag for carrying a BRCA1/2 mutation. 
 
Power analysis 
  Post hoc power analyses were conducted since this was a secondary data analysis.  
Effect size is hypothesized to be small (d=0.2).  No reports of effect size were found 
among studies on increasing the use of genetic counseling or genetic testing.  The 
effect size is hypothesized to be small due to persistently low rates of BRCA1/2 
mutation testing, approximately 30-36% (Levy et al., 2011; Cragun et al., 2015).  Using 
a small effect size will err on the conservative side.  This is preferable to using a larger 
effect size in calculating sample size, which may lead to underpowered findings.  
G*Power was used post hoc to calculate the approximate power obtained.  
 
Data analysis    
Data analysis will begin with examination of data for missing data, outliers, and 
other abnormalities that could affect statistical procedures.  Descriptive statistics of each 
independent variable and dependent variable will be done first for the entire sample of 
YBCS.  Descriptive statistics of each variable will then be further analyzed by group with 
medically underserved defined as YBCS living in a federally designated medically 
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underserved area (MUA) and medically served defined as YBCS not living in an MUA.  
The HRSA website http://datawarehouse.hrsa.gov/tools/analyzers/muafind.aspx will be 
used to determine whether participants’ residential zip code is designated as being in a 
medically underserved area.   
 
Aim 1: Evaluating whether genetic counseling use differs between medically 
underserved and medically served.   
The outcome variable, genetic counseling, will be dichotomous, treated as 
categorical.  For this level of measurement, test of proportions will be used to 
evaluate whether there is a significant difference in genetic counseling between 
medically underserved and medically served.  Significance level will be set at 
p=.05.  This calculation will be done using SPSS v.24.   
 
Aim 2: Identifying the correlates of using genetic counseling for hereditary breast and 
ovarian cancer risk among the medically underserved versus medically served in this 
sample of YBCS.   
Point-biserial correlation coefficients will be determined for all of the independent 
variables in Table 2.2 and the outcomes of genetic counseling.  Point-biserial 
correlations are selected because the independent variables are quantitative and 
the dependent variable is dichotomous.  
 
Aim 3:  Explore the ability of the Triandis model in explaining the use of genetic 
services.   
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First, univariate logistic regression will be done with each independent variable 
being regressed on the dependent variable, genetic counseling.  Variables with 
p-value < 0.10 (according to convention) will be candidates for a first 
multivariable model.  The variables will be examined critically for clinical or 
practical importance.  Variance inflation factors (VIF) will be checked as an 
indicator of multicollinearity. 
 
Next, model building will be done by conducting a series of logistic regressions.  
Regressions will confirm relationships between theoretical constructs.  Variables will be 
added to regression equations according to construct groups of the Triandis theory.  For 
example, variables under the Facilitating Conditions construct with p-value < 0.10 
(established above) will be regressed on the variable(s) under the Habits construct.  
(For simplicity, “variables under the x construct” will hereafter be indicated as “X”.)  
Habits will be regressed on Behavior, and Facilitating Conditions will also be regressed 
on Behavior.  Significance will be set at p<0.05.   
A regression with the background factors being controlled for will serve as a base 
model.  Background factors found to be significant will be included in subsequent 
models.  Next, Habits and Background Factors will be regressed on Behavior (genetic 
counseling).  This will be compared with Intention and Background Factors regressed 
on Behavior.  See below for more examples. 
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Model0: Behavior = Constant only 
Model1: Behavior = Background Factors  
Model2: Behavior = Background Factors + Social factors + Affect + Perceived 
Consequences 
Model3: Behavior = Background Factors + Social factors + Affect + Perceived 
Consequences + Facilitating conditions 
Model4: Behavior = Background Factors + Social factors + Affect + Perceived 
Consequences + Facilitating conditions + Intention 
Model5: Behavior = Background Factors + Social factors + Affect + Perceived 
Consequences + Facilitating conditions + Intention + Habits 
Model6: Behavior = Statistically significant variables from Model 3 (determined most 
parsimonious) + Intention + Habits  
Model7: Behavior = Background Factors + Social factors + Affect + Perceived 
Consequences + Facilitating Conditions + Habits 
 
 
The above models are only a few examples of the regressions that will be done.  
Model performance will be evaluated using multiple fit measures:  Omnibus test of 
model coefficients, -2 Log Likelihood values, pseudo R2 values from Cox & Snell R2 and 
Nagelkerke R2, and classification accuracy.  Model fit will be evaluated by likelihood 
ratio test and receiver operating characteristic (ROC) curve values.  The model showing 
greater area under the ROC curve will indicate the better model. Improvements in the -2 
Log likelihood values, pseudo R2s, and classification will be used to determine the most 
parsimonious yet accurate model.   
Triandis’s theory suggests a directional flow or path of relationships (i.e., Social 
Factors, Affect, and Perceived Consequences leading to Intention; then, Intention 
leading to Behavior).  These and other paths and relationships between constructs will 
be evaluated with Structural Equation Modeling.  One example of why doing SEM will 
be useful is in the following:  Triandis’s theory states that behaviors that are performed 
rather frequently come to require little thinking.  In these instances, habits are more 
likely to predict the behavior than is intention.  However, when the behavior is not one 
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that is performed frequently, more thought is likely to be required, and intention 
becomes more important in predicting behavior.  Findings of the SEM may be helpful in 
understanding the relationships of these and other constructs in the context of using 
genetic counseling among this sample of young breast cancer survivors. 
Expected outcomes and next steps 
This study will contribute to understanding use of genetic services among a high-
risk sample from medically underserved areas.  Because the original study oversampled 
for blacks living in counties with the highest mortality rates for young women with breast 
cancer, findings are expected to contribute to knowledge about use of genetic services 
among two currently underrepresented groups in research on the topic: one or more 
ethnic minority groups and perhaps a segment of the rural population in Michigan.   
 
Strengths and limitations 
A strength of this proposed study is that it will contribute to multiple knowledge 
gaps in the literature.  It will contribute to knowledge about barriers and facilitators of 
YBCS in medically underserved areas versus YBCS in areas not defined as medically 
underserved.  Discrepancies exist in the current literature regarding predictors of using 
genetic services, and only few studies contribute knowledge about 1) rural and other 
underrepresented populations, and 2) the perspectives of YBCS, who have been 
diagnosed with breast cancer between the ages of 20 and 45, for whom genetic 
services are indicated but underutilized.  Secondly, this study uses the HRSA definition 
of medically underserved area to define medically underserved groups.  The HRSA 
designation of an MUA seems to more comprehensively capture medically underserved 
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groups rather than choosing rural or urban setting, poverty level, race/ethnicity, or 
insurance type alone or in some combination.  Furthermore, using the HRSA 
designation of MUA provides a clear and measurable definition that can facilitate 
identification of groups in further research.  Because the proposed study is a secondary 
analysis, findings may present an area for further, prospective studies in the future.    
Another strength of this study is the use of a centralized state cancer registry for 
the identification and recruitment of study participants.  This is favorable because it 
allows for a population-based sample and minimizes bias resulting from including only 
individuals who have access to centers conducting this type of research.  This study 
may serve as a model for the use of other cancer registry databases to explore the 
same questions among geographically different samples, enabling stronger conclusions 
to be drawn.  This knowledge can be used toward developing intervention studies to 
increase the use of genetic services among those at high risk for an inherited 
predisposition to cancer who may be interested in using genetic services but face 
additional or unique barriers as a result of living in medically underserved areas.   
Several limitations of the proposed study are related to the nature of a secondary 
analysis.  First, the data being analyzed are only from the baseline surveys and 
therefore are cross-sectional data.  Prospective studies would be needed to verify any 
conclusions and additional hypotheses drawn from the proposed study.  Additionally, 
because the original study was not designed with the specific aims of the proposed 
study, the secondary analysis will be using data obtained with measures that may not 
be optimal for the questions being asked in the proposed study.  However, given the 
limited numbers of YBCS and keeping in mind the burden on these individuals resulting 
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from multiple requests for participation in research, using existing data to gain further 
knowledge about the group and develop hypotheses should be considered.  Another 
limitation of the proposed study is that a different theoretical framework was used to 
develop and design the original study.  Therefore, some of the concepts are not exactly 
the same as those in the proposed study, some variables were measured differently, 
and some of the variables of interest for the proposed study were not in the original 
study (and therefore had to be omitted).  However, the concepts are similar and related.  
Triandis’s theory of interpersonal behavior may show greater potential for predicting 
behavior in the context of using genetic services.  Findings from this study may present 
a different perspective and new insights for further exploration.  An additional limitation 
of the proposed study which is that the data are from participants only from the state of 
Michigan and therefore findings may be generalizable only to the Michigan population.  
However, lessons learned from conducting the secondary analysis may be applied to 
exploring the same questions in other states.
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Table 3.2   Table of Triandis concepts, variables, and measures 
Triandis 
concepts 
Variables, from 
lit. rev. 
Specific variable-measure, from dataset Calculated score Level of 
measurement 
Rationale for 
using measure 
Dependent variable 
Behavior 1) Use of 
genetic 
counseling or 
genetic testing 
Variable from dataset: Current screening practices. 
Instrument: Behavioral risk factors surveillance system.  
Q114.  Have you ever had cancer genetic services?  (No, Yes, 
Don’t know) 
Q118.  Have you ever had genetic testing for a gene mutation 
connected to breast or ovarian cancer?  (No, Yes → Age: __ yrs 
old, Don’t know) 
Q114 
2=Yes=1 
1,3=No=0 
 
Q118 
2=Yes=1 
1,3=No=0 
Dichotomous Measures 
engagement in 
behavior of interest 
Independent variables 
Social 
factors 
1)  Perceived 
expectations 
from family  
2)  Perceived 
expectations 
from healthcare 
provider 
Variable from dataset: Perceived family expectations about breast 
cancer screening. 
Instrument: (developed from Ajzen and Fischbein: Understanding 
attitudes and predicting behavior; 1980). 
Q155.  Do you believe that your relatives want you to get 
mammograms and other tests to find cancer at an early stage?  
(Definitely no=1, No=2, Somewhat no=3, Neutral=4, Somewhat 
yes=5, Yes=6, Definitely yes=7) 
 
Q156.  Do you believe that your doctor or other healthcare provider 
wants you to get mammograms and other tests to find cancer at an 
early stage? (Definitely no=1, No=2, Somewhat no=3, Neutral=4, 
Somewhat yes=5, Yes=6, Definitely yes=7)  
Q155  
As marked (for 
greater sensitivity) 
 
Q156 
As marked (for 
greater sensitivity) 
Ordinal  
 
 
Triandis defines 
social factors as 
influential factors 
derived from the 
relationship 
between the 
person and other 
people.  
Relationships with 
relatives and/or 
healthcare 
provider can be 
considered  social 
factors.   
 
Analyze items 
separately since 
one does not 
necessarily 
influence or is the 
same as the other  
1)  Motivation to 
comply with 
expectations of 
family 
2) Motivation to 
Variable from dataset: Motivation to comply with family members’ 
expectations 
Instrument: 
(developed from Ajzen and Fischbein: Understanding attitudes and 
predicting behavior; 1980). 
Q157 
As marked (for 
greater sensitivity) 
 
Q158 
Ordinal  
 
 
 
 
Literature suggests 
motivation to 
comply with 
expectations as 
predictor in some 
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comply with 
expectations of 
healthcare 
provider 
Q157.  How often do you try to do what your relatives want you to 
do about finding cancer at an early stage?  (Never=1, Almost 
never=2, Sometimes=3, Neutral=4, Most times=5, Almost 
always=6, Always=7) 
 
Q158.  How often do you try to do what your doctor or other 
healthcare provider wants you to do about finding cancer at an 
early stage? (Never=1, Almost never=2, Sometimes=3, Neutral=4, 
Most times=5, Almost always=6, Always=7) 
As marked (for 
greater sensitivity) 
 
 
groups (e.g., 
Hispanic).  Include 
this variable to 
explore 
relationship further 
among this sample 
Affect      
1)  Worry Variable from dataset:  NA 
Instrument: 
Q118d:  (Q118: Have you ever had genetic testing for a gene 
mutation connected to breast or ovarian cancer?)  If no, please tell 
us why you have not had genetic testing (check all that apply):   
 
No one ever suggested it; The genetic counselor told me it was not 
the right test for me; Issues with medical insurance coverage (no 
coverage, too high cost out-of-pocket); I am worried the result 
could be used against me (by employer, health insurance); I would 
rather not know if I have a mutation connected to cancer; 
Family members would not want me to go; Family members might 
be upset with test results; Cultural and/or religious beliefs do not 
support genetic testing; I did not know that genetic testing existed; 
A healthcare provider told me not to have the test; Other – please 
explain. 
If Q118=No 
 
Q118d    
5=Yes=1 
1,2,3,4,6,7,8,9,10=N
o=0 
 
Dichotomous In literature, “rather 
not know” has 
been discussed in 
context of worry   
     
Perceived 
consequenc
es 
1)  Perceived 
consequences 
to self 
- Positiv
e 
 
Variable from dataset:  NA 
Instrument: 
Q118b: (Q118:  Have you ever had genetic testing for a gene 
mutation connected to breast or ovarian cancer?)  If you had 
genetic testing, what helped you decide to have testing (check all 
that apply): 
 
I wanted to know if I have a mutation connected to cancer; I 
wanted to learn more about my future cancer risk; Results 
may change my cancer treatment (preventive surgery, 
chemotherapy, etc.); I already know someone in my family who 
has a mutation connected to cancer; Results will benefit my family; 
Using cancer genetic services seemed very important; Family 
members wanted me to; My healthcare provider suggested that I 
If Q118=Yes, 
 
Q118b     
2 or 3=Yes=1 
1, 4, 5, 6, 7, 8, 9, 10, 
11, 12, 13, 14, 
15=No=0 
 
Dichotomous I wanted to learn 
more about my 
future cancer 
risk; Results may 
change my 
cancer treatment 
(preventive 
surgery, 
chemotherapy, 
etc.) are perceived 
positive 
consequences to 
oneself.  These 
have been 
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do; The clinic was close to home; I have available transportation; I 
have available child care; I was able to obtain these services by 
phone; My medical insurance covered the visit; My medical 
insurance covered the cost of the test; Other – please explain 
associated with 
use of genetic 
services in existing 
literature. 
- Negativ
e 
Variable from dataset:  NA 
Instrument: 
Q118d:  If no, please tell us why you have not had genetic testing 
(check all that apply): 
 
No one ever suggested it; The genetic counselor told me it was not 
the right test for me; Issues with medical insurance coverage (no 
coverage, too high cost out-of-pocket); I am worried the result 
could be used against me (by employer, health insurance); I 
would rather not know if I have a mutation connected to cancer; 
Family members would not want me to go; Family members might 
be upset with test results; Cultural and/or religious beliefs do not 
support genetic testing; I did not know that genetic testing existed; 
A healthcare provider told me not to have the test; Other – please 
explain ___. 
If Q118=No 
 
Q118d 
4=Yes=1 
1,2,3,5,6,7,8,9,10,11
=No=0 
Dichotomous I am worried the 
result could be 
used against me 
(by employer, 
health insurance) 
is a perceived 
negative 
consequence to 
oneself.  This has 
been reported in 
existing literature 
as influencing use 
of genetic 
services. 
2)  Perceived 
consequences 
to family 
- Positiv
e 
 
Variable from dataset:  NA 
Instrument: 
From Q118b: I wanted to know if I have a mutation connected to 
cancer; I wanted to learn more about my future cancer risk; 
Results may change my cancer treatment (preventive surgery, 
chemotherapy, etc.); I already know someone in my family who 
has a mutation connected to cancer; Results will benefit my 
family; Using cancer genetic services seemed very important; 
Family members wanted me to; My healthcare provider suggested 
that I do; The clinic was close to home; I have available 
transportation; I have available child care; I was able to obtain 
these services by phone; My medical insurance covered the visit; 
My medical insurance covered the cost of the test; Other – please 
explain 
If Q118=Yes 
 
Q118b 
5=Yes=1 
1,2,3,4,6,7,8,9,10,11
,12,13,14,15=No=0 
Dichotomous Results will 
benefit my family 
is a perceived 
positive 
consequence to 
family.  This has 
been reported in 
existing literature 
as predictor of 
using genetic 
services. 
- Negativ
e 
 
Variable from dataset:  NA 
Instrument: 
From Q118d: No one ever suggested it; The genetic counselor told 
me it was not the right test for me; Issues with medical insurance 
coverage (no coverage, too high cost out-of-pocket); I am worried 
If Q118=No, go to 
Q118d 
 
Q118d 
7=Yes=1 
Dichotomous Family members 
might be upset 
with test results 
is a perceived 
negative 
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the result could be used against me (by employer, health 
insurance); I would rather not know if I have a mutation connected 
to cancer; Family members would not want me to go; Family 
members might be upset with test results; Cultural and/or 
religious beliefs do not support genetic testing; I did not know that 
genetic testing existed; A healthcare provider told me not to have 
the test; Other – please explain ___. 
1,2,3,4,5,6,7,8,9,10,
11=No=0 
consequence to 
family.  This has 
been reported in 
existing literature 
as predictor of 
using genetic 
services. 
Intention 1)  Self-reported 
intention  
Variable from dataset: Intention to pursue mammography, CBE, 
cancer genetic services (when applicable). 
Instrument: (developed from Ajzen and Fischbein: Understanding 
attitudes and predicting behavior; 1980). 
Q115: During the next 12 months, how likely are you to ask your 
healthcare provider if genetic testing for a gene connected to 
hereditary cancer is a right test for you?  (Very unlikely=1, 
Likely=2, Somewhat unlikely=3, Neutral=4, Somewhat likely=5, 
Likely=6, Very likely=7, Does not apply=NA). 
As marked. 
Range 1-7  
Ordinal This approach to 
measuring 
intention has been 
widely used and 
accepted by Ajzen 
and Fischbein in 
studies to predict 
behavior.  Keep all 
options for greater 
sensitivity of 
measure.   
Facilitating 
conditions 
1)  Provider 
referral 
Variable from dataset:  NA 
Instrument: 
Q114a: (Q114: Have you ever had cancer genetic services?)  If no, 
please tell us why you have not used cancer genetic services – 
check all that apply: 
No one ever suggested it; I am too busy; I cannot get time off 
work; My disability makes it difficult to carry out daily activities; 
Lack of transportation; Lack of child care; Clinic hours do not fit my 
schedule; Clinics are too far away; Other life issues that come up 
are more important; I am too sick from cancer treatment; Other – 
please explain. 
 
From Q118b: I wanted to know if I have a mutation connected to 
cancer; I wanted to learn more about my future cancer risk; 
Results may change my cancer treatment (preventive surgery, 
chemotherapy, etc.); I already know someone in my family who 
has a mutation connected to cancer; Results will benefit my family; 
Using cancer genetic services seemed very important; Family 
members wanted me to; My healthcare provider suggested that 
I do; The clinic was close to home; I have available transportation; 
I have available child care; I was able to obtain these services by 
phone; My medical insurance covered the visit; My medical 
insurance covered the cost of the test; Other – please explain 
If Q114=No 
 
Q114a 
1=Yes=1 
2,3,4,5,6,7,8,9,10,11
=No=0 
 
 
 
If Q118=Yes 
 
Q118b 
8=Yes=1 
1,2,3,4,5,6,7,9,10,11
,12,13,14,15=No=0 
Dichotomous No one ever 
suggested it; My 
healthcare 
provider 
suggested that I 
do.  Provider 
recommendation 
has been reported 
in existing 
literature as 
predictor of using 
genetic services.  
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2)  Perceived 
risk  
Variable from dataset: Perceived breast cancer risk. 
Instrument:  
Developed from: 
Verbal: “Rate your chances of developing breast cancer from 0–
10,” coupled with verbal anchors: 0–1 (definitely not), 2–3 
(probably not), 4–6 (50/50), 7–8 (probably will), and 9–10 
(definitely will).   
 
Numeric: ”Rate your lifetime chances of developing breast cancer 
from 0% (absolutely no chance) to 100% (definitely)” (Katapodi et 
al., 2009). PMID: 19403452 
(Cronbach’s alpha=0.9)  
*From article: The verbal scale had low sensitivity (0.37) but high 
specificity (0.93) in identifying women with very high perceived risk 
as well as high sensitivity (0.81) and specificity (0.93) in identifying 
women with very low perceived risk. The comparative scale had 
high sensitivity (0.90) and specificity (0.99) in identifying women 
with very high perceived breast cancer risk as well as high 
sensitivity (0.89) and specificity (0.91) in identifying women with 
very low perceived breast cancer risk. In the present study, internal 
consistency reliability between the two scales was high (Cronbach 
alpha = 0.78). 
 
Q153:  On a scale from 0 (Definitely Will Not) to 10 (Definitely Will), 
please circle a number that best describes what you believe is 
your chance for getting breast cancer. 
As marked. 
Range 0-10 
Ordinal This approach to 
measuring 
perceived risk has 
been used and 
found to be 
acceptable in prior 
research. (Katapodi 
et al., 2011; Katapodi, 
Dodd, Lee, & Facione, 
2009)  
 
 
3)  Knowledge Variable from dataset: Knowledge of breast cancer genetics.  
Instrument: Knowledge of breast cancer gene inheritance.  A 17-
item instrument with questions about causes of breast cancer, 
breast cancer genetics, genetic testing, and methods to reduce 
breast cancer risk (Cronbach’s alpha=0.72). (Appendix A: 
Knowledge Assessment Questionnaire.  (Wang et al., 2005).  
PMID: 15690408 
Sum correct 
answers. 
Range 0-17. 
Interval This measure has 
been used in prior 
research in similar 
context and has 
demonstrated 
reliability. 
4)  Convenience Variable from dataset:  NA 
Instrument: 
Q114a: (Q114: Have you ever had cancer genetic services?)  If no, 
please tell us why you have not used cancer genetic services – 
check all that apply: 
 
No one ever suggested it; I am too busy; I cannot get time off 
work; My disability makes it difficult to carry out daily activities; 
Lack of transportation; Lack of child care; Clinic hours do not 
Q114=No 
 
Q114a 
2,3,5,6,7,8=Yes=1 
1,4,9,10,11,12=No=
0 
 
 
 
Dichotomous These have been 
reported in 
literature as 
reasons for not 
using genetic 
services. 
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fit my schedule; Clinics are too far away; Other life issues that 
come up are more important; I am too sick from cancer treatment; 
Other – please explain. 
 
Q118b: (Q118: Have you ever had genetic testing for a gene 
mutation connected to breast or ovarian cancer?)  If you have 
genetic testing, what helped you decide to have testing (check all 
that apply):  
 
I wanted to know if I have a mutation connected to cancer; I 
wanted to learn more about my future cancer risk; Results may 
change my cancer treatment (preventive surgery, chemotherapy, 
etc.); I already know someone in my family who has a mutation 
connected to cancer; Results will benefit my family; Using cancer 
genetic services seemed very important; Family members wanted 
me to; My healthcare provider suggested that I do; The clinic was 
close to home; I have available transportation; I have available 
child care; I was able to obtain these services by phone; My 
medical insurance covered the visit; My medical insurance covered 
the cost of the test; Other – please explain 
Q118=Yes 
Q118b 
9,10,11,12=Yes=1 
1,2,3,4,5,6,7,8,13,14
,15=No=0 
 
5) Insurance or 
ability to pay for 
services 
Variable from dataset:  NA 
Instrument: 
Q118b:  (see above) 
 
I wanted to know if I have a mutation connected to cancer; I 
wanted to learn more about my future cancer risk; Results may 
change my cancer treatment (preventive surgery, chemotherapy, 
etc.); I already know someone in my family who has a mutation 
connected to cancer; Results will benefit my family; Using cancer 
genetic services seemed very important; Family members wanted 
me to; My healthcare provider suggested that I do; The clinic was 
close to home; I have available transportation; I have available 
child care; I was able to obtain these services by phone; My 
medical insurance covered the visit; My medical insurance 
covered the cost of the test; Other – please explain 
Q118=Yes 
 
Q118b 
13,14=Yes=1 
1,2,3,4,5,6,7,8,9,10,
11,12,15=No=0 
Dichotomous These have been 
reported in 
literature as 
reasons for using 
genetic services. 
6) Family 
support 
Variable from dataset: Perceived family support for breast cancer 
screening. 
Instrument: Q51-75.  
 
[cited in protocol paper:  Social support for breast cancer screening. Described 
in Katapodi et al., 2002. 
Item 1: “When I need suggestions on how to deal with a personal problem, I have 
someone I can turn to.” 
Sum of responses. 
 
25 items: 1=Never 
true; 2=Almost never 
true; 3=Seldom true; 
4=Sometimes true; 
5=Often true; 
Ordinal, being 
treated as 
interval   
This measure has 
been used in a 
prior study (Katapodi, 
Facione, Miaskowski, 
Dodd, & Waters, 2002) 
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Item 2: “If I was sick, I could easily find someone to help me with my daily work.” 
Item 3: “There is at least one person I know whose advice I really trust.” 
Item 4: “I often do not have anyone to turn to”  
Item 5: “I do not know anyone whom I can confide in”  
(Cronbach’s alpha=0.81).] 
 
6=Almost always 
true; 7=Always true. 
 
Range 25-175. 
 
7) Live in 
medically 
underserved 
area 
Variable from dataset: County/Zip code 
Instrument:  
 
 
 
 
Nominal, 
treated as 
Categorical 
 
 8) Distance from 
facility offering 
genetic services 
Variable from dataset: [to be created] 
Distance between Zip code of YBCS and Zip code of facilities 
offering genetic services within a 50-mile radius will be calculated.  
Minimum and maximum distances will be used in analyses.  
 Ratio Explore the 
following:  
1) availability of 
facilities offering 
genetic services in 
medically 
underserved 
areas, 2) possible 
effect on use of 
genetic services, 
3) whether 
residence in MUA 
helps explain use 
of genetic services 
Habits 1)  History of 
using health 
services 
 
. 
Variable from dataset: Current screening practices. 
Instrument: from Behavioral risk factors surveillance system 
Q80.  A clinical breast exam is when a doctor or nurse checks the 
breasts for lumps.  Have you ever had a clinical breast exam?  
(No, Yes, Don’t know). 
Q80a.  If yes, how often did you have a clinical breast exam over 
the past 12 months?  (Every 3-4 months, Every 6 months, Every 
12 months, It has been more than 12 months since my last clinical 
breast exam, Don’t know, Other – please explain). 
 
Q81.  A mammogram is an x-ray of each breast to look for breast 
cancer.  Have you ever had a mammogram?  (No, Yes, Don’t 
know). 
Q81a.  If yes, how often did you have a mammogram over the past 
12 months?  (Every 3-4 months, Every 6 months, Every 12 
months, It has been more than 12 months since my last 
mammogram, Don’t know, Other – please explain). 
 
Q80 
2=Yes=1 
1,3= No=0 
 
Q80a 
1,2,3=Yes=1 
4,5,6=No=0 
 
 
Q81 
2=Yes=1 
1,3,=No=0 
 
Q81a 
1,2,3=Yes=1 
4,5,6,=No=0 
 
Q82 
Dichotomous Having had any of 
these services 
creates/increases 
history of using 
health services.  
These measures 
will explore 
relationship 
between having a 
history of using 
health services 
and using genetic 
services.   
 
Analyze each 
separately since 
use of one may not 
mean use of 
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Q82.  A breast MRI, or magnetic resonance image, involves lying 
on your stomach on a bed that moves into a tunnel-shaped 
machine.  You may have an IV during the procedure, and images 
of your breasts are taken.  Have you ever had a breast MRI?  (No, 
Yes, Don’t know). 
Q82a.  If yes, how many breast MRIs have you had over the past 
12 months? (Every 3-4 months, Every 6 months, Every 12 months, 
It has been more than 12 months since my last breast MRI, Don’t 
know, Other – please explain). 
1,2,3,4=Yes=1 
 
5,6=No=0 
another. 
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CHAPTER IV 
Results of specific aim 1:  Use of Genetic Counseling for Hereditary Breast 
Cancer in the United States: An Integrative Review 
The results of aim 1 are described in this first manuscript.  
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INTRODUCTION 
Cancer imposes a significant burden on individuals, their families, and to society 
because of economic impact, premature death, and disability. Mutations in the breast 
cancer genes, BRCA1 and BRCA2, are two of a few clinically actionable mutations 
where identification of risk alters recommendations to prevent or treat disease. A 
mutation in the BRCA1 or BRCA2 gene translates to a significantly higher risk of 
developing breast and other cancers compared to the general population 1. For a 
woman with a BRCA1 mutation, the risk of developing breast cancer can be four to five 
times higher than the risk for a woman who does not carry the mutation 2,3. Mutation 
carriers also have an increased risk for cancers in the ovary, prostate, and pancreas, 
and have a higher chance that their breast cancer is “triple negative” 4. Triple negative 
breast cancers lack the three main hormone receptors that the most effective therapies 
for breast cancer target and therefore generally have a poorer prognosis 5. Individuals 
with mutations in the BRCA1/2 genes tend to develop cancer at younger than 50 years 
of age, when cancer is less expected and surveillance is less likely to be occurring. 
Furthermore, small families and paternal inheritance can reduce suspicion of risk for 
carrying a mutation 6.  
Engaging in preventive strategies can reduce morbidity and mortality, but the 
benefits may be greatest before cancer occurs. There is limited evidence for the 
effectiveness of lifestyle modification at this time 7. Observational studies have found 
that risk-reducing bilateral mastectomy reduced diagnoses of breast cancer among 
high-risk women and women with BRCA mutations by 85 to 100%8–10. However, risk-
reducing surgery can be considered an aggressive strategy due to physical 
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complications and psychosocial sequelae11.  An individual’s risk should therefore be 
assessed properly and risk management strategies tailored to the appropriate 
individuals. Population screening for BRCA1/2 mutations, though currently 
controversial, is on the horizon with some prominent leaders in the field advocating for it 
12. Implementing population screening could overwhelm limited resources such as 
genetic counselors and genetic testing facilities, as well as increase morbidity from 
surveillance (e.g., mammography) false positives, morbidity from prophylactic surgeries, 
and unfavorable sequelae of other risk-reducing strategies. National guidelines 13,14 and 
several professional groups 15–17 recommend genetic counseling for individuals with 
certain risk factors. Predictive genetic testing can determine whether an individual has 
an increased risk of developing a disease prior to experiencing any symptoms. Effective 
use of genetic services has the potential to minimize onset of cancer, in some cases 
multiple cancers or particularly aggressive cancers, and the physiological, emotional, 
and financial burden of treatment could be reduced substantially. However, among 
individuals for whom genetic counseling is indicated, based on widely accepted national 
guidelines 13,14, rates of counseling use are often below 50% 18–21.  Counseling use can 
have a multitude of implications, including ability to notify family members, increased 
frequency and/or intensity of screening, prophylactic drug therapy, prophylactic 
surgeries.  Alternatively, individuals could do nothing if that is their preference.  The 
decision on action to take, however, should be based on a solid understanding of 
potential benefits and risks.  
 There is evidence of potential disparities in who engages in genetic services.  In 
many studies of predictors of genetic counseling use, participants are largely non-
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Hispanic White, college educated, insured individuals with higher household income. 
These studies report non-Hispanic White women being more likely than women of other 
races or ethnicities to receive referral for genetic counseling or testing 18,22 and being 
more aware or informed about the BRCA genes and mutation testing 23,24.  While cancer 
genetics carries a potential to improve health outcomes, it also carries the potential for 
widening health disparities. Recently, studies are focusing on subgroups that have been 
traditionally underrepresented in genetics and genomics research, including ethnic 
minorities, residents of rural areas, low-income, and uninsured individuals. Predictors of 
uptake of genetic counseling are not well understood among more widely studied 
groups and may be even less well understood among groups traditionally 
underrepresented in research.  
The purpose of this literature review is to explore factors predicting the use of 
genetic services, both testing and counseling. Uptake of genetic counseling for a 
heritable mutation associated with a substantial risk for cancer is multi-faceted and can 
involve influences from and implications on interpersonal relationships. A model of 
interpersonal behavior 25 which considers the complex interplay of human cognition, 
emotion, social influences, and physical or structural barriers in predicting behavior was 
used as a guiding conceptual framework for this review.  
 
CONCEPTUAL FRAMEWORK 
The Triandis model of interpersonal behavior 
Triandis has done extensive work leading to the establishment of cross-cultural 
psychology as a discipline 26,27. His work on how culture affects the way people think, 
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feel, and act may be helpful in the context of understanding the use of genetic 
counseling, for which the effect of culture is poorly understood. Culture has been 
defined as “the ideas, customs, and social behavior of a particular people or society.” 28 
Culture is often associated with race or ethnicity. However, a culture can exist among 
other group classifications such as geographic location. Triandis’s theory allows for 
various ways that the influences of culture can manifest. Figure 4.1 shows how the 
concepts of Triandis’s theory may be related to the area of genetic counseling use.   
Triandis’s model includes several aspects of what the literature suggests may be 
associated with use of genetic counseling.  Constructs range from background factors 
which are primarily sociodemographic factors such as age, race, income, and 
education, to those with a cognitive aspect such as perceived consequences, to 
emotions such as worry.  There is also a time component in the constructs of habit 
(past) and intention (future).  Furthermore, variables can span from individual level, 
interpersonal, or broader societal.  Whether factors are at the individual, interpersonal, 
or broader societal level may be less important, however, as they may be intertwined 
and separation may be unrealistic.  Culture may affect behavior on an individual level, 
interpersonal level, and societal level.  For the purpose of identifying an area of focus 
for facilitating use of genetic counseling, the way that concepts are organized may be 
helpful. 
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Figure 4.1. Conceptual framework developed from Triandis model of interpersonal 
behavior25 
 
 
METHODS 
A review of the literature was conducted in PubMed (includes Medline), Scopus, 
and CINAHL and included the key terms genetic testing, genetic counseling, intention, 
BRCA, decision making, psychology, social support, and health knowledge, attitudes 
and practice. Both genetic testing and genetic counseling were used because 
counseling may not necessarily precede testing and testing may not necessarily follow 
counseling. However, important lessons may be learned from the literature in both 
cases. Decision making, psychology, social support, health knowledge, and attitudes 
were chosen to retrieve studies on the cognitive aspect of determining a preference to 
use genetic testing and genetic counseling. Practice was included to retrieve studies on 
the actual uptake of services. The search using this combination of terms produced 
results with the highest relevance to the aim of this review. Reports of the link between 
Background 
factors
Habits
Affect
Consequences
Facilitating 
conditions
Social 
factors
Intention
Use of 
genetic 
counseling
  
 
 
101 
the BRCA genes and increased predisposition to breast, ovarian, and other cancers 
were reported in the late 1990s 29,30, therefore articles published between 2000 and 
2017 were included.  Abstracts were reviewed for applicability. Articles were chosen if 
they examined factors that influenced the use of genetic testing or genetic counseling 
for hereditary breast cancer. Because genetic tests for other syndromes with hereditary 
links to breast cancer such as Cowden’s syndrome and Li-Fraumeni syndrome are not 
as well established, results were limited to articles on BRCA1/2 mutations. Studies 
conducted outside of the United States were excluded due to differences in procedures 
for using genetic services. Some related articles from search results were included. 
Both qualitative and quantitative studies were included.  
The findings of the review are summarized in Table 4.1. Table 4.1 is organized 
by the constructs of the Triandis model (social factors, affect, perceived consequences, 
facilitating conditions, habits, and intention) in the left column, and variables associated 
with use of genetic counseling or testing reported in the literature in the right column. 
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Social factors 
Triandis theorized that intention to engage in a behavior results from three 
concepts: social factors, affect or emotion associated with the behavior, and perceived 
value of consequences. Social factors are derived from the relationship between a 
person and other people 25. In the context of genetic counseling for a BRCA1/2 
mutation, social factors in the literature have shown a more negative influence on using 
genetic counseling than a positive one.  
Some of the reasons for not using counseling are related to religious or cultural 
beliefs. For example, some women of Arabic background will allow only female 
healthcare providers to do physical examinations. In one qualitative study Arab 
American women reported that cultural beliefs about modesty can discourage them 
from undergoing examinations performed by a predominantly male physician workforce 
31. This potentially precludes them from obtaining clinical information often obtained 
prior to genetic counseling. More than one study, including another qualitative study, 
reported Latino cultural beliefs and expectations about prioritizing care of the family over 
care of oneself 32,33. Genetic counseling would be considered a personal need and 
therefore deferred when faced with family responsibilities. These studies, each 
consisting of participants with a single, specific ethnic minority background, tended to be 
qualitative with small sample sizes. A strength of the studies is the qualitative design 
which yielded rich information -- valuable when little is known about a topic. However, 
the ability to generalize the findings is limited by the number of participants in each 
study.  
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Individuals of African American 33,34 and Ashkenazi Jewish 35–37 backgrounds 
have reported concerns about stigma of having a mutation, potential discrimination 
resulting from a breach in privacy, and shame related to perceiving a mutation as a flaw. 
The association with having a mutation can affect close interpersonal relationships as 
well as the broader perception of the ethnic group as a whole. These concerns are 
important given the atrocities committed against the groups historically – the eugenics 
movement and forced sterilization in America, and the Holocaust in Germany. Some 
members of the Ashkenazi Jewish community value the increased awareness and 
higher likelihood of referral to appropriate services. For some, the potential benefits of 
testing could outweigh the negative effects of discrimination.  However, some members 
of the Ashkenazi Jewish community have expressed concern about stigma and 
discrimination resulting from studies highlighting their increased risk 35,36, with some 
believing that the recent focus on the Ashkenazi Jewish community is “giving the world 
the impression that we have all the bad genes” (Rabbi M. Tendler in 36). For fear of 
being associated with a group that “carries bad genes” or implications of inbreeding, 
individuals from other communities that also have founder mutations may be 
discouraged from disclosing important family history and other relevant risk factors to 
healthcare providers or from seeking other necessary support. Consequently, they 
lessen their chances of managing an increased risk appropriately.  
Concerns about stigma have been found in small, qualitative studies 33, and also 
in slightly larger quantitative 34 and population-based studies 35. In the slightly larger 
quantitative study of African American women, approximately 20% of the sample of 80 
participants declined genetic counseling and also reported concerns about stigma as a 
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reason for not using counseling. In this study, counseling was offered without cost and 
counseling sessions were conducted by an African American genetic counselor. The 
population-based study with participants of Ashkenazi Jewish ancestry was slightly 
larger with a sample of 200 participants. The proportion of individuals reporting 
concerns about stigma in this study was 5%. This was a minority of the sample but 
nonetheless deserves recognition as it may be an underlying concern among others.  
Because of the genetic and social link with each other, family members can be 
influential in the decision to get genetic counseling and/or testing. In a study of high-risk 
women who received a diagnosis of cancer at younger than 50 years of age – 
suggestive of risk for carrying a predisposing mutation -- benefitting the family’s future 
was reported as a top reason for getting genetic counseling. This was a moderately-
sized population-based study of women considered high-risk and for whom genetic 
counseling is indicated. Using genetic testing to obtain information about children’s risk 
was associated with increased interest among another moderately-sized population-
based sample. This was a sample of 200 Ashkenazi Jewish women 35, also considered 
at increased risk due to their ancestry.   
The motivation for using genetic counseling or testing to benefit the family may 
be altruistic, but this may not always be the case. Completion of genetic counseling at 
the request of family has been reported by a small portion of high-risk participants 20. It 
is unclear, however, whether the request was made to benefit the study participant, or 
whether the request was made in order to help identify risk for other family members.  
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Affect 
Affect, the emotions that a person feels at the thought of using genetic services, 
likely plays a role in whether individuals use genetic services.  The emotions can vary 
widely, ranging from relief and empowerment in knowing and having the ability to act, to 
shame, anger, fear, and distress. Existing literature related to affect is largely on 
emotions related to anticipated consequences to the self, but literature on emotions 
related to consequences to family is also noteworthy.  
Positive emotions associated with getting genetic counseling and testing included 
feeling relief from a negative result (not having a mutation) 34. However, although 
knowing the truth or receiving a diagnosis would make some feel empowered with the 
opportunity to then take actions to potentially affect their outcome, to others, the truth 
may be disabling if they were to become consumed with worry. This finding came from 
a relatively large survey of individuals from four different ethnic groups followed by more 
in-depth qualitative interviews of a small fraction of the sample found differences in 
telling the truth about a diagnosis of cancer and prognosis 38. Participants of European-
American and African-American backgrounds tended to prefer to know, reporting that it 
would be distressing not to know. Korean-American and Mexican-American participants, 
however, felt it would be distressing to know that one had been diagnosed with cancer 
and the prognosis, and one would feel pain in knowing. This study presented a 
hypothetical scenario about cancer in general but its findings may apply in the context of 
possibly having a mutation associated with cancer. The findings of the study are 
somewhat limited by the involvement of only older adults and the smaller sample size of 
the qualitative portion. However, medical anthropologists who were of the same ethnic 
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background were available and could conduct the in-depth interviews in the participant’s 
language of choice.  This suggests that special efforts were made to increase comfort 
level and elicit genuine, in-depth responses from participants. Moreover, responses 
viewed as atypical were explored further to obtain additional insight into diversity within 
groups. 
Other studies’ findings have supported the underlying role of culture in the 
emotions associated with genetic counseling and genetic testing. Among studies with 
Latinas 32,39, a sense of guilt or selfishness was reported if they were to get genetic 
counseling. Getting genetic counseling would be putting their health ahead of the needs 
of their families. Found among Caucasians, another type of guilt termed “survivor guilt” 
has been found among noncarriers of a BRCA mutation in families where there is a 
carrier 40. Among Asians, when it came to genetic testing, some Asians reported 
discomfort with Western preventive medicine as a potential discouraging factor, finding 
it too foreign and dissimilar to their traditional practices 33. Distress from learning that 
one carries a cancer-predisposing mutation has also been reported from a relatively 
large qualitative study of Ashkenazi Jewish women 37. Knowledge about influential 
factors among understudied populations such as ethnic minorities is increasing but the 
knowledge is still in its early development. At this stage, the studies are few and often 
qualitative, generally with smaller sample sizes. No strict conclusions can be made 
about beliefs of ethnic groups since there is potential for within-group diversity but it is 
important for clinicians to understand that preferences may vary by ethnic group even in 
emotional response. Literature may provide some general idea but it will still be 
important to assess anticipated emotions on an individual basis.  
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Perceived consequences 
 Triandis describes the value of perceived consequences as the sum of the products 
of the subjective probabilities that particular consequences will follow a behavior, and 
the value of (affect attached to) those consequences 25. Perceived consequences of 
genetic counseling and genetic testing ranged from anticipated consequences to the 
self and family to science and society at large. Several perceived or anticipated positive 
as well as negative consequences (hereafter referred to as perceived positive or 
negative consequences) have been reported (shown in Table 4.1).  
Along with the many positive consequences identified by individuals for 
themselves, positive consequences for family members are considered as well 20,23,35,39. 
The positive consequences perceived by individuals for the family are likely highly 
valued. Positive consequences to family has been reported as the most frequently 
reported20 or primary reason 39 for getting genetic counseling. In one study, 87% of 
participants would be willing to undergo BRCA testing for the sole purpose of helping 
their family 23; another study reported mean score of 8.5 for value of obtaining 
information about children’s risk (scale of 1 to 10 where 10 indicates ‘extremely 
valuable’) 35. The ability to contribute to science and society has also been reported 33,35 
but how highly this is valued and extent to which it motivates use of genetic counseling 
or testing was not discussed.  
 Perceived negative consequences have been reported by individuals as well, such 
as possible depression 33, anger or potential hopelessness and despair 34, shame 33, 
stigmatization and discrimination 31,33–35. Negative consequences related to concerns 
about privacy and potential discrimination are a concern for both individuals and their 
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family members and seems to be important or have a high value for some 33–36. 
Perceived negative consequences were similar, whether with respect to consequences 
to the individual or to family members. These concerns were reported in studies on 
genetic counseling alone 20,39, genetic testing alone 23,33,35, and counseling and testing 
together 34.   
Similar perceived positive consequences have been reported by multiple groups 
of different racial and ethnic backgrounds. For example, benefitting family has been 
reported by samples that are largely non-Hispanic White 20,23,35, Ashkenazi Jewish 35, 
Hispanic 39, and African American 34. Some differences by race or ethnicity were found 
in the anticipated potential negative consequences. However, sample sizes were not 
sufficiently large or diverse to allow for any conclusions at this time. 
 
Facilitating conditions 
 Perhaps the largest amount of literature regarding the use of genetic services is on 
facilitating conditions. According to Triandis, facilitating conditions enable an individual 
to follow through with a desire to engage in a behavior. Regardless of the habits and 
intention to engage in a behavior, the facilitating conditions must be present and 
sufficient. The facilitating conditions for using genetic services can be categorized into 
personal, interpersonal, and societal areas.  
Personal 
Individual factors such as the availability of transportation and childcare, 
perceived risk, and having received a referral for genetic counseling have been 
described as facilitators 20,32; whereas lack of knowledge about genetic services and 
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next steps, and being too busy or viewing other things as being more important, have 
been reported as barriers 20,33. The factors listed as facilitators can just as likely be 
barriers. Breast cancer genetics knowledge, for example, has been significantly and 
positively associated with genetic counseling and testing in a sample of ethnic minority 
breast/ovarian cancer survivors considered at risk for hereditary breast cancer 41. If a 
factor aligns with the individual’s desire to use genetic services or enables the individual 
to use services, it is considered a facilitator. If the factor does not align with the 
individual’s desire to use genetic services or if the factor is not present, the factor is 
considered a barrier. Individuals who were married were more interested in BRCA 42 
testing but the reason behind this is unclear. This finding was from a moderately sized 
study with a family history suggestive of hereditary breast cancer. From a large multisite 
randomized controlled trial of high-risk women, having a spouse or partner has been 
suggested as possibly creating a conducive environment for BRCA1/2 testing and 
subsequent decision-making about risk-management strategies if genetic counseling is 
received 43. 
Interpersonal 
Having family that is supportive and helpful can facilitate the use of genetic risk 
assessment and counseling among those who wish to do so. In a study exploring the 
knowledge, attitudes and beliefs of Arab-American women regarding inherited cancer 
risk, many of the women reported family support, especially from the husband, after a 
cancer diagnosis 31. Some anecdotal experiences were shared by the women that 
illustrated family support and several women mentioned the importance of getting 
friends and family involved in discussions about cancer and inherited risk. The study 
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was a qualitative focus group, with a small sample size. The sample was community-
based, recruited from a community center of one region with a high concentration of 
Arab Americans, through a trusted worker at the center. Participants had a personal or 
family history of breast cancer. No restrictions were placed with family members 
participating in the focus groups and there was no mention how many participants were 
relatives. A group of related individuals reporting on their experience could bias reported 
experiences to seem more prevalent among the sample. However, the perspective of a 
group which is so underrepresented in the literature is still important for understanding 
and as groundwork to build upon. 
Related family support may be the concept of family hardiness. Family hardiness 
is a measure of family resiliency, which is defined as cohesion and ability to cope with 
adverse events 44. Family hardiness has been positively associated with genetic testing 
in a moderately sized sample of family dyads recruited from hereditary cancer genetics 
clinics at a large comprehensive cancer center 45.  
Structural 
Lack of familiarity with the healthcare system presents a barrier that can be 
difficult to overcome, especially among underserved groups. Recent immigrants may 
lack experience with or knowledge about the healthcare system and may also have 
language barriers or cultural differences. Lacking insurance or sufficient income also 
present barriers. As described earlier, Asians reported in one study a discomfort or lack 
of familiarity with Western preventive medicine and genetic testing for the prevention of 
disease was a foreign concept 33. Compounding this problem is the lack of ethnic and 
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cultural diversity among genetic specialists.  Reports of efforts being made by the 
healthcare system to reach individuals facing these barriers are lacking in the literature. 
The literature reports some ways that healthcare providers can be facilitators or 
present barriers to using genetic services. Provider recommendation has been cited as 
one of the most consistent predictors of genetic counseling 20 and genetic testing 42,46. A 
recent large, population-based study aimed at evaluating rates and predictors of 
physician recommendation for BRCA1/2 testing among patients with breast cancer 
found the correlation between provider recommendation and undergoing testing to be 
greater than .9 46. Over 80% of women who reported receiving a provider 
recommendation had testing, while fewer than 6% of those not receiving a 
recommendation went ahead to pursue testing. The same study suggests that a 
significant percentage of women at high risk of carrying a BRCA1/2 mutation may not 
receive a recommendation for testing from their provider. Women aged 51 years to 64 
years had >5 times the odds of not receiving a recommendation, even though the study 
criteria based on current guidelines identified them as high-risk. Provider knowledge of 
cancer genetics 18,47,48, knowledge of genetic testing for BRCA1/2 mutations 24, and 
comfort level with cancer genetics risk assessment 49,50 were identified as facilitators to 
genetic counseling or testing. Lack of recommendation or discussion by the provider 
18,51, provider lack of knowledge or confidence 52, lack of follow-up on discussion about 
genetic testing 53, and being told by a provider not to go20 were associated with not 
using genetic counseling. 
 Individuals without access to a knowledgeable healthcare provider or extensive 
network of individuals with personal experience may be at a disadvantage when it 
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comes to receiving appropriate recommendations. This vulnerability can be significant 
given what seems to be the current state of knowledge and practices among healthcare 
providers in the area of genetic services. A systematic review of the literature on the 
integration of genetic/genomic knowledge into clinical practice 54 found the most 
consistent barrier to be the “self-assessed inadequacy of the primary care workforce to 
deliver genetic services.” The most important and consistent finding was that the 
primary care workforce, which will be at the front lines of the integration of genomics 
into the regular practice of medicine, “feels woefully underprepared to do so.” More 
recent studies continue to report lack of knowledge among providers in the appropriate 
identification of high-risk individuals, screening, testing, test result interpretation 47, 
interpretation of risk and referral to genetic counseling 55. These studies have the 
strengths of large sample sizes, a national sample, or looking at practices at high-
volume, internationally renowned medical centers.  
Characteristics of the healthcare system can also be facilitators or barriers in the 
use of genetic services. Insurance coverage, having a clinic close to home, having a 
clinic with flexible hours, and the provision of services by phone have been reported to 
facilitate use of genetic counseling 20. These same factors can be barriers when they 
are not present or available to those who wish to use genetic services. Concerns about 
insurance coverage and cost of counseling and testing have been frequently reported in 
the literature as a barrier 20,33. These concerns will likely remain uncertain for the next 
several years while healthcare reforms are made. It will be important to assess the use 
of genetic services with the policy changes that theoretically increase access to these 
services. The psychological and emotional effects resulting from an inability to act on 
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knowledge gained from genetic testing may be more harmful than helpful. This is a gap 
in the literature and in policy.   
In order to meet a need among those who find the cost of genetic testing to be 
prohibitive or otherwise inaccessible, a market has developed that provides genetic 
testing direct-to-consumer (DTC).  DTC testing for BRCA mutations have evolved and 
garnered attention for some time.  Although direct-to-consumer advertising is felt by 
some to be helpful as a means of providing information, study participants still preferred 
to have the professional input and personalized guidance of their provider when 
deciding to undergo testing 56.   
 
Habits 
 According to Triandis, habits can contribute to the likelihood of a behavior 
occurring. Habits stem from behaviors that occur with certain frequency and can be 
identified by assessing the number of times the individual has committed the behavior in 
the past. Although improvements in the predictive ability of genetic testing technologies 
may attract some individuals who have previously undergone genetic testing to get 
tested again, genetic testing for a hereditary condition is unlikely to occur frequently 
enough to be considered habitual. One study found a predisposition to use health 
services to be associated with higher likelihood of breast cancer screening behaviors 57. 
The participants were not necessarily at increased risk for having a cancer-predisposing 
mutation. However, it was a moderately sized, community-based, culturally diverse 
sample. The relationship between use of health services in general and use of genetic 
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services more specifically is unclear. Table 4.1 shows very few studies related to this 
topic.  
In one qualitative study with an ethnically diverse sample, the sparse 
understanding of one’s health history resulting from the lack of using health services 
was reported by some individuals to make them feel inadequate, lacking information to 
share with their provider 33. A benefit of its qualitative design, this study provided insight 
into cultural factors and perceived barriers to testing among underrepresented ethnic 
groups not well-documented in the literature. The study was not limited to women 
eligible for genetic testing per se, but focused on participants with a history of breast or 
ovarian cancer or were first degree relatives of survivors. It is possible that a 
predisposition to use health services may translate to a higher likelihood of using 
genetic services but this relationship needs further investigation.  
 
Intention  
Triandis defines intention as “the cognitive antecedent of a behavior“ 25.  He 
posits that intention is a product of social factors, affect, and perceived consequences. 
Few recent studies, within the past ten to fifteen years, have identified intention to 
pursue genetic counseling or testing as a specific outcome. A recent study of women in 
the general population recruited through a large multispecialty clinic in one urban area, 
found the following to be significantly associated with intention: awareness of genetic 
testing, cancer worry, insurance coverage of testing cost, and just wanting to know 
whether she possessed a mutation in the BRCA1/2 gene 58. In another study, with a 
sample whose risk was considered to be moderate to high, factors significantly 
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associated with intention to undergo testing in a regression model were more specific to 
personal risk:  number of relatives with a history of breast and/or ovarian cancer and 
perceived risk of having a BRCA1/2 mutation 59. Although belief in the benefits of testing 
was high over limitations and risks, intention defined as a response of “would definitely 
get tested” was reported by only a small fraction of the sample -- 30%. The findings of 
this study suggest a disconnect between belief in benefits and intention. This was a 
small sample of African American women recruited through a variety of approaches 
(i.e., provider referral from a large health system and community clinics, health fairs, 
support groups, and newspaper ads). 
 
LIMITATIONS 
This review was limited to studies examining factors that influence the use of 
genetic counseling or genetic testing related to a BRCA1 or BRCA2 mutation. Articles 
may have been missed if they were indexed with key words that are different from the 
ones described in the search strategy of the Methods section above or did not have any 
key words for indexing. The search strategy used for this review did include ‘intention’ 
initially, along with ‘BRCA’. ‘BRCA’ was used rather than ‘hereditary breast cancer’ in 
order to filter out articles on genetic counseling or testing related to Cowden’s 
syndrome, Li-Fraumeni syndrome, and other conditions related to hereditary breast 
cancer. However, ‘hereditary breast cancer’ was added later when the search yielded 
no articles with intention as a variable of interest. Relevant results from the past two 
years were included in this review.  Limiting studies to those conducted in the United 
States, presents another limitation, as well and should be explored in another paper.  
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CONCLUSION 
The existing literature illustrates the complexity in the act of using genetic 
counseling. Not only are individual factors involved, but interpersonal and structural 
factors also seem to be important factors. The factors reported in the literature as 
influencing use of genetic counseling can be categorized under the concepts of 
Triandis’s interpersonal theory. This suggests that the theory may be helpful for further 
exploration of the relationships between the various factors. In turn, the theory may be 
helpful in understanding the use of genetic services among individuals from a variety of 
backgrounds.  
The largest number of factors reported to influence use of genetic services fit 
under the concept of facilitating conditions, with social factors and perceived 
consequences following closely. One of the most compelling factors under the concept 
of facilitating conditions involves providers in the healthcare system. The association 
between use of genetic counseling and having had genetic counseling recommended 
by a provider has been found to be strong in a large population-based study 46. Coupled 
with a number of studies finding provider knowledge or comfort to be lacking 22,47,49, 
providers’ knowledge and appropriate recommendation for genetic counseling could be 
a focus for interventions.   
The influence of family also has been demonstrated in several studies. Though 
many of these may have had small sample sizes, several studies have reported family 
considerations. The limitation of small sample sizes can be mitigated by the number of 
studies reporting similar findings, as well as the depth with which family influence was 
described. 
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Another important theme across many of the studies that were part of this review 
is the underlying effect of culture. Many studies on the influence of culture are small with 
a qualitative design. Furthermore, there are none or only a limited number of studies for 
some cultures (for example, in this review, there was only one study on Arab 
Americans; two studies reported beliefs and attitudes of a small sample of Asian 
Americans).  Although there was no identified influence of culture seen in the perceived 
positive consequences of using genetic counseling, culture did have a presence in the 
perceived negative consequences. Because these may be barriers to using genetic 
counseling among individuals who could benefit, more efforts to understand perceived 
negative consequences in more cultures could be beneficial in supporting or anticipating 
needs of those groups. 
A clear gap in the literature is in the studies on underserved groups. Ethnic 
minorities are often associated with underserved. However, ethnic minorities are not 
always underserved, and underserved are not always ethnic minorities. There were no 
studies that described samples as rural. Current knowledge may be limited by a sort of 
selection bias with samples many times having been recruited from breast cancer 
clinics or even hereditary cancer risk assessment clinics. Population-based approaches 
(e.g., recruitment using state cancer registries) seem to be more popular recently. 
However, this approach may still exclude individuals who are not fully integrated into the 
healthcare system and who may have additional or unique set of needs or beliefs that 
influence their use of genetic services.    
In summary, further studies should focus on the relative amounts of importance 
that individuals place on the factors determining use of genetic services. New 
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approaches to reaching underserved and underrepresented populations should also be 
pursued. 
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Table 4.1. Variables associated with the use of genetic counseling or testing and the constructs of the Triandis model.  
 
Constructs of the Triandis model Variables associated with use of genetic counseling or testing 
 
Social factors 
 
Influential factors derived from the 
relationship between the person and 
other people; includes norms, roles, 
contractual arrangements, self-
monitoring, self-concept 
 
Concerns about modesty, availability of female providers 31  
Concerns about being a burden 32 
Traditional cultural beliefs (e.g., machismo, fatalism, destino among some 
Latinas; younger women may be less likely to ascribe to these) 33,39 
Prioritizing family responsibilities over personal needs 32,33 
Mistrust of medicine and research 33 
Mistrust related to privacy, mishandling of information 33,37 
Ability to contribute to science and society  
Requested by family 20 
 
 
Affect 
Emotions that the person feels at the 
thought of an act; can be positive 
(pleasant) or negative (unpleasant), 
and strong or weak 
 
Fear 32 
Distress 32,37,43 
Uncertainty about next steps 56 
Shame related to implications of inbreeding 36 
Shame of having the mutation (seen as a flaw) 48 
Anger 48 
Relief from negative result (not having the mutation) 48 
Positive and negative views about truth-telling 38 
 
 
Perceived consequences 
 
What might happen from a behavior 
(Note: Triandis defines this as how 
good or bad one might feel is a 
particular consequence actually 
happened. However, this was not 
measured in any studies. Therefore, 
only actual perceived consequences 
found in the literature are listed here.)  
 
Negative 
Stigma, discrimination against self 33,35,48 
Stigma, discrimination against children and relatives 33 
Anticipated negative emotional response 48 
Family would be worried 32,33 
Potential benefits outnumbered by risks and limitations  
 
Positive 
Information might help guide or affect treatment 20,23 
Obtain information to reduce cancer risk 33,48,59 
Help make life plans (e.g., marriage, children, career) 48 
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Knowledge of negative results (not a carrier) would lead to relief 48 
Just having the information 35 
It would benefit their family 20,23,35,39 
 
Facilitating conditions 
 
Conditions that enable the person to 
carry out an act; includes the person’s 
ability, arousal, and knowledge to carry 
out an act 
 
Barriers  (lack of enabling conditions) 
Lack of clinician recommendation or not discussed by provider 18,51 
Told by provider not to go 20 
Provider lacked knowledge or confidence 52,54,61 
Provider did not follow up on discussion about testing 53 
Risk not recognized by provider 22 
Cost 23,32,33 
Lack of insurance coverage 20,32 
Lack of knowledge about where to go 32 
Requirement of affected individual to be the proband 62 
Competing demands (too busy taking care of family, other things to worry 
about) 20,32,39 
Limited use of services resulting in limited knowledge 33 
Difficulty navigating the system 31 
Currently undergoing treatment 63 
 
Facilitators 
Received a referral or discussed with provider 19,20,32 
Provider felt comfortable or qualified 49,50 
Family history 24,51 
Personal history 51 
Perceived risk 32,43 
Knowledge about breast cancer genetics or BRCA genes 18,41,43,48 
Knowledge about genetic testing 24 
Have transportation, childcare 20 
Insurance covered services 20 or having private insurance 19 
Clinic close to home 20 
Clinic hours flexible, fit patient’s schedule 20 
Services by phone 20 
Perceived risk 32 
Marital status 42 
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Have social support 31 
Self-efficacy 41 
 
Telephone counseling 43  
 
 
Habits 
 
Behaviors that occur with frequency; 
number of times the person has 
committed the act 
 
 
 
 
Family hardiness 45 
 
Intention 
 
The cognitive antecedent of a behavior 
 
 
 
 
Awareness of genetic testing 58 
Cancer worry 58 
Insurance coverage of testing cost 58 
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CHAPTER V 
Results of specific aim 2:  The relationship between residence in a medically 
underserved area and use of genetic counseling among a sample of young breast 
cancer survivors in the United States 
 The results of aim 2 are described in this second manuscript. 
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Introduction 
 More than 20 years have passed since mutations in the BRCA1 and BRCA2 
(hereafter BRCA) cancer susceptibility genes were linked to breast cancer (Miki et al., 
1994; Wooster et al., 1995). Yet, current research suggests that opportunities to use 
this information in clinical care are being missed, and many women are not getting 
genetic services that could be lifesaving.  Mutations in the BRCA genes are estimated 
to be present in 0.2-1% of the general population (Kurian, 2010).  The lifetime risk of 
being diagnosed with breast cancer for the general population is 12.4% (American 
Cancer Society, 2017).  For carriers of a mutation in the BRCA1 and BRCA2 genes, this 
risk is increased to 57-65% and 45-49%, respectively (Antoniou et al., 2003; Chen & 
Parmigiani, 2007; Risch et al., 2006).  For individuals at high risk, risk-reducing 
strategies have shown promise.  Prophylactic mastectomy, for example, has 
demonstrated a 90% or more reduction of risk (Domchek et al., 2010; Evans et al., 
2009; Hartmann et al., 1999, 2001; Heemskerk-Gerritsen et al., 2007; Meijers-Heijboer 
et al., 2001; Rebbeck et al., 2004).  The decision to undergo a prophylactic mastectomy, 
however, carries its own risks and potentially unfavorable sequelae related to surgery, 
and should be undertaken only with a solid understanding of risks and benefits.   
Genetic counselors can facilitate discussions about risks, benefits, and 
associated concerns that are key to individuals making informed decisions about 
minimizing risk.  However, rates of genetic counseling are unfortunately low.  In 2005, 
one large national survey reported that only 34.6% of women at risk for carrying a 
BRCA mutations received genetic counseling (HealthyPeople.gov, 2013).  That same 
year, the United States Preventive Services Task Force (USPSTF) recommended that 
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“women whose family histories are associated with increased risks for clinically 
significant, or deleterious, mutations in the BRCA1 or BRCA2 gene be referred for 
genetic counseling and evaluation for mutation testing” (Nelson, Huffman, Fu, Harris, & 
U.S. Preventive Services Task Force, 2005).   Yet, as recently as 2015, studies where 
participants had either a personal history of breast cancer younger than 50 years of age 
(Anderson et al., 2012; Cragun et al., 2015) or whose healthcare provider felt genetic 
testing was indicated  (J. Armstrong et al., 2015) still reported that fewer than 50% of 
study participants pursued genetic counseling.  In one study, 21% of the at-risk sample 
saw a genetic counselor and only 35% of the entire sample had been referred for 
genetic counseling (Cragun et al., 2015).   
Predictors of genetic counseling use remain unclear.  Provider recommendation 
has been reported as a strong facilitator and motivator (Anderson et al., 2012; Chin et 
al., 2005; Morgan, Sylvester, Lucas, & Miesfeldt, 2009), whereas lack of provider 
recommendation has been reported as the most commonly reported reason for not 
receiving genetic counseling (Anderson et al., 2012; J. Armstrong et al., 2015).  The role 
of other factors such as race, ethnicity, income, and insurance coverage is either 
inconsistent, or studies had small sample sizes, or were too few to be conclusive (K. 
Armstrong, 2005; Thompson et al, 2002; Glenn, Chawla & Bastani 2012; Anderson, et 
al, 2012).  For example, a case-control study of 408 women found African American 
women to be significantly less likely to undergo genetic counseling for BRCA testing 
than their white counterparts, a difference which was not explained by differences in the 
probability of carrying a mutation, socioeconomic status, attitudes about testing, 
discussions with their physicians about testing, or cancer risk perception and worry (K. 
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Armstrong, 2005).  In a study of Hispanic women, concerns about insurance coverage 
were prominent, with most participants wanting to ensure insurance coverage prior to 
making an appointment for genetic counseling (Sussner, Jandorf, Thompson, & 
Valdimarsdottir, 2013).   Income has not been reported as a significant factor when 
using genetic counseling.  Taken together, findings from these studies suggest that 
uptake of genetic counseling is not consistently linked to ethnicity, income, insurance 
coverage, or other singular factor (Anderson et al., 2012; K. Armstrong, 2005; Glenn, 
Chawla, & Bastani, 2012; Thompson et al., 2002).  Residence in a medically 
underserved area may capture a composite or set of variables which, when combined, 
may be related to use of genetic counseling for a heritable cancer syndrome.  Some 
social behavioral theories (Triandis, 1993) may also suggest this. 
While the diagnosis of cancer at any age can be tumultuous, a diagnosis of 
cancer at younger than 50 years old, as is often the case in those with BRCA mutations, 
may be especially challenging.  There may be numerous barriers such as reproductive 
considerations, time off work and travel time to appointments, coupled with additional 
demands of young families, that can add to an already difficult balancing act (Hamilton, 
Innella, & Bounds, 2016). Little is known about the key predictors of getting genetic 
services, so effective intervention strategies cannot be efficiently explored.  The 
purpose of this study was to understand genetic service use among young breast 
cancer survivors who are at high risk for having a heritable predisposition to cancer, and 
in particular, whether there is a relationship between residence in a medically 
underserved area and use of genetic counseling services.  The specific aims of the 
study were to evaluate whether use of genetic counseling differs between participants 
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living in medically underserved areas versus medically served areas; and to evaluate 
variables associated with use of genetic counseling and differences between medically 
underserved and medically served participants.   
An interpersonal theory developed by Triandis (1977) was used to guide this 
study. This model was selected because of Triandis’s extensive work on differences in 
behavior from observations of different cultures (Triandis, 1993).  Culture is not one 
particular construct in the theory; rather, the underlying influence of culture is 
understood to be pervasive, manifesting through cognition and emotion, social factors 
such as norms and expectations, habits, and facilitating conditions.  Cultural effects can 
manifest on a personal, interpersonal relationships, as well as societal level.  Triandis’s 
model includes several important concepts associated with genetic counseling use as 
reported in the literature and therefore may help explain relationships between variables 
that predict genetic counseling use.  A conceptual framework developed from Triandis’s 
theory is shown in Figure 5.1.  Variables explored in this study were determined based 
on variables associated with use of genetic counseling in existing literature and these fit 
into the model as depicted below.  Residence in a medically underserved area (or not) 
is considered a facilitating condition in this study and its influence may be seen on 
habits and intention.   
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Figure 5.1. Conceptual framework developed from the Triandis model of interpersonal 
behavior (Triandis, 1977) 
 
 
Methods 
Sample 
The study used baseline data from a randomized trial designed to increase 
cancer surveillance and use of genetic services among women diagnosed with breast 
cancer younger than 50 years of age (Katapodi et al., 2017; Katapodi, Northouse, 
Schafenacker, et al., 2013).  The purpose of this study was to explore whether 
residence in a medically underserved area is related to use of genetic counseling for a 
BRCA mutation.  Participants were recruited from the Michigan Cancer Surveillance 
Program (MCSP).  This state-based cancer registry was established in 1984 and 
collects reports of cases of in situ and invasive malignancies.  From 9,000 cases 
Background 
factors
Habits
Affect
Consequences
Facilitating 
conditions
Social 
factors
Intention
Use of 
genetic 
counseling
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reported between the years of 1994 and 2008, 3,000 women diagnosed with breast 
cancer between the ages of 20 and 45 were stratified for Black vs. White/Other race 
and were randomly selected.  The study oversampled for Black women (1500 randomly 
selected) who also live in counties with the highest mortality rates for young women with 
breast cancer to increase the representation of minority and underserved women.  
Women who were pregnant, incarcerated, or institutionalized at the time of the study 
were excluded because they might not have been able to follow recommendations for 
breast cancer screening or genetic counseling.   
 
Variables and measures  
The study asked participants to complete a self-administered paper 
questionnaire adapted from previously-validated measures (Anderson et al., 2012; 
“Centers for Disease Control and Prevention: Behavioral Risk Factor Surveillance 
System: 2001 Survey Questions,” 2002; Katapodi, Dodd, Lee, & Facione, 2009; 
Katapodi, Facione, Miaskowski, Dodd, & Waters, 2002; Katapodi, Northouse, Milliron, 
Liu, & Merajver, 2013; Wang, Gonzalez, Milliron, Strecher, & Merajver, 2005) that 
included questions on demographics, personal and family history, perceived 
expectations and motivation to comply with expectations of relatives and healthcare 
providers, worry related to possibly having a genetic mutation related to cancer, 
perceived consequences of genetic testing to self and to relatives if testing was 
indicated, and convenience factors. The survey also assessed intention to use genetic 
counseling, and history of using health services.  There were items on perceived 
expectations of relatives and healthcare providers with respect to “mammograms and 
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other tests to find cancer at an early stage” and also items on motivation to comply with 
expectations of relatives and healthcare provider.  Variables ranged from individual 
factors to interpersonal, broader structural factors.  The outcome of interest was use of 
genetic counseling, assessed by “Have you ever had cancer genetic services?”  The 
description of cancer genetic services given in the survey was as follows: “Cancer 
genetics services help people know if their own cancer or the cancer in their family 
might be due to heredity (due to genes that can be passed down in the family, from one 
generation to the next). Genetic services usually involve meeting with a genetic 
counselor or doctor who takes your family history, talks about your risk for hereditary 
cancer and gives you information about genetic testing and cancer screening.”  Other 
variables and instruments included in this study are shown in Table 5.1, organized by 
the constructs of the Triandis model.   
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Table 5.1.  Variables and measures used in this study  
Variable Measure 
Demographics including personal and family history 
Age 
Race 
Ethnicity 
Ashkenazi Jewish background 
Income 
Education 
Adopted 
Family history of male breast cancer 
Number of pregnancies  
Additional risk factors* 
*in addition to breast cancer onset 
at age  50  
Adapted from the Behavioral Risk Factors 
Surveillance System (“Centers for 
Disease Control and Prevention: 
Behavioral Risk Factor Surveillance 
System: 2001 Survey Questions,” 2002)  
 
 
 
 
Examined this study. List of risk factors 
from U.S. Preventive Services Task 
Force (U.S. Preventive Services Task 
Force, 2005).  Referral to genetic 
counseling indicated if ‘yes’ to 2 of the 
following:  
• Ovarian cancer, at any age: 
self 
mother 
sister 
daughter 
maternal grandmother 
maternal aunt 
paternal grandmother 
paternal aunt 
• Breast cancer at age  50 y.o.: 
self 
mother 
sister 
daughter 
maternal grandmother  
maternal aunt 
paternal grandmother 
paternal aunt 
 
Social factors 
 
Perceived expectations of relatives 
Perceived expectations of healthcare 
provider 
 
 
 
Adapted from Ajzen et al. (Ajzen & 
Fishbein, 1980) 
Ex.: “Do you believe that your 
relatives want you to get 
mammograms and other tests to 
find cancer at an early stage?” 
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Motivation to comply with relatives 
Motivation to comply with healthcare 
provider 
Ex.: “How often do you try to do 
what your relatives want you to do 
about finding cancer at an early 
stage?” 
Affect 
Worry Examined in this study 
Ex.: “Have you ever had genetic 
testing for a gene mutation 
connected to breast or ovarian 
cancer?  If no, please tell us why 
you have not had genetic testing 
(check all that apply).”   
 
Worry was indicated if the following 
was checked: 
“I would rather not know if I 
have a mutation connected to 
cancer.” 
Perceived consequences 
Perceived positive consequences to 
self 
Perceived negative consequences to 
self 
Perceived positive consequences to 
family 
Perceived negative consequences to 
family 
Examined in this study  
Ex.: “Have you ever had genetic 
testing for a gene mutation 
connected to breast or ovarian 
cancer?  If you had genetic testing, 
what helped you decide to have 
testing (check all that apply). 
 
Perceived positive consequences to 
self was indicated if the following 
were checked:   
“I wanted to learn more about 
my future cancer risk; Results 
may change my cancer 
treatment (preventive surgery, 
chemotherapy, etc.)” 
Facilitating conditions 
Provider recommended genetic 
counseling 
Examined in this study  
Ex. “Have you ever had cancer 
genetic services?  If no, please tell 
us why you have not used cancer 
genetic services – check all that 
apply” 
 
Provider recommended if the 
following was checked: 
“My healthcare provider 
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suggested that I do.” 
Perceived risk Previously used (Katapodi et al., 2009; 
Katapodi, Northouse, Milliron, et al., 
2013)  
 
Ex. “On a scale from 0 (Definitely 
Will Not) to 10 (Definitely Will), 
please circle a number that best 
describes what you believe is your 
chance for getting breast cancer.” 
Knowledge of breast cancer genetics Adapted from Knowledge Assessment 
Questionnaire (Wang et al., 2005); 
(Cronbach’s alpha=0.72) 
Convenience  Previously used (Anderson et al., 2012)  
Ex. “Have you ever had cancer genetic 
services?  If no, please tell us why you 
have not used cancer genetic services – 
check all that apply.” 
 
Convenience variable was created 
if the following were checked:   
“I am too busy; I cannot get 
time off work; Lack of 
transportation; Lack of child 
care; Clinic hours do not fit my 
schedule’ Clinics are too far 
away” 
Insured Previously used (Anderson et al., 2012)  
 
Ex. “Have you ever had genetic 
testing for a gene mutation 
connected to breast or ovarian 
cancer?)  If you have genetic 
testing, what helped you decide to 
have testing (check all that apply) 
 
Participant considered insured if the 
following were checked:  
“My medical insurance 
covered the visit; My medical 
insurance covered the cost of 
the test” 
Family support Previously used (Katapodi et al., 2002);  
 
Social support for breast cancer 
screening (Cronbach’s 
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alpha=0.81) 
Residence in a medically 
underserved area 
Examined in this study 
 
Geocoded U.S. Census Tracts and 
HRSA designation as a medically 
underserved area (MUA) (Yes/No) 
Distance to genetic counseling Examined in this study 
 
Distance to nearest facility offering 
genetic counseling  
 
Intention to use genetic counseling Adapted from Ajzen et al. (Ajzen & 
Fishbein, 1980) 
 
“During the next 12 months, how 
likely are you to ask your healthcare 
provider if genetic testing for a gene 
connected to hereditary cancer is a 
right test for you?” 
History of using health services Adapted from the Behavioral Risk Factors 
Surveillance System (“Centers for 
Disease Control and Prevention: 
Behavioral Risk Factor Surveillance 
System: 2001 Survey Questions,” 2002) 
 
Participant considered to have a history 
of using health services if answered yes 
to any of the following: 
 
Have you ever had a clinical breast 
exam?;  Have you ever had a 
mammogram?; Have you ever had 
a breast MRI? 
 
For the purposes of this analysis, some variables were created from the baseline 
data of the original study.  A variable for residence in a medically underserved area was 
created using the definition offered by the Health Resources & Services Administration 
(HRSA).  HRSA designates an area as “medically underserved” (MUA) according to a 
set of variables termed the Index of Medical Underservice, or IMU.  IMU is comprised of 
four variables:  1) ratio of primary care medical care physicians per 1,000 population, 2) 
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infant mortality rate for a service area or for the county or sub county area which 
includes it, 3) percentage of the population with incomes below the poverty level, and 4) 
percentage of the population age 65 or older.  For this study, medically underserved 
was defined as being a resident in a U.S. Census Tract designated by HRSA as an 
MUA (Yes/No) and was determined using Geocoded U.S. Census data.  
Another variable that was created was that for additional risk factors indicating a 
referral for genetic counseling.  The variable was created from the 2005 USPSTF 
Referral Screening Tool (U.S. Preventive Services Task Force, 2005), one of the main 
recommendation guidelines offered at the time of data collection for the parent study.  
The tool recommends a patient complete the checklist if she has a family history of 
breast or ovarian cancer; the patient should receive a referral for genetic counseling if 
two or more items are marked ‘yes’.  A reproduction of the Referral Screening Tool is 
shown in Figure 5.2. 
 
Figure 5.2.   Referral Screening Tool.  Reproduced from the 2005 USPSTF 
recommendation statement for genetic risk assessment and BRCA mutation testing for 
breast and ovarian cancer susceptibility (U.S. Preventive Services Task Force, 2005) 
Risk Factor Breast Cancer at Age  
50 y 
Ovarian Cancer at Any 
Age 
Yourself   
Mother   
Sister   
Daughter   
Mother’s side   
Grandmother   
Aunt   
Father’s side   
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Grandmother   
Aunt   
2 cases of breast cancer after age 50 y on the same side of the family 
Male breast cancer at any age in any relative 
Jewish ancestry 
 
 
Statistical analyses 
Research question 1: Evaluate whether use of genetic counseling differs 
between participants living in medically underserved area versus medically served 
areas.  Chi-square test was used to assess for the difference in the use of genetic 
counseling by medically served and underserved groups.  The response variable for 
use of genetic counseling was dichotomous with “yes” or “no” responses.  “Don’t know” 
was treated as missing data. 
Research question 2: Evaluate what variables are associated with use of genetic 
counseling and whether any differences exist between medically underserved and 
medically served participants.  Point-biserial correlations determined strength and 
direction of relationships between explanatory variables and the response variable.  
This special type of Pearson’s product-moment correlation was used because the 
response variable (use of genetic counseling) is dichotomous.  Interpretation of 
association strength was based on Cohen (1988).  
Approximately 3% of all values were missing.  Two variables had greater than 
10% of responses missing:  Intention (36% missing), and Income (14% missing).  
Perceived risk and ethnicity had 8% and 7% missing, respectively; all other variables 
had less than 5% of values missing.  No multiple imputation was done.  Analysis of 
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missing values by SPSS suggests no pattern in missing values.  Data are thus assumed 
to be missing at random.   
G*Power 3.1.9.2 (Faul, Erdfelder, Lang, & Buchner, 2007) was used to calculate 
the power for these analyses.  Power for the outcome of using genetic counseling 
(Yes/No) was calculated post-hoc based on the numbers in this secondary analysis.   
Power was determined to be 16%, likely due to the large imbalance in the number of 
medically served versus underserved participants (n=790 and n=68, respectively).   
 
Results 
 A total of 859 women diagnosed with breast cancer younger than 45 years old 
completed the baseline survey.  Participants ranged in age from 30 to 63 years old with 
a mean of 51 years (±5.9).  Over half of participants were White/Other (63%); 37% were 
Black.  Over half of the participants (59.5%) had either some college or completed a 
college education.  Slightly less than half reported incomes above $80,000 (43%).  
Additional characteristics of the sample can be found in Table 5.2. 
Analyses considered two groups: participants who were residents of medically 
underserved areas and those who were not.  There were fewer participants in medically 
underserved areas (n=68) than not (n=790).  Characteristics of the two groups were 
reviewed and are shown alongside characteristics of the entire sample in Table 5.2.  
The demographics of the two groups are similar proportionally for the most part, with 
one exception being a higher proportion of adopted participants in the medically 
underserved group. 
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Table 5.2.  Characteristics of participants  
 
 
Entire 
sample   
(n, %) 
N=859 
Medically 
underserved 
(n, %) 
n=68 
Medically 
served 
(n, %) 
n=790 
Age 
Mean (SD) 
 
50.9 (5.9) 
 
50.1 (6.0) 
 
51.0 (5.8) 
Self-reported race, n (%) 
White 
Black 
American Indian 
Asian or Southeast 
Asian 
Arab-American 
Hawaiian 
Prefer not to answer 
 
503  (58.6%) 
314  (36.6%) 
22  (2.6%) 
11  (1.3%) 
3  (0.3%) 
1  (0.1%) 
21  (2.4%) 
 
44  (64.7%) 
22  (32.3%) 
1  (1.4%) 
1  (1.4%) 
0  (0 %) 
0  (0%) 
1  (1.4%) 
 
459  (58.1%) 
292  (37.0%) 
21  (2.7%) 
10  (1.3%) 
3  (0.4%) 
1  (0.1%) 
20  (2.5%) 
Ethnicity 
Hispanic or Latina 
Not Hispanic or Latina 
Prefer not to answer 
Don’t know 
 
14  (1.8%) 
705  (88.5%) 
45  (5.6% 
33  (4.1%) 
 
0  (0%) 
59  (86.8%) 
3  (4.4%) 
2  (2.9%) 
 
14  (1.8%) 
646  (81.8%) 
42  (5.3%) 
31  (3.9%) 
Income 
<$40,000 
$40,000-79,999 
$80,000-119,999 
$120,000 or higher 
Don’t know or Missing 
 
253  (29.5%) 
237  (27.6%) 
133  (15.5%) 
114  (13.3%) 
122  (14.2%) 
 
24  (35.3%) 
20  (29.4%) 
9  (13.2%) 
8  (11.8%) 
7  (10.3%) 
 
229  (29.0%) 
217  (27.5%) 
124  (15.7%) 
106  (13.4%) 
115  (14.5%) 
Education 
High school/Tech 
school grad or less 
Some college, no 
degree or completed 
college 
Postgraduate degree 
Missing 
 
199  (23.2%) 
512  (59.6%) 
 
138  (16.1%) 
10  (1.16%) 
 
13  (19.1%) 
45  (66.2%) 
 
8  (11.8%) 
2  (2.9%) 
 
186  (23.8%) 
467  (59.6%) 
 
130  (16.6%) 
8  (1.0%) 
Marital status 
Single 
Married/life partner 
 
338  (39.3%) 
516  (60.1%) 
 
25  (37.9%) 
41  (62.1%) 
 
313  (39.7%) 
475  (60.3%) 
Adopted 23  (2.7%) 6  (8.8%) 17  (2.2%) 
Number of times pregnant 
Mean (SD) 
 
2.6 (±1.7) 
 
2.7 (±1.9) 
 
2.5 (±1.7) 
Has family history of male 
breast cancer 17  (2.0%) 1  (1.5%) 16  (2.0%) 
Age at first cancer diagnosis 
Mean (SD) 
 
39.89 (±4.98) 
 
39.33 (±4.70) 
 
39.94 (±5.01) 
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Had at least one other risk 
factor in addition to breast 
cancer diagnosis  50 yrs. old 
 
196  (23%) 
 
14  (20.6%) 
 
182  (23.2%) 
Used genetic counseling 
Yes 
No 
Don’t know 
Missing 
 
281  (32.7%) 
547  (63.7%) 
25  (2.9%)  
6  (0.7%) 
 
25  (36.8%) 
38  (55.9%) 
3  (4.4%) 
2  (2.9%) 
 
256  (32.4%) 
509  (64.4%) 
22  (2.8%) 
4  (0.5%) 
 
Overall, use of genetic counseling was reported by 281 participants and was 
higher among medically underserved participants (36.8%) compared to medically 
served participants (32.4%).  However, the difference between groups is not statistically 
significant (=.05, p=.32).  Numbers and frequencies of genetic counseling use are 
shown in Table 5.3. 
 
Table 5.3.  Number of participants that used genetic counseling  
 
 
Entire sample  (n, 
%) 
N=859 
Medically 
underserved 
(n, %) 
n=68 
Medically  
served 
(n, %) 
n=790 
Used genetic counseling 
 
Yes 
No 
Don’t know 
Missing 
 
 
281 (32.7%) 
547 (63.7) 
25 (2.9%) 
6 (0.7%) 
 
 
25 (36.8%) 
38 (55.9%) 
3 (4.4%) 
2 (2.9%) 
 
 
256 (32.4%) 
509 (64.4%) 
22 (2.8%) 
4 (0.5%) 
 
The variables that were highly correlated with genetic counseling use were: 
perceived positive consequences related to family (Pearson’s r=.73 for served, r=.84 for 
underserved), perceived positive consequences to self (Pearson’s r=.62 for served, 
r=.78 for underserved), and having genetic counseling recommended by a provider 
(Pearson’s r=.55 for served, r=.57 for underserved). The correlations for these variables 
were positive and could be interpreted as facilitators.   
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Variables negatively correlated with counseling, which could be interpreted as 
barriers, showed only weak correlations.  For the served, the strongest negative 
association was perceived negative consequences to self (Pearson’s r=-.13).  For the 
underserved, the strongest negative association was convenience factors (Pearson’s 
r=-.24).  Correlation coefficients for these and other variables can be found in Table 5.4.   
 
Table 5.4.  Correlation coefficients between all variables and use of genetic counseling.   
**Correlation is significant at the 0.01 level (2-tailed); *Correlation is significant at the 
0.05 level (2-tailed) 
 
 Variables  Correlation coefficients, 
r 
 
 
 
Medically 
underserved 
Sig. Medically 
served 
Sig. 
Background 
factors 
  
 
 
 
 Income 0.232  0.239  ** 
 Race  0.062  -0.108 ** 
 Education 0.096  0.125 ** 
 Ethnicity 0.038  0.011  
  Age -0.381 ** -0.167 ** 
 Family history of 
male breast cancer 
-0.146 
 
-0.045 
 
 Number of 
pregnancies 
-0.083 
 
-0.047 
 
 Adopted -0.042  -0.037  
 Ashkenazi Jewish none  0.102 ** 
 Had at least one 
additional risk 
factor, in addition to 
breast cancer onset 
at age  50 y  
.191 
 
.186 
 
** 
Social factors      
  Perceived 
expectations of 
healthcare provider 
0.163 
 
-0.011 
 
 Perceived 
expectations of 
relatives 
0.105 
 
0.031 
 
 Motivation to 
comply with 
0.079 
 
0.096 
 
** 
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healthcare provider 
  Motivation to 
comply with 
relatives 
-0.002 
 
0.034 
 
Affect      
  Worry -0.147  -0.121 ** 
Perceived 
consequences 
  
 
 
 
  
   
Perceived positive 
consequences for 
family 
0.841 
 
** 0.728 
 
** 
 Perceived positive 
consequences for 
self 
0.780 
** 
0.624 
 
** 
  Perceived negative 
consequences for 
family 
-0.181 
 
-0.05 
 
 Perceived negative 
consequences for 
self 
-0.147 
 
-0.132 
 
** 
Facilitating 
conditions 
  
 
 
 
  Provider 
recommended 
genetic counseling 
0.567 
 
** 0.546 
 
** 
 Knowledge of 
breast cancer 
genetics 
0.150 
 
0.294 
 
** 
 Family support 0.072  0.050  
  Convenience -0.238  -0.088 * 
 Minimum distance 
to facility offering 
genetic counseling 
-0.218 
 
-0.001 
 
 Perceived risk -0.158  -0.033  
 Have insurance -0.157  0.120 ** 
Habits      
  History of using 
health services 
0.102 
 
0.134 
** 
Intention       
  Intention -0.037  0.082  
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Table 5.5. Variables showing the strongest negative association with the outcome of 
genetic counseling (GC).  Negative correlations indicate possible barriers to genetic 
counseling.  Facilitating conditions may present largest barrier (BF = background factor; 
SF = social factor; A = affect; PC = perceived consequence; FC = facilitating condition; 
H = habit; I = intention) 
Medically underserved Construct in Triandis 
model 
Variables Correlation 
coefficients, 
r 
BF S
F 
A PC FC H I 
Age -0.381        
Convenience factors -0.238        
Minimum distance to facility 
offering GC 
-0.218 
       
Perceived negative 
consequences for family 
-0.181 
       
Perceived risk -0.158        
Insurance -0.157        
Medically served  
Variables Correlation 
coefficients, 
r 
       
Age -0.167        
Perceived negative 
consequences for self 
-0.132 
       
Worry -0.121        
Race -0.104        
Convenience factors -0.088        
Perceived negative 
consequences for family 
-0.050 
       
 
Discussion 
Findings suggest a possible difference in use of genetic counseling between 
medically underserved and medically served groups but not in the hypothesized 
direction.  Regarding the actual use of genetic counseling, a slightly higher proportion of 
MUS used counseling compared to the MS.  This finding was the opposite of what was 
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expected.  However, the finding is slightly underpowered due to the low number of 
participants who were considered medically underserved, according to the HRSA 
definition.  Thus, this finding should be interpreted with caution.  
Race and ethnicity might help explain the unexpected finding of genetic 
counseling use among a higher proportion of the medically underserved than served.  
There was a higher percentage of Black, American Indian, Hispanic or Latina, and Arab-
American participants in the MS group (42%) compared to the MUS group (33.9%).  
Thus far, no reports exist about use of genetic counseling among American Indian 
groups and only one with a sample of Arab-American women.  However, studies have 
reported Black, Hispanic or Latina, and Arab-American women to decline or be less 
likely to use genetic counseling.  Concerns reported by Black women include mistrust 
about confidentiality, possible discrimination, and lack of information about the family’s 
health history due to less use of health services (Glenn et al., 2012; Thompson et al., 
2002).  Concerns reported by Hispanic and Latina women are related to cultural beliefs 
and attitudes that place the needs of the family before the woman’s personal needs 
(Glenn et al., 2012; Sussner et al., 2015, 2013).  Concerns reported by Arab-American 
women are related to cultural beliefs and attitudes involving modesty and lack of 
familiarity with the healthcare system (Mellon, Gauthier, Cichon, Hammad, & Simon, 
2013).  The lower proportion of genetic counseling use among the medically served 
group in this study may be a reflection of the higher percentage of Black, American 
Indian, Hispanic or Latina, and Arab-American women in that group. 
Another variable that might help explain the unexpected finding of a higher 
proportion of MUS using genetic counseling is adopted status.  A higher proportion of 
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the MUS group was adopted (8.8%) compared to the MS group (2.2%).  It is possible 
that adopted participants had higher rates of using genetic counseling in order to gather 
more information about their risk if no family health history from their birth parents or 
other blood relatives was available.  It is unclear whether the relationship results more 
from participants seeking out genetic counseling to obtain more information about their 
risk or whether healthcare providers are more likely to recommend counseling to 
adopted individuals who lack the health history suggesting a hereditary component.  No 
reports about a possible association between adopted status and use of genetic 
counseling for a heritable predisposition to breast cancer have been found in existing 
literature.  However, the possible association may be worth exploring in future studies to 
evaluate the driving forces in use of genetic counseling services. 
The variables showing correlations with use of genetic counseling greater than 
.50 and .60 (moderately strong to strong) were the same for both groups: perceived 
positive consequences for family, perceived positive consequences for self, and 
provider recommended genetic counseling.  These factors have been reported in 
existing literature to be important in whether one uses genetic counseling (Anderson et 
al., 2012).  Of these three variables which were most strongly related to use of genetic 
counseling in both groups, two are rooted in the patient’s perspective, and the third 
comes from the healthcare provider.  The correlation between provider recommending 
genetic counseling and use of genetic counseling was between .55 and .57 for served 
and underserved, respectively.  This suggests that the provider facilitates counseling 
use.   
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Perhaps more interesting, for the purpose of identifying barriers which can be the 
focus of interventions, are the variables showing negative associations with use of 
genetic counseling and the differences between groups.  A negative association 
suggests a variable was a barrier or deterring factor to using genetic counseling.  As 
acknowledged earlier, the strength of the associations could be regarded by some as 
relatively low.  Although conclusions about those relationships cannot be made with 
certainty from these data also due to the small sample size of MUS breast cancer 
survivors, it is possible that there are real relationships there that are masked by 
unidentified or uncontrollable factors (Cohen, 1988).   
For the MUS, convenience factors, minimum distance to a facility, and insurance 
were among the variables that showed the strongest negative associations.  Multiple 
barriers may be faced by individuals.  For example, in Michigan, where these data were 
collected, one of the largest cancer research and provider networks in Michigan with a 
long-standing tradition of genetic counseling is in the city of Detroit, an urban area with 
38.1% (±0.7%) of individuals living below the poverty level at the time the data were 
collected (U.S. Census Bureau, 2012).  Despite living in such proximity to the facility, an 
individual might still not be able to obtain services due to lack of insurance coverage.  
Interventions aimed at facilitating use of genetic counseling among the underserved, 
who may be more likely to face barriers related to access, likely need to be multifactorial 
and address insurance and convenience factors such as extended or alternate clinic 
hours, transportation, and child care.  
For both groups, variables negatively correlated with genetic counseling use had 
correlations of -.24 or less.  Age had a correlation of -.17 among the served and -.38 
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among the underserved.  However, the importance of this is unclear since this age 
variable indicates age of the participant at the time of the study.  Therefore, age will be 
excluded from further analyses.  
 Convenience factors had a correlation with use of genetic counseling of -.24 among 
the underserved.  Among the served, the correlation of convenience factors with 
counseling was -.09.  These are both considered weak but this would be an interesting 
relationship to explore further in future studies as Cohen (1988) stated that a real 
relationship might exist but might be masked by unidentified or uncontrollable factors.  
Further exploration of these factors in prospective studies could signal areas for 
intervention to facilitate genetic counseling use.  Prospective studies could be done on 
convenience factors, for example, which included extended or alternative clinic hours, 
appointments by telephone, and childcare transportation.  
Another interesting finding was that the survey-based measures were more 
consistently and significantly associated with genetic counseling use than other 
measures.  This highlights the need for researchers and public health agencies to solicit 
information on barriers and facilitators to genetic service use from at-risk participants 
directly.  
Limitations 
 
The number of participants described as medically underserved (n=68) was the 
greatest limitation, making statistical analyses underpowered.  The binary (yes or no) 
nature of the medically underserved status, as determined by HRSA definition, may 
have contributed to the low number of participants defined by medically underserved 
status.  This study aimed to understand the behavior of women considered at high risk 
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for hereditary breast cancer through the lens of being medically underserved or not, 
based on residence in a HRSA-designated medically underserved area.  HRSA 
designation as an MUA was the most consistent and reproducible way in which 
underserved has been defined in the literature, facilitating comparison of findings.  
However, given the low numbers in that category despite the original study 
oversampling Black women in high breast cancer mortality counties, it is unclear 
whether this was a sufficient methodology or whether HRSA designation of medically 
underserved is relevant in the context of cancer genetic services.  
 Residence in an area designated as a medically underserved area (MUA) may be an 
imperfect measure of whether an individual is actually medically underserved. The 
factors that make up the index defining an area as medically underserved (too few 
primary care providers, high infant mortality, high poverty, and large elderly population) 
may be less relevant in the context of using such a specialized health service such as 
genetic counseling.  Additionally, there may be individuals living in MUAs who are not 
underserved.  MUA designation may not be a specific and sensitive way to identify truly 
underserved individuals.  Future studies might explore ways to develop a more sensitive 
and specific measure for identifying truly underserved individuals.  In addition, residence 
was determined at the time of study participation, not at the time of diagnosis.  
Residence at the time of diagnosis is not known; if known and included, it may have 
yielded different results.  
 The way that other variables were operationalized for this study may have affected or 
limited the ability to detect some relationships as well.  Variables were created using 
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existing data.  Prospective studies might consider the use of the Triandis model to guide 
the selection of more sensitive and specific measures.   
 
Conclusions 
This study supports other studies’ findings that recommendation for genetic 
counseling by a provider is related to use of genetic counseling.  However, because 
receiving a recommendation from a provider is currently unreliable even when an 
individual has a red flag of a breast cancer diagnosis at age younger than 50, improving 
genetic counseling use may be further achieved by a better understanding of barriers 
faced by individuals (i.e., patients) and by empowering individuals and their family.  
Future research might aim at increasing access to services by exploring the effect of 
various convenience factors such as extended or shifted clinic hours (e.g., evening and 
weekend appointments), appointments via video conferencing or telephone, offering 
child care, or offering transportation.  Future research might also explore approaches to 
including families in discussions and ways to elicit beliefs and attitudes from all parties 
on the risks and benefits of genetic services. 
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CHAPTER VI 
Results of aim 3: Exploring a theoretical framework to explain use of genetic 
counseling for hereditary breast cancer 
 The results of aim 3 are described in this third manuscript.
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Introduction 
Use of genetic counseling for a mutation in the BRCA cancer susceptibility 
genes, a heritable mutation that substantially increases one’s risk of developing breast 
and other cancers, remains suboptimal with recent studies reporting rates of 50% or 
lower even among individuals considered high risk and for whom counseling is 
recommended (Anderson et al., 2012; J. Armstrong et al., 2015; Cragun et al., 2015; 
National Comprehensive Cancer Network., 2017).  Incidence of BRCA-related cancer 
and mortality from the cancer may be reduced through interventions such as risk-
reducing mastectomy and/or salpingo-oophorectomy (Domchek et al., 2010; Evans et 
al., 2009; Hartmann et al., 1999, 2001; Rebbeck et al., 2004), medications such as 
Tamoxifen and raloxifene (Cuzick et al., 2007; Fisher et al., 2005; Nelson et al., 2009; 
Nelson, Smith, Griffin, & Fu, 2013; Powles, Ashley, Tidy, Smith, & Dowsett, 2007; 
Veronesi et al., 2007), or increased surveillance.  However, these interventions have 
their own risks and unfavorable sequelae and should be considered only by those for 
whom the potential benefits outweigh the risks.  Genetic counseling involves evaluation 
of risk, patient education, discussion of benefits and harms of mutation testing, 
interpretation of results, and discussion of risk management options.  It can facilitate 
understanding of the multiple facets of identifying and managing risk, and can reduce 
anxiety and depression (Braithwaite, Sutton, Mackay, Stein, & Emery, 2005; Pieterse, 
Ausems, Spreeuwenberg, & van Dulmen, 2011; Roshanai, Rosenquist, Lampic, & 
Nordin, 2009), and worry (Bennett et al., 2008; Bowen, Burke, Culver, Press, & Crystal, 
2006; Brain, Parsons, Bennett, Cannings-John, & Hood, 2011; Braithwaite et al., 2005).   
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The benefits of genetic counseling are being realized by only a fraction of the 
appropriate individuals, however.  The low rate of genetic counseling use leads to 
several questions, including whether some groups continue to face unique or 
unidentified challenges to using genetic counseling, and whether interventions being 
designed to facilitate use of counseling are addressing the most important barriers.   
The most prevalent reasons for using genetic counseling have been consistently 
reported as 1) to obtain information to reduce risk (Chin et al., 2005; Glenn, Chawla, & 
Bastani, 2012; Thompson et al., 2002) or guide treatment decisions (Anderson et al., 
2012), and 2) to benefit family members through identification and knowledge of risk 
(Anderson et al., 2012; K. Armstrong et al., 2000; Thompson et al., 2002).  However, 
there is a gap in knowledge and understanding about the reasons for not using genetic 
counseling.  Reported reasons for not using genetic counseling are numerous without 
clear and consistent findings.  Furthermore, small sample sizes, highly selected 
samples, and few studies with similar approaches limit the ability to generalize and 
compare findings.  Use of a theory-based conceptual model could aid comparison of 
findings across different populations by providing a clear and consistent framework for 
exploring the relationships between predictors.  The model would guide variable 
selection, exploration of relationships, and formulation of subsequent research 
questions.  Use of such a model currently seems to be lacking.  
One example how a conceptual model might facilitate research and 
understanding about use of genetic counseling is through the use of a behavioral model 
developed by Triandis (Triandis, 1977).  Triandis theorized that behaviors may be 
determined more by either habit or intention.  Behaviors that occur only rarely or are 
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faced for the first time involve more mental processing and intention.  In contrast, 
behaviors that have occurred before may be part of a habit.  Habits may involve little or 
less thinking, and sometimes are done automatically.  Genetic counseling for a BRCA 
mutation would likely require more mental processing and intention.  However, it is 
possible that genetic counseling could be considered part of health maintenance 
behaviors, some of which have been accepted and are engaged in routinely.  There is 
no direct evidence for this in existing literature.  Having that knowledge might guide 
development of interventions that could facilitate use of counseling.  Identifying a model 
that can be used as an organizing framework may help explore this and similar gaps in 
knowledge about the most important predictors of genetic counseling use and 
opportunities for interventions.     
Information about predictors of genetic counseling use may be particularly 
informative coming from individuals for whom its use is relevant and recommended.  
Because mutations in the BRCA1 or BRCA2 genes are estimated to be present in only 
0.2 to 1% of the general population in the United States (Kurian, 2010), the number of 
individuals for whom this topic is relevant and who are available for research studies, is 
limited.  In order to maximize use of data already collected from this group, this study 
sought to explore whether the research questions could be answered from existing 
data.   
The purpose of this study was to explore the ability of Triandis’s theory of 
interpersonal behavior to explain genetic counseling use in the context of a heritable 
predisposition to breast cancer.  The concepts included in Triandis’s model may be 
sufficient to explain the predictors of genetic counseling use; however, it has not been 
  168 
identified as a guiding framework in existing studies, nor have any studies evaluated its 
suitability.  Modeling was done to explore what concepts and variables might be most 
important in determining use of genetic counseling and whether the model can 
adequately explain and predict use of counseling.  It was hypothesized that all of the 
constructs in Triandis’s model are relevant in predicting use of genetic counseling in this 
context of possibly having a mutation in the BRCA1 or BRCA2 genes, with significance 
being found in each construct.  
 
Organizing framework 
The Triandis model has roots in the role of culture in behavior (Triandis, 1977, 
1989) and may help explore use of genetic counseling in a way that it has not been 
explored in existing literature.  Attitudes of a particular race or ethnicity have been 
explored (Chin et al., 2005; Glenn et al., 2012; Sussner et al., 2015; Thompson et al., 
2002).  However, societies today are integrated and multicultural, and individuals are 
multiethnic and multiracial, making pinpointing behavior to a particular ethnic or cultural 
background challenging, if not impossible.  The Triandis model considers the complex 
interplay of a host of factors which may be influenced by culture over time.  For 
example, the model takes into consideration that ethnic or social cultural background 
can influence behavior through social factors – one’s perceived expectations along with 
their motivation to comply with others’ expectations.  The model also considers 
influential factors to span from personal to interpersonal and broader societal factors.  
The model (Figure 5.1) organizes the factors that may predict a behavior by constructs 
such as background factors, social factors, affect or emotions, perceived 
  169 
consequences, facilitating conditions, habits, and intention.  Within those constructs are 
concepts that may be considered personal, interpersonal, or broader societal.  The 
model suggests that whether factors are personal, interpersonal, or broader 
societal/structural is less important, however.  Culture may affect them all, and 
separating them may be unrealistic.  Interventions may be aimed toward specific 
facilitating conditions, habits, or perceived consequences, however, making 
understanding of these more actionable.   
 
Figure 6.1. Conceptual framework developed from Triandis’s model of interpersonal 
behavior 
 
 
Methods 
Study Sample and Recruitment 
This study used data from the baseline survey of a randomized trial designed to 
increase cancer surveillance and use of genetic services among a group of young 
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Habits
Affect
Consequences
Facilitating 
conditions
Social 
factors
Intention
Use of 
genetic 
counseling
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breast cancer survivors, women diagnosed with breast cancer younger than 50 years 
old (Katapodi, Northouse, Schafenacker, et al., 2013; Katapodi et al., 2017).  
Participants were identified using the Michigan Cancer Registry.  From the 9,000 cases 
of in situ and invasive breast malignancies reported between 1994 and 2008, 3,000 
women diagnosed between the ages of 20 and 45 years old were randomly selected.  
The initial study oversampled for Black women residing in counties with the highest 
mortality rates for young women with breast cancer.  This was done in order to increase 
the inclusion of minority and underserved women.  The study excluded from 
participation women who were pregnant, incarcerated, or institutionalized at the time of 
the study because they might not have been able to follow recommendations for breast 
cancer screening or genetic counseling.   
Variables and measures 
The survey was a 187-item self-administered questionnaire from the initial study.  
It was mailed to participants along with an invitation letter to participate in the study.  
The variables and measures used were from previously used and validated measures 
where possible.  Triandis’s concepts and the way they were operationalized for this 
study are shown in Table 6.1.  
Variables of interest for this secondary data analysis were chosen based on a 
review of literature on factors associated with use of genetic counseling or genetic 
testing that were consistent with Triandis’s model.  Two variables were created for this 
study.  First, a medically underserved variable was created using U.S. Census Tract 
information and the Health Resources and Services Administration (HRSA) designation 
of Census tracts as a medically underserved area (MUA).  Literature on the use of 
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health services by underserved groups reveals a multitude of ways in which 
“underserved” is defined.  The clearest and most consistent was the HRSA definition.  
Medically underserved in this study was defined as being a resident in a U.S. Census 
Tract designated by HRSA as an MUA.  
The second variable that was created was minimum distance from a facility 
offering genetic counseling.  Facilities listed on the website of the National Society of 
Genetic Counselors were contacted and asked whether genetic counseling was offered 
at the facility at the time that data were being collected for the initial study.  Distances 
were calculated based on a previously used methodology (Bliss, Katz, Wright, & Losina, 
2012).  
 
Table 6.1. Variables and how they were operationalized  
Triandis 
concept 
Variable Measure 
Background factors 
 Age 
Race 
Ethnicity 
Ashkenazi Jewish 
background 
Income 
Education 
Adopted 
Family history of male 
breast cancer 
Number of pregnancies  
Additional risk factors 
 
Adapted from the Behavioral Risk 
Factors Surveillance System (2002)  
 
 
 
 
 
 
Adapted from U.S. Preventive Services 
Task Force (U.S. Preventive Services 
Task Force, 2005b), individual meets 
criteria for referral to GC if ‘yes’ to 2 of 
the following:  
• Ovarian cancer, at any age: 
self 
mother 
sister 
daughter 
maternal grandmother 
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maternal aunt 
paternal grandmother 
paternal aunt 
• Breast cancer at age  50 y.o.: 
self 
mother 
sister 
daughter 
maternal grandmother  
maternal aunt 
paternal grandmother 
paternal aunt 
Social factors 
 Perceived expectations 
of relatives 
 
 
 
Perceived expectations 
of healthcare provider 
 
 
 
 
Motivation to comply with 
relatives 
 
 
 
Motivation to comply with 
healthcare provider 
“Do you believe that your relatives want 
you to get mammograms and other tests 
to find cancer at an early stage?”  
(Definitely No/No/Somewhat No, Neutral, 
Somewhat Yes/Yes/Definitely Yes) 
 
“Do you believe that your doctor or 
healthcare provider wants you to get 
mammograms and other tests to find 
cancer at an early stage?”  (Definitely 
No/No/Somewhat No, Neutral, 
Somewhat Yes/Yes/Definitely Yes) 
 
“How often do you try to do what your 
relatives want you to do about finding 
cancer at an early stage?”  
(Never/Almost Never/Sometimes, 
Neutral, Most times/Almost 
Always/Always) 
 
“How often do you try to do what your 
doctor or other healthcare provider wants 
you to do about finding cancer at an early 
stage?”  (Never/Almost 
Never/Sometimes, Neutral, Most 
Times/Almost Always/Always) 
 
Adapted from Ajzen et al. (Ajzen and 
Fishbein, 1980b) 
Affect 
 Worry  “Have you ever had genetic testing for a 
gene mutation connected to breast or 
ovarian cancer?  If no, please tell us why 
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you have not had genetic testing (check 
all that apply).”   
 
Worry was indicated if the following was 
checked: 
“I would rather not know if I have a 
mutation connected to cancer.” 
Perceived consequences 
 Perceived positive 
consequences to self 
 
 
 
 
 
 
 
 
 
 
Perceived negative 
consequences to self 
 
 
 
 
 
 
 
 
 
Perceived positive 
consequences to family 
 
 
 
 
 
 
Perceived negative 
consequences to family 
“Have you ever had genetic testing for a 
gene mutation connected to breast or 
ovarian cancer?  If you had genetic 
testing, what helped you decide to have 
testing (check all that apply).” 
 
Perceived positive consequences to self 
was indicated if either of the following 
were checked:   
“I wanted to learn more about my future 
cancer risk; Results may change my 
cancer treatment (preventive surgery, 
chemotherapy, etc.)” 
 
 
“Have you ever had genetic testing for a 
gene mutation connected to breast or 
ovarian cancer?  “If no, please tell us 
why you have not had genetic testing 
(check all that apply).” 
 
Perceived negative consequences to self 
was indicated if the following was 
checked: 
“I am worried the result could be used 
against me (by employer, health 
insurance).” 
 
 
“Have you ever had genetic testing for a 
gene mutation connected to breast or 
ovarian cancer?” 
 
Perceived positive consequences to 
family was indicated if the following was 
checked: 
“Results will benefit my family.” 
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“Have you ever had genetic testing for a 
gene mutation connected to breast or 
ovarian cancer?  If no, please tell us why 
you have not had genetic testing (check 
all that apply).” 
 
Perceived negative consequences to 
family was indicated if the following was 
checked:  
“Family members might be upset with 
test results.” 
 
Facilitating conditions 
 Provider recommended 
genetic counseling 
“Have you ever had genetic testing for a 
gene mutation connected to breast or 
ovarian cancer?” 
 
Provider recommended was indicated if 
the following was checked: 
“My healthcare provider suggested that I 
do.” 
 Perceived risk “On a scale from 0 (Definitely Will Not) to 
10 (Definitely Will), please circle a 
number that best describes what you 
believe is your chance for getting breast 
cancer.”  
 
Likert-type scale, 0-10 for “Definitely Will 
Not/Probably Will Not/Equal 
Chances/Probably Will/Definitely Will 
 
Previously used (Katapodi et al., 2009b, 
2013b)  
 Knowledge of breast 
cancer genetics 
For each item, “Please mark an X in the 
box that best describes whether these 
statements are true or false.”  (Options 
given were: True/False/Don’t Know)  
 
Cancer can be caused by...  
...chemicals and radiation   
...a deleterious mutation that 
happens by chance during a 
person’s life   
...a deleterious mutation that is 
passed on from one generation to 
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the next   
 
Breast cancer... 
...affects about 1 in 8 women (12%) 
in the U.S.  
...that is connected to heredity affects 
about 1 in 10 women (10%) who get 
breast cancer 
...that is not connected to heredity is 
called “sporadic.”  Most cases of 
breast cancer are sporadic 
...that is sporadic, occurs earlier in 
life (younger than 50 years old) 
...that is connected to heredity is 
caused mostly by deleterious 
mutations in the BRCA1 and the 
BRCA2 genes 
 
Families that have a deleterious mutation 
in the BRCA1 or BRCA2 genes are more 
likely than other families to have...  
... cases of breast cancer in more 
than one generation  
...women with cancer in both breasts 
...cases of breast cancer diagnosed 
under the age of 50 
...cases of breast cancer in men 
 
Adapted from Knowledge Assessment 
Questionnaire (Wang et al., 2005); 
(Cronbach’s alpha=0.72) 
 Convenience  “Have you ever had cancer genetic 
services?  If no, please tell us why you 
have not used cancer genetic services – 
check all that apply.” 
 
Convenience variable was created if any 
of the following were checked:   
“I am too busy; I cannot get time off work; 
Lack of transportation; Lack of child care; 
Clinic hours do not fit my schedule; 
Clinics are too far away”  
 
Adapted from previously used (Anderson 
et al., 2012b) 
 Insured “Have you ever had genetic testing for a 
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gene mutation connected to breast or 
ovarian cancer?)  If you have genetic 
testing, what helped you decide to have 
testing (check all that apply) 
 
Insured if any of the following were 
checked:  
“My medical insurance covered the visit; 
My medical insurance covered the cost 
of the test”  
 
Adapted from previously used (Anderson 
et al., 2012b)  
 Family support Social support for breast cancer 
screening (Cronbach’s alpha=0.81)  
 
For each item, “Please read each 
statement below and decide which 
answer describes your family. You may 
skip any question(s) that make you feel 
uncomfortable or sad.”  Likert-type scale 
of 1-7 for Never True, Almost Never 
True, Seldom True, Sometimes True, 
Often True, Almost Always True, Always 
True 
 
The people in my family... 
...are willing to listen to me when I just 
need to talk 
...give me a great deal of affection and 
warmth 
...ignore or make light of my concerns 
...support me as I try to cope with 
problems in my life 
...change the topic when I discuss my 
concerns 
...work as a team to manage concerns 
we have 
...give me positive feedback for my 
attempts to cope with problems that I 
have 
...offer to help me do things that are 
difficult for me to do 
...do not like to talk about problems and 
concerns 
...avoid talking about negative feelings 
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and sad events 
...disagree on how problems affect us 
...disagree on how to solve problems we 
have 
...hide their true feelings from each other 
...make me feel comfortable when 
discussing my concerns 
...make me feel that talking about my 
problems creates a lot of tension among 
us 
 
In our family, when I have a health 
problem... 
...I have someone I can turn to 
...I could easily find someone to help me 
with my daily work 
...there is at least one person whose 
advice I really trust 
...there is no one to turn to 
...I can find someone to help me get to 
the doctor 
...I can talk to someone about my 
concerns and fears 
...there is someone helping me get the 
care that I need 
...I can get help with costs and expenses 
...there is no one to help me get 
theinformation that I need 
...I don’t have anyone I can confide in 
 
Previously used (Katapodi et al., 2002b) 
 Residence in a medically 
underserved area 
Geocoded U.S. Census Tracts and 
HRSA designation as a medically 
underserved area (MUA)  
 
Examined in this study 
 Distance to genetic 
counseling 
Distance to nearest facility offering 
genetic counseling  
 
Examined in this study 
Habits  
 History of using health 
services 
Participant considered to have a history 
of using health services if answered yes 
to any of the following: 
 
“Have you ever had a clinical breast 
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exam?; Have you ever had a 
mammogram?; Have you ever had a 
breast MRI?” 
 
Adapted from the Behavioral Risk 
Factors Surveillance System (2002) 
Intention   
 Intention to use genetic 
counseling 
“During the next 12 months, how likely 
are you to ask your healthcare provider if 
genetic testing for a gene connected to 
hereditary cancer is a right test for you?”  
 
Likert-type scale, of 1-7 or NA for Very 
Unlikely, Likely, Somewhat Unlikely, 
Neutral, Somewhat Likely, Likely, Very 
Likely, Does Not Apply 
 
Adapted from Ajzen et al. (Ajzen and 
Fishbein, 1980b) 
 
Data Collection and Analysis 
Data from the baseline survey of the initial study were analyzed for the entire 
sample of 859 participants.  Descriptive statistics characterized the sample in terms of 
sociodemographics, cancer-related medical history, perceived risk, perceived 
consequences, perceived expectations from family and healthcare provider, motivation 
to comply with those expectations, knowledge of breast cancer genetics, intention, and 
history of health services use.  Bivariate correlations were assessed to rule out 
multicollinearity, defined as correlations of 0.9 or higher (Pallant, 2007).  Prior to 
performing logistic regression, multiple imputation was done for missing data.  Pooled 
data were used for regression analyses.  Multiple imputation and all analyses were 
done using SPSS v. 24.  
Logistic regression models for the dichotomous outcome were developed based 
on the Triandis model.  Predictors for each model were added by block in order 
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according to the theoretical constructs of the Triandis model.  The progression of model 
development is shown in Figure 2.  The Omnibus test of model coefficients, Cox & Snell 
R2 and Nagelkerke R2 were used to evaluate how well a model fit the data relative to 
other models.  Fit tests were analyzed to determine the most parsimonious model that 
might explain the use of genetic counseling in this sample of YBCS.  Fit was assessed 
for each block addition and to compare models to the constant-only baseline model, 
model 0.   
Two additional models were explored.  First, only the variables that were 
significant in model 3 were tested with Intention and Habits.  The second additional 
model was similar to model 4, but substituted Habits for Intention.  Model 4 explored 
Triandis’s theory that behaviors done less frequently would involve more thought and 
intention; the additional model explored whether a health maintenance habit could be 
better at explaining use of genetic counseling than intention.  These are also shown in 
Figure 6.2.  
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Figure 6.2.  Constructs of Triandis theory included in each model 
 
Model 0 Model 1 Model 2 Model 3 Model 4 Model 5 
Constan
t only 
Backgroun
d factors 
 
Background 
factors 
+ 
Social factors, 
Affect, 
Perceived 
consequence
s 
Background 
factors 
+ 
Social factors, 
Affect, 
Perceived 
consequence
s 
+ 
Facilitating 
conditions 
Background 
factors 
+ 
Social factors, 
Affect, 
Perceived 
consequence
s 
+ 
Facilitating 
conditions 
+ 
Intention 
Background 
factors 
+ 
Social factors, 
Affect, 
Perceived 
consequence
s 
+ 
Facilitating 
conditions 
+ 
Intention 
+ 
Habits 
 
Model 6 Model 7 
Statistically 
significant 
variables from 
Model 3 
(determined 
most 
parsimonious) 
+ 
Intention 
+  
Habits 
Background 
factors 
+ 
Social factors, 
Affect, 
Perceived 
consequences 
+ 
Facilitating 
conditions 
+ 
Habits 
 
 
Fit measures 
Multiple measures of fit were used to assess the performance of each model.  
The first, the Omnibus test of model coefficients, was used to evaluate significance 
compared to the previous block in the model, and significance for the whole model 
compared to constant-only model.  Chi-square tests of significance were used to 
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indicate model fit.  Nagelkerke R2, a pseudo R2, was also used to evaluate model fit with 
higher values indicating better model fit.  Cox & Snell R2, another pseudo R2 was also 
assessed for comparison.  The most parsimonious model was the one that showed 
greatest fit with the outcome of interest with only the most essential variables.  
 
Results 
Of the 859 participants who completed the baseline survey, all of whom were 
young breast cancer survivors, 32.7 % (n= 281) used genetic counseling.  Age at first 
cancer diagnosis ranged from 25 to 50 years old; median age was 41.  A majority of the 
sample was educated, with 62.1% having completed college or at least some college, 
and 21.4% reporting a postgraduate degree.  Other characteristics of participants who 
used genetic counseling as well as those who did not are shown in Table 6.2.  
Many participants (89%) believed that their relatives want them to get 
mammograms and other tests to find cancer at an early stage and most (92%) believed 
their doctor or healthcare provider wants them to get mammograms and other tests to 
find cancer at an early stage.  Many participants (77%) try to do what their relatives 
want them to do about finding cancer at an early stage most times, almost always, or 
always; even more (91%) try to do what their doctor or other healthcare provider wants 
them to do about finding cancer at an early stage most times, almost always, or always.   
The most selected reason for not having used cancer genetic services 
(understood as genetic counseling in this study) was that “No one ever suggested it”.  
This item was selected by 357 of the 546 participants (65.4%) who did not use genetic 
counseling.  Mean score on the scale for Knowledge of Breast Cancer Genetics was 
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6.72 (SD 3.04) with most frequently occurring score being 9.0 (possible scores from 1 to 
12).  The second most chosen reason for not having used cancer genetic services, 
selected by 72 of the 546 participants (13.2%), was that out-of-pocket expenses are too 
high or not covered by insurance.  
 
Table 6.2.  Characteristics of participants who used genetic counseling and participants 
who did not.  (Note: Participants reporting “Don’t know” to use of genetic counseling 
n=25) 
 
Used  
genetic 
counseling 
 (n, %) 
n=281 
Did not use 
genetic 
counseling 
(n, %) 
n=546 
Age 
Mean (SD) 
Range 
 
  49.4 (±6.0) 
  32-63 
 
  51.72 (±5.6  ) 
  30-63 
Race 
White/Other 
Black 
 
192  (68.3%) 
  89  (31.7%)  
 
319  (58.3%) 
228  (41.7%) 
Ethnicity 
Hispanic or Latina 
Not Hispanic or Latina 
Prefer not to answer 
Don’t know 
 
    1  (0.4%) 
241  (89.9%) 
  15  (5.6%) 
  11  (4.1%) 
 
  10  (2.0%) 
447 (88.7%) 
  29  (5.8%) 
  18  (3.6%) 
Ashkenazi Jewish      7  (2.5%)     2  (0.4%) 
Income 
<$40,000 
$40,000-79,999 
$80,000-119,999 
$120,000 or higher 
Don’t know or Missing 
 
  58  (23.2%) 
  69  (27.6%) 
  60  (24.0%) 
  63  (25.2%) 
  31 
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163  (35.3%) 
  71  (15.4%) 
  50  (10.8%) 
  85 
Education 
High school/Tech school grad or less 
Some college, no degree or Completed 
college 
Postgraduate degree 
 
  46  (16.4%) 
174  (62.1%) 
  60  (21.4%) 
 
138  (25.6%) 
323  (59.9%) 
  78  (14.5%) 
Marital status 
Single 
 
127  (45.5%) 
 
198  (36.4%) 
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Married/life partner 152  (54.5%) 346  (63.6%) 
Adopted    6  (2.1%)   16  (2.9%) 
Number of times pregnant 
Mean (SD) 
 
   2.4  (±1.6) 
 
   2.63  (±1.8) 
Has family history of male breast cancer    9  (3.2%) 8  (1.5%) 
Age at first cancer diagnosis 
Median 
Range 
 
  41  
  25-50 
 
  41 
  22-58 
Had one or more additional risk factor other 
than breast cancer diagnosis at age younger 
than 50 years 
 
  96  (34%) 
 
  96  (17.7%) 
Reside in a medically underserved area   25  (8.9%)   38  (6.9%) 
 
 
Predictors of genetic counseling use  
 Twenty-nine variables in total were identified from the literature as possible predictors 
of genetic counseling use and were organized according to the constructs of the 
Triandis model (shown earlier in Table 6.1).  Descriptive characteristics of each of these 
variables were explored, along with the relationship of each variable with other predictor 
variables and with the outcome.  Four variables had very low number of participants and 
were excluded from the modeling.  For example, there were only 9 Ashkenazi Jewish 
women in the sample.  Other variables that were excluded due to having too few 
participants were:  ethnicity, adopted, and having a family history of male breast cancer.   
Nine variables were excluded for too few responses in some categories.  Too few 
responses can be problematic for statistical analyses which require the assumption of 
normality.  Data for these nine variables are shown in Table 6.3.  These variables were: 
worry, positive perceived consequences to the self, negative perceived consequences 
to the self, positive perceived consequences to the family, negative perceived 
consequences to the family, provider recommendation, convenience factors, habits, and 
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intention. Age was also excluded because this referred to the age of the participants at 
the time of the survey and was determined as lacking a strong theoretical relationship to 
the outcome.  There was a total of 15 variables included in the model.  These are 
shown in Table 4.   
 
Table 6.3.  Data for variables excluded due to having too few responses in a group 
 Outcome (used 
genetic counseling) 
   Outcome (used 
genetic counseling) 
 No Yes    No Yes 
Worry   Convenience factors 
No 519 280   No 526 280 
Yes 28 1   Yes 21 1 
        
Perceived Positive 
Consequences to Self 
  Perceived Positive Consequences 
to Family 
No 2 63   No 5 36 
Yes 5 158   Yes 2 185 
Did not 
apply 
540 60   Did not apply 540 60 
        
Perceived Negative 
Consequences to Self 
  Perceived Negative Consequences 
to Family 
No 453 48   No 479 49 
Yes 40 3   Yes 14 2 
Did not 
apply 
54 230   Did not apply 54 230 
        
Provider recommended   Intention 
No 4 109   1 301 8 
Yes 3 112   2 68 3 
Did not 
apply 
540 60   3 152 9 
        
Habits    
No 36 2      
Yes 507 275      
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Results of logistic regression 
Variables were added in a stepwise fashion, by block, grouped by constructs of 
the Triandis model.  Three variables were statistically significant predictors in the 
regression of the full model: having an additional risk factor, knowledge of breast cancer 
genetics, and motivation to comply with one’s doctor or healthcare provider. Fit 
measures, shown in Table 6.4, suggest that the full model predicts use of genetic 
counseling better than background factors alone or background factors plus the social 
factors in Block 2.  The results of logistic regression of the full model to predict genetic 
counseling use using the full model are shown in Table 6.5.   
 
  186 
Table 6.4.  Results of stepwise regression to predict use of genetic counseling using the 
full model 
 Model 0 Model 1 Model 2 Model 3 
Omnibus tests of 
model coefficients+ 
Model  
 
 
Block 
 
  
 
2=41.671, 
p=.000 
 
2=41.671, 
p=.000 
 
 
2=50.270, 
p=.000 
 
2=8.598,  
p=.072 
 
 
2=80.114, 
p=.000 
 
2=29.845, 
p=.000 
Cox & Snell R2  .082 .098 .151 
Nagelkerke R2  .111 .133 .206 
Variables in model Variables significant in each model 
Background factors 
1. Race 
2. Income 
3. Education 
4. Number of 
pregnancies 
5. Additional risk 
factor 
 
Social factors 
6. Perceived 
expectations of 
relatives 
7. Perceived 
expectations of 
HCP 
8. Motivation to 
comply with 
relatives 
9. Motivation to 
comply with HCP 
 
Facilitating conditions 
10. Perceived risk 
11. Knowledge 
12. Insured 
13. Family support 
14. Residence in 
MUA 
15. Minimum 
distance to facility 
offering GC 
 
  
 
Income*** 
 
 
 
Additional 
risk factor*** 
 
 
Income*** 
 
 
 
Additional 
risk factor*** 
 
 
 
 
 
 
 
 
 
 
 
Motivation to 
comply with 
HCP** 
 
 
 
 
Income** 
 
 
 
Additional risk 
factor*** 
 
 
 
 
 
 
 
 
 
 
 
Motivation to 
comply with 
HCP* 
 
 
Knowledge*** 
***p<.001; **p<.01; *p<.05 
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Table 6.5.  Performance measures for full model to predict use of genetic counseling 
 
Variable B SE  Exp(B) 
Block 1 
Race 
Income 
Education 
Number of pregnancies 
Additional risk factor 
 
Block 2 
Perceived expectations of 
relatives 
Perceived expectations of HCP 
Motivation to comply with 
relatives 
Motivation to comply with HCP 
 
Block 3 
Perceived risk 
Knowledge 
Insured 
Family support 
Residence in MUA 
Minimum distance to facility 
offering GC 
 
.100 
.280 
-.036 
-.035 
.829 
 
 
-.130 
 
.511 
.058 
 
-1.021 
 
 
-.085 
.189 
.752 
.052 
.309 
.001 
 
.194 
.093 
.141 
.049 
.182 
 
 
.345 
 
.383 
.234 
 
.408 
 
 
.106 
.031 
.423 
.069 
.291 
.003 
 
1.105 
1.323** 
.964 
.965 
2.292*** 
 
 
.878 
 
1.668 
1.059 
 
.360* 
 
 
.918 
1.208*** 
2.122 
1.053 
1.363 
1.001 
***p<.001; **p<.01; *p<.05 
 
 
As shown in Table 6.4, among models 1, 2, and 3, model 3 fits the data better 
than models 1 and 2.  Model 3 shows the highest 2 as well as highest Cox & Snell R2 
and Nagelkerke R2.  In this model, the variables that were significant at =.05 were: 
income (p=.003), having an additional risk factor (p=.000), motivation to comply with 
their healthcare provider (p=.013), and knowledge of breast cancer genetics (p=.000).   
As shown in Table 5, having an additional risk factor showed the highest odds for 
using genetic counseling.  Individuals with an additional risk factor were 2.3 times more 
likely to use genetic counseling (95% CI=1.604-3.275; p=.000).  Individuals with higher 
income were 1.3 times more likely to use genetic counseling (95% CI=1.091-1.686; 
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p=.006).  Individuals with more knowledge about breast cancer genetics were 1.2 times 
more likely to use or have used genetic counseling (95% CI=1.137-1.282; p=.000).  
However, the direction of this relationship is unclear because some participants had 
already received genetic counseling at the time of the study.  Therefore, higher scores 
on the knowledge measure may be an outcome of genetic counseling rather than a 
predictor of it.  An unexpected finding was that participants with higher motivation to 
comply with their healthcare provider were 36% less likely to have used genetic 
counseling.  The reason for this is unclear.  This relationship may just be a result of the 
fact that many participants (63.6%) had not used genetic counseling and a majority of 
participants even more (91%) try to do what their doctor or other healthcare provider 
wants them to do about finding cancer at an early stage most times, almost always, or 
always.   
Models with the habit and intention variables were unable to be explored 
because of their exclusion due to too few responses in some categories.  Additional 
models were explored with variable selection based primarily on a conceptual basis with 
some consideration for which variables showed significant relationships in the full 
model.  In addition to being described here, these models are shown in Table 6.6.  
Model 4 controlled for three background factors -- race, income, and education -- and 
explored the significance of all four social factors along with two facilitating conditions -- 
knowledge and insurance.  Model 5 controlled only for income, and added the variable 
of additional risk factor to the other variables explored in Model 4.  Model 6 controlled 
for two background factors -- income and education, and explored the facilitating 
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conditions of knowledge and insurance.  Model 7 explored only additional risk factor, 
with the facilitating conditions of knowledge and insurance. 
  
Table 6.6.  Additional models tested to identify a more parsimonious model 
 Model 4 Model 5 Model 6 Model 7 
Omnibus tests of 
model coefficients+ 
Model 
 
 
2=88.728, 
p=.000 
 
 
2=104.371, 
p=.000 
 
 
2=85.417, 
p=.000 
 
 
2=97.486, 
p=.000 
Cox & Snell R2 .120 .140 .114 .112 
Nagelkerke R2 .165 .192 .156 .155 
 Variables significant in each model 
 
Variables in model 
 
 
1. Race 
2. Income** 
3. Education 
4. Motivation to 
comply with 
relatives 
5. Motivation to 
comply with 
HCP* 
6. 
Knowledge*** 
7. Insured 
 
 
1. Income** 
2. Additional 
risk factor*** 
3. Motivation 
to comply with 
relatives 
4. Motivation 
to comply with 
HCP* 
5. 
Knowledge*** 
6. Insured 
 
 
 
 
1. Income** 
2. Education 
3. 
Knowledge*** 
4. Insured 
 
 
1. Additional 
risk factor*** 
2. 
Knowledge***  
3. Insured* 
 
 
 
 
Table 6.7.  Results of regression to predict use of genetic counseling using Model 7 
Variable B SE Exp(B) 
Block 1 
Additional risk factor 
 
Block 2 
Knowledge 
Insured 
 
.838 
 
 
.209 
1.011 
 
.177 
 
 
.028 
.408 
 
 
2.312*** 
  
 
1.233*** 
2.748* 
***p<.001; **p<.01; *p<.05    
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Based on the 2 values, Cox & Snell R2, and Nagelkerke R2, model 5 fits the data 
better than models 4, 6, and 7.  However, model 7, has the second highest 2, Cox & 
Snell R2, and Nagelkerke R2 values, has fewer variables, and would be considered the 
most parsimonious.  In both models 5 and 7, additional risk factor and knowledge are 
statistically significant.  In these and the other models, income is significant; if income is 
not in the model, insured is significant.  In model 7, insured may be acting as a proxy for 
income or socioeconomic status.   
Using model 7, insured seems to be quite important in predicting genetic 
counseling use; it suggests that insured individuals are 2.7 times more likely to use 
genetic counseling that individuals who are not insured.  Having an additional risk factor 
also shows higher likelihood of using genetic counseling (2.3 times).  These are shown 
in Table 6.7. 
 
Limitations 
The limitations of this study are in large part due to using an existing dataset from 
a study that was designed with different research aims and using a different theoretical 
framework.  Some concepts that were of interest in this study were not included in the 
initial study and variables were operationalized based on concepts in that model.  
Inclusion of variables explored in this study were limited to what was collected in the 
initial study.  Stigma and mistrust, for example, were unable to be included in the 
modeling done in this study because it was not part of the model used for the initial 
study, nor was there a suitable similar concept or measure.  Similarly, other emotions 
may have been explored in addition to worry.  
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Additionally, there were items in the survey of the initial study that were relevant, 
but posed challenges when operationalized for this study.  Positive and negative 
perceived consequences to self as well as family were concepts of interest in this study, 
as were habits and intentions.  However, these variables were not of primary interest in 
the initial study.  For this study, they were operationalized using responses to select 
items in the survey rather than complete validated measures.  In light of the limited 
availability of young breast cancer survivors and the exploratory nature of this study, the 
potential limitations were accepted initially so as to maximize use of data already 
collected and to minimize research burden on this group.   
 
Discussion 
This study yielded interesting and important results.  First, for this sample of 
young breast cancer survivors, for whom genetic counseling is relevant and 
recommended, only 32.7% of the women used genetic counseling.  This is consistent 
with the low rates of counseling reported in other studies mentioned earlier.  
Additionally, the most reported reason for not having used genetic counseling was that 
“No one ever suggested it”.  This was reported by 65.4% of the participants who did not 
use genetic counseling, despite having received a diagnosis of cancer at a young age.  
This suggests that there is still much work to be done in getting healthcare providers to 
recognize the risk factors and recommending use of genetic counseling.  Perhaps even 
better would be to ensure that the public is aware of the risk factors for having a 
mutation that can predispose one to developing cancer at a young age, thereby 
empowering the public with the knowledge.  
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The modeling also yielded interesting results.  Income or being insured, and 
having an additional risk factor were statistically significant in all models.  Knowledge of 
breast cancer genetics was also significant.  However, this cannot be assumed as being 
a predictor to counseling use but instead may have been an outcome of using genetic 
counseling.  The direction of this relationship is not clear as 33% of participants had 
already received genetic counseling at the time of the study.   
The most parsimonious model is extremely pared down from the original model, 
suggesting that the original model is not suitable for predicting genetic counseling use.  
Although the data used for this study does not support the ability of the Triandis model 
to explain the use of genetic counseling use in the context of young breast cancer 
survivors, the model continues to show promise as a model for exploring relationships 
among other variables that were unable to be included in analyses for this study.  Some 
variables, and in some cases entire concepts of the Triandis model, were excluded due 
to issues with the way that variables could be operationalized.  In addition to this, not all 
constructs of the model had variables significantly associated with the outcome of 
genetic counseling use.  A prospective study designed to explore the research 
questions and aims of this study specifically may yield different results.   
 
Variables excluded due to unsuitable measures 
The difference in the way that variables should have been operationalized for this 
study and the way that they were operationalized in the initial study could have 
contributed to lack of significance of variables in some constructs.  For example, the 
intention and worry measures asked about these concepts with regard to genetic 
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testing.  Intention to get genetic testing could be very different from intention to get 
genetic counseling, and worry due to genetic testing as opposed to genetic counseling 
may also be different.  However, these were the closest measures available from the 
dataset.  Other variables that involved measures pertaining to genetic testing were: 
positive perceived consequences to self, negative perceived consequences to self, 
positive perceived consequences to family, negative perceived consequences to family, 
and provider recommendation.  The social factors construct was comprised of the four 
variables on perceived consequences.  Therefore, this construct could not be analyzed 
effectively.   
The measure for habit was also inadequate.  There is little data from individuals 
who have used genetic counseling more than once.  Therefore, breast health 
maintenance habits were used as a proxy.  This was operationalized using survey items 
on prior mammography, clinical breast exam, and breast MRI.  However, most of the 
study participants likely would have undergone these services due to their breast cancer 
diagnosis.  In fact, this led to too few responses in a group for some categories and the 
habits variable was not able to be included in the model.  Better measures for habit and 
intention would have perhaps resulted in their inclusion in the modeling.       
 
Variables excluded due to few responses in a group 
In addition to the measures for these variables pertaining to genetic testing, the 
variables were operationalized using select items that were not complete and validated 
measures.  There were too few responses for the majority of these items (shown earlier 
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in Table 3), and the conclusions that could be drawn from the responses were not 
suitable for this study.  
 
Conclusion 
Although the Triandis model was not able to explain genetic counseling in this 
study, there were several limitations related to this being a secondary data analysis and 
the way that variables were operationalized.  The ability of the Triandis model to explain 
or predict genetic counseling may be worth exploring further.  The model includes 
concepts such as emotions, interpersonal relationships, societal norms, and factors 
related to the healthcare system (e.g., availability of a knowledgeable healthcare 
provider who recognizes the risk factors for a cancer-predisposing heritable mutation 
such as BRCA1 or BRCA2) in addition to concepts found in more widely used health-
specific behavior prediction models.  Prospective studies, with the opportunity to 
operationalize variables and use measures chosen specifically for this research 
question and concepts of the Triandis model, might yield different results.  Future 
studies would ideally also have a population-based recruitment strategy, such as 
through use of cancer registries, in order to maximize the potential for obtaining a 
diverse sample.  A clear and consistent theoretically-based conceptual model to guide 
studies on predictors will be helpful in producing results that can be compared, thus 
enabling confidence in study findings, facilitating development of interventions and 
policies that can effectively make an impact on the use of genetic counseling.  This will 
help the field move toward increasing genetic counseling use for individuals who could 
benefit from it. 
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CHAPTER VII 
Summary 
Although there were some challenges related to doing a secondary analysis of 
existing data, this study yielded some interesting findings and highlighted ideas needing 
further exploration.  The literature review found several possible predictors of genetic 
counseling use, some of which were also explored in this study.  The findings of this 
study provide some support for existing knowledge.  First, this study found provider 
recommendation, perceived positive consequences (i.e., benefits) to family and 
perceived positive consequences to self to be correlated with genetic counseling use 
with correlations over .5.  These have been identified from existing literature as 
frequently reported reasons for using genetic counseling.   However, these were some 
of the variables that were excluded from the logistic regression analyses.  The findings 
in terms of predictors of genetic counseling use therefore requires some caution in 
interpretation since variables (some of which were highly correlated with counseling use 
with correlations over .60) were excluded from the analyses on predictors in this study.  
Similar to a few studies described earlier, this study also found rates of genetic 
counseling to be suboptimal, even among individuals considered high risk, for whom it 
is recommended and for whom it could present life-saving benefits.  Additionally, this 
study, like many existing studies, lacked a diverse sample.  It oversampled for blacks 
and individuals residing in Michigan counties with the highest rates of mortality for 
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breast cancer.  However, there were still few participants of other racial and ethnic 
backgrounds such as Hispanic and Arabic, though there are large numbers of 
individuals with those ethnic backgrounds residing in Michigan.    
Among this group of women diagnosed with cancer at an early age (younger 
than 50), only 32.7% used genetic counseling; furthermore, the most reported reason 
for not using genetic counseling, reported by 65.4% of the participants who did not use 
counseling, was that “No one ever suggested it.”  Education efforts to healthcare 
providers should continue but perhaps more fruitful may be empowering patients and 
the public with education about risk factors for having a cancer-predisposing heritable 
mutation, of which cancer at an early age is a hallmark.   
Findings of this study suggest that socioeconomic factors such as income and 
insurance are likely important in whether one uses genetic counseling.  In all regression 
models explored in this study, one or the other were significant.  In this study, women 
were 1.3 times (32%) more likely to use genetic counseling if they had higher income.  
Related to this, women were found to be more likely to use genetic counseling if they 
had an additional risk factor other than breast cancer diagnosis at age younger than 50.  
Although genetic counseling is now covered without cost sharing as a preventive 
service for individuals with the appropriate risk factors, awareness of this and of one’s 
risk factors may still depend on how integrated an individual is with the healthcare 
system and having a knowledgeable healthcare provider who can identify risk factors 
and discuss appropriate next steps such as genetic counseling.    
One finding of this study that deserves extra caution with interpreting is that 
participants with higher knowledge scores on the breast cancer genetics measure were 
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1.2 times (21%) more likely to have used genetic counseling.  The direction of this 
relationship is unclear.  Nearly 33% of participants had already received genetic 
counseling at the time of the study; more knowledge of breast cancer genetics may be a 
reflection of counseling use rather than knowledge predicting counseling use.  
An unexpected finding of this study was that there was no significant difference in 
rates of genetic counseling use based on medically served or underserved status.  The 
test to determine this was underpowered, however, so confidence in this finding is low.  
There are a few possible reasons for the lack of a significant difference in counseling 
use according to medically served or underserved status.  First is the way in which 
medically served or underserved status was operationalized in this study.  Underserved 
status was operationalized as residence in an area designated by HRSA as a medically 
underserved area (MUA).  In existing literature on barriers faced by underserved 
groups, underserved is defined in a multitude of ways, making comparison and 
synthesis of findings challenging.  HRSA designation as an MUA was chosen for its 
characteristic as a sort of standardized measure which could be used to facilitate 
comparison of findings among multiple future studies.  However, this designation 
considers 1) population to provider ratio; 2) percent of the population below federal 
poverty level; 3) percent of the population over age 65; and 4) infant mortality rate.  
These criteria might not be highly relevant in the context of specialized services such as 
cancer genetic counseling.   
Another possible reason for lack of a significant difference in counseling use 
between served and underserved groups might be the imbalance in number of served 
and underserved participants.  There was a far larger number of medically served 
  206 
participants than underserved.  Participants were identified using a state cancer 
registry.  This should help increase the chances of obtaining a diverse sample in terms 
of race and ethnicity as well as rural and urban residences.  However, individuals may 
still decline to participate in the study leading to samples that lack in diversity.  
Recruitment of participants may need to be more purposive, oversampling for rural in 
addition to ethnic minority individuals.  
The findings of the literature review, described in the first manuscript, were 
organized according to the conceptual framework and informed selection of variables of 
interest for this study.  The correlation of these variables with genetic counseling use, 
described in the second manuscript, provided some insight into possible barriers and 
possible facilitators to counseling use based on positive or negative relationship with 
counseling use.  The relationships between these variables and the outcome of 
counseling use were explored further using regression analyses in the final manuscript, 
and the conceptual framework was evaluated for its potential to guide future research in 
this area.  However, the regression analyses could not include variables that had too 
few responses in some response categories.  The variables identified as predictors to 
counseling use based on regression analyses were different from the variables showing 
correlations over .50 in the correlation analyses.  Although the data used for this study 
did not support the framework as suitable for predicting counseling use (primarily 
because some variables and constructs were excluded from analyses due to too few 
responses for some categories), the framework still shows potential for use in future 
research on the topic.   
Next steps 
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A prospective study to follow up on some of the findings of this secondary 
analysis would again recruit women who were diagnosed with cancer at age younger 
than 50.  Young breast cancer survivors would be a target population because they 
have been identified as high risk; additionally, genetic counseling is recommended for 
them and could lead to decision-making about potentially life-saving approaches to 
reducing risk for developing cancers associated with a heritable mutation.  Recruitment 
of women using state cancer registries may be an effective approach, oversampling for 
rural populations as well as individuals of racial and ethnic minority backgrounds.  
Additionally, recruiting from multiple state cancer registries may be helpful for 
maximizing potential of obtaining large numbers of diverse groups, increasing power of 
analyses.  Participants should be diverse in sociodemographic characteristics such as 
racial and ethnic makeup, median income and poverty levels, proportion of insured to 
uninsured individuals, and large metropolitan as well as rural populations.  Availability of 
a large cancer center in the state may be a variable of interest as well.    
In line with obtaining a diverse sample and increasing inclusion of underserved 
individuals, an effort should be made to identify criteria for being underserved in the 
context of specialized health services such as cancer genetic counseling.  This could 
build on the HRSA criteria for MUA, perhaps removing the criterion of percent of the 
population over age 65 and instead including the criterion of integration into the health 
care system.  The measure for this could be regular use of preventive health services.  
Regular use of preventive health services could improve the chances that risk factors 
such as personal and family history of cancer are identified and followed over time.  
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Special attention should also be given to identifying validated measures 
previously used in studies on use of breast cancer genetic services among high risk 
individuals.  If not available, then next preferable would be validated measures from 
studies on hereditary cancer, followed by breast cancer.  Suitable measures also should 
include the assessment of barriers and facilitators at multiple time points since there are 
multiple times when decision-making about genetic counseling and genetic testing may 
be considered.  There were some limitations in the ability to do some of the analyses for 
this study related to the initial study having been developed using a different conceptual 
framework.  Some concepts of interest for this study were not part of the initial study.  
The relationship of stigma, emotions such as relief and fear, and locus of control (the 
extent to which one believes she has control over events and outcomes) with use of 
counseling might be interesting to explore in future studies.  Furthermore, the use of 
conditional-type questions should be avoided if possible in order to maximize available 
data from each participant. 
The magnitude of the work to be done is clear.  The urgency is even more 
pronounced in light of calls by revolutionaries in the field such as Mary Claire King (King 
et al., 2014) for population-based screening.  The findings of this study highlight the 
potential for existing disparities in health outcomes to worsen in the context of lack of 
understanding about risk and risk management related to a heritable cancer-
predisposing mutation.  Fortunately, there already exists several individuals and groups 
interested in identifying barriers to use of cancer genetics services for mutations in the 
BRCA1 and BRCA2 genes, specifically.  However, the limitations of existing knowledge 
need to be addressed in order for progress to occur.  Nursing could be playing a larger 
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role in research in this context.  Nurses care for individuals with cancers associated with 
BRCA mutations at the bedside, in the clinics, and in the community, as bedside nurses 
or advanced practice nurses with certifications in Advanced Genetics.  Nurses can play 
a key role in research as well as in the translation of research into clinical practice.  
There is great potential for reducing burden from cancer and great opportunities for 
turning potential into reality.  Nursing’s holistic approach, with its focus on individuals, 
families, and societies, is a natural fit for making this potential become reality.   
